

Neptune Technologies & Bioresources Inc.
Form 20-F
August 31, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 20-F

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the fiscal year ended February 28, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For transition period from _____ to _____

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of event requiring this shell company report _____

Commission file number 1-33526

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

(Exact Name of the Registrant as Specified in its Charter)

Québec, Canada

(Jurisdiction of Incorporation or Organization)

225 Promenade du Centropolis, Suite 200, Laval, Québec, H7T 0B3
(Address of Principal Executive Offices)

Henri Harland
225 Promenade du Centropolis
Suite 200
Laval, Québec
H7T 0B3

Phone: +1-888-664-9166

Fax: +1-450-687-2272

	<u>Title of Each Class</u>	<u>Name of Each Exchange On Which Registered</u>
Securities registered or to be registered pursuant to Section 12(b) of the Act:	Common Shares	The Nasdaq Stock Market
Securities registered or to be registered pursuant to Section 12(g) of the Act:		

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report. 38,234,745

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

YES NO

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

YES NO

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant the Rule 405 of Regulation S-T (s 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP International Financial Reporting Standards Other

Indicate by check mark which financial statement item the registrant has elected to follow.

Item 17 Item 18

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES NO

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

NOT APPLICABLE

TABLE OF CONTENTS

	<u>Page</u>
<u>PART I</u>	3
ITEMIDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS	3
1: ITEMOFFER STATISTICS AND EXPECTED TIMETABLE	3
2: ITEMKEY INFORMATION	3
3: ITEMINFORMATION ON THE COMPANY	8
4: ITEMOPERATING AND FINANCIAL REVIEW AND PROSPECTS	24
5: ITEMDIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	46
6: ITEMMAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	61
7: ITEMFINANCIAL INFORMATION	61
8: ITEMTHE OFFER AND LISTING	63
9: ITEMADDITIONAL INFORMATION	64
10: ITEMQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	73
11: ITEMDESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	78
12: <u>PART II</u>	79
ITEMDEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	79
13: ITEMATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE	79
14: OF PROCEEDS	
ITEMCONTROLS AND PROCEDURES	79
15: ITEMAUDIT COMMITTEE FINANCIAL EXPERT	80
16A: ITEMCODE OF ETHICS	80
16B: ITEMPRINCIPAL ACCOUNTANT FEES AND SERVICES	81
16C: ITEMEXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES	81
16D: ITEMPURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED	82
16E: PURCHASERS	
ITEMCHANGE IN CERTIFYING ACCOUNTANT	82
16F: ITEMCORPORATE GOVERNANCE	82
16G: <u>PART III</u>	85

17:	ITEMFINANCIAL STATEMENTS	85
18:	ITEMFINANCIAL STATEMENTS	85
19:	ITEMEXHIBITS	85

As used in this annual report on Form 20-F (this annual report), unless the context otherwise indicates, the terms Neptune Technologies, the Company, the Corporation, we, us, our, or Neptune means Neptune Technologies and its subsidiaries. The terms Acasti or Acasti Pharma refer to Neptune's subsidiary Acasti Pharma Inc. The terms Neuro or Neurobio refer to Neptune's subsidiary Neurobiopharm Inc.

EXCHANGE RATE INFORMATION

Unless otherwise indicated, all monetary references herein are denominated in Canadian dollars. References to dollars or \$ are to Canadian dollars and references to US\$ or U.S. dollars are to United States dollars. See Item 3 for further exchange rate information.

STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements under Item 4: Information on the Company and Item 5: Operating and Financial Review and Prospects and elsewhere in this annual report are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical facts but, rather, on our current expectations and our projections about future events, including our current expectations regarding:

- the future demand for, and sales volumes of, our products;
- future production volumes, efficiencies and operating costs;
- increases or decreases in the prices of our products;
- the future availability and price of raw material needed to manufacture our products;
- our future stability and growth prospects;
- the success of measures to implement our business strategies and the benefits to be derived therefrom;
- our future profitability and capital needs, including capital expenditures;
- currency exchange rates;
- the outlook for and other developments in the industries in which we participate, as well as general economic and market conditions; and
- the effect on us of new accounting releases.

These factors, many of which are beyond the control of Neptune, include Neptune's ability to:

- effectively manage its operations during uncertain economic conditions;
 - identify and capitalize on possible collaboration, strategic partnering or divestiture opportunities;
 - obtain suitable financing to support its operations and clinical trials;
 - manage its growth and the commercialization of its products;
 - achieve operating efficiencies;
 - successfully compete in its markets;
 - realize the results it anticipates from the clinical trials of its products;
-

- succeed in finding and retaining joint venture and collaboration partners to assist it in the successful marketing, distribution and commercialization of its products;
- achieve regulatory clearances for its products;
- obtain on commercially reasonable terms adequate product liability insurance for its commercialized products;
- adequately protect its proprietary information and technology from competitors and avoid infringement of proprietary information and technology of its competitors;
- assure that its products, if successfully developed and commercialized following regulatory approval, are not rendered obsolete by products or technologies of competitors; and
- manage its relationships with third parties, including customers, suppliers and key personnel, upon whom it is dependent.

These forward-looking statements generally can be identified by the use of statements that include words such as believe , expect , anticipate , intend , plan , likely , will , predicts , estimates , forecasts or other similar words, although not all forward looking statements contain such words. Similarly, statements that describe our objectives, plans or goals are or may be forward-looking statements. These forward-looking statements are subject to risks, uncertainties and other factors that could cause our actual results to differ materially from the future results expressed or implied by the forward-looking statements. These risks and uncertainties are described under Item 3D: Risk Factors .

Any forward-looking statements made by us in this annual report are subject to these factors. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this annual report may not occur. Actual results could differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors could also harm our future results. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this annual report are made only as of the date of this annual report. We do not intend, and do not assume any obligation, to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this annual report and the documents, if any, that we incorporate by reference with the understanding that the actual future results may be materially different from what we expect. We may not update these forward-looking statements, even if our situation changes in the future. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

PART I**ITEM 1: IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS**

Not applicable.

ITEM 2: OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3: KEY INFORMATION**A. Selected Financial Data**

The following table sets forth selected consolidated financial data for Neptune for the periods indicated, derived from financial statements prepared in accordance with generally accepted accounting principles (GAAP). We prepare our financial statements in accordance with Canadian GAAP and include, as a note to the statements, a reconciliation of material differences to United States GAAP. The consolidated financial statements have been audited by KPMG LLP, Montréal, Canada as at and for the periods ended May 31, 2007, May 31, 2008, February 28, 2009 and February 28, 2010 and by Raymond Chabot Grant Thornton LLP as at and for the period ended May 31, 2006. The selected financial data below are derived from our audited consolidated financial statements and are reported in Canadian dollars. The summary data set forth below should be read in conjunction with the Company s consolidated financial statements and notes thereto, included in Part I, Item 8 of this annual report.

Selected Financial Data (Canadian GAAP/Canadian Dollars)

(for the period ended)	February 28,	Feb. 28, 2009	May 31, 2008	May 31, 2007	May 31, 2006
	2010	(9 months) ¹			
Net sales	12,664,462	8,589,272	10,263,825	8,126,192	6,911,725
Net loss	(1,535,198)	(1,884,615)	(4,779,344)	(2,677,433)	(886,150)
Net loss per share	(0.04)	(0.05)	(0.13)	(0.075)	(0.029)
Total assets	17,566,141	18,154,056	14,206,159	13,461,117	8,113,812
Net assets	7,995,689	9,002,263	7,943,661	7,552,302	2,936,863
Capital stock and warrants	25,530,162	25,233,271	24,902,594	23,182,472	17,002,009
Shares used in computing per share amounts	37,913,163	37,622,735	37,105,672	35,510,919	30,790,786
Dividends	-	9,380	-	-	-
Selected Financial Data (US GAAP) (Canadian dollars) ²					
Net loss	(2,940,202)	(1,786,197)	(5,177,308)	(2,677,433)	(876,953)
Net loss per share	(0.08)	(0.05)	(0.14)	(0.075)	(0.029)
Total assets	17,464,070	18,242,438	13,964,665	13,617,587	N/A
Net assets	7,845,098	8,710,654	7,702,167	7,708,772	2,936,863

1. During 2009, the company changed its fiscal year end from May 31 to February 28.
2. Refer to note 27 to the 2010 audited consolidated financial statements.
3. Selected financial data has been recast to reflect adoption of CICA Handbook sections 3064, Goodwill and other intangible assets, and section 3450, Research and Development costs, effective March 1, 2009. Refer to note 2(a) to the 2010 consolidated financial statements.

Exchange Rate Data

The following tables set forth certain exchange rates based on the Bank of Canada noon buying rate (the Noon Buying Rate). Such rates are set forth as U.S. dollars per Canadian dollar.

	08/18/2010	Year-ended February 28, 2010	Nine-Month Period ended 02/28/2009	Year-ended May 31,		
				2008	2007	2006
Average ⁽¹⁾	US\$0.9719	US\$0.9078	US\$0.87598	US\$0.99005	US\$0.88455	US\$0.8785

(1) The average of the exchange rates on the last day of each month during the period indicated.

	Month					
	July 2010	June 2010	May 2010	April 2010	March 2010	Feb. 2010
High	US\$0.9724	US\$0.9805	US\$0.9868	US\$1.0039	US\$0.9888	US\$0.9597
Low	US\$0.9381	US\$0.9429	US\$0.9278	US\$0.9803	US\$0.9596	US\$0.9316

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

Investing in our securities involves a significant amount of risk. You should carefully consider the risks described below, together with all of the other information in our publicly filed documents which does not consist of an exhaustive list of risk factors an investor should consider, before making an investment decision. If any of the following risks actually occurs, our business, financial conditions or results of operations could be adversely affected. In such an event, the trading price of our Common Shares could decline and you may lose part or all of your investment in our securities. Any reference in this section to our products includes a reference to our products and future products we may develop.

Risks related to Neptune's business*History of Prior Losses*

Since commencement of its activities, the Corporation has incurred losses. At February 28, 2010, the Corporation's accumulated deficit was \$26,813,240. The Corporation had net losses of \$1,535,198, \$1,884,615, and \$4,779,344 in the fiscal periods ended February 28, 2010, February 28, 2009, and May 31, 2008, respectively. It is expected that the Corporation will continue to experience operating losses until product sales and royalty payments generate sufficient revenues to fund its operations, including research and product development. Quarterly fluctuations are also anticipated in respect of sales, expenses, losses and cash flows. We cannot say when, if ever, the Corporation will become profitable. Profitability will depend on our ability to generate revenues from the sale of our products and the licensing of our technology that will offset the significant expenditures required for us to advance our research, protect and extend our intellectual property and develop, manufacture, license, market, distribute and sell our technology and products successfully. Similar types of expenditures in the past resulted in the net losses reported above.

Reliance on Key Personnel

The Corporation is reliant on certain members of its management and scientific staff, and the loss of the services of one or more of these individuals could adversely affect the Corporation. The Corporation will be required to continue to implement and improve its management systems and to recruit and train qualified employees. Although the

Corporation has in the past been successful in attracting and retaining skilled and experienced personnel, there can be no assurance that the Corporation will continue to do so in the future.

Patents and Proprietary Technology

The Corporation's success depends in part on its ability to obtain patents, protect its trade secrets and operate without infringing third-party exclusive rights or without others infringing the Corporation's exclusive rights or those granted to it under license. The Corporation has filed patent applications in Canada, the United States, Europe and elsewhere and is actively pursuing these matters. The patent position of biopharmaceutical firms is generally uncertain and involves complex legal, factual and scientific issues, several of which may remain unresolved. The Corporation does not know whether any of its pending patent applications will be granted or whether the Corporation will be able to develop other patentable proprietary products. Furthermore, the Corporation does not know whether its existing or future patents will provide a competitive advantage or afford protection against competitors with similar technology. Furthermore, the Corporation cannot give any assurance that such patents will not be challenged or circumvented by others using alternative technology or whether existing third-party patents will prevent the Corporation from marketing its products. In addition, competitors or potential competitors may independently develop, or have independently developed products as effective as those of the Corporation or invent or have invented other products based on the Corporation's patented products.

If third-party licenses are required, there can be no assurance that the Corporation will be able to obtain such licenses, or if obtainable, that they would be available on reasonable terms. Furthermore, there can be no assurance that the Corporation will be able to develop or obtain alternative technologies related to third-party patents that may inadvertently cover its products. Inability to obtain such licenses or alternative technologies could delay the market launch of certain Neptune products, or even prevent the Corporation from developing, manufacturing or selling certain products. In addition, the Corporation could incur significant costs in defending itself in patent infringement proceedings initiated against it or in bringing infringement proceedings against others.

The Corporation cannot determine with any certainty if it has priority in relation to a product or process covered by a patent application or if it was the first to file a patent application for any such invention. Further, in the event of patent litigation there can be no assurance that the Corporation's patents, if issued, would be held valid or enforceable by a court of competent jurisdiction or that a court would rule that the competitor's products or technologies constitute patent infringement.

Moreover, a significant part of the Corporation's technological know-how constitutes trade secrets. The Corporation, therefore, requires that its employees, consultants, advisers and collaborators sign confidentiality agreements. However, there can be no assurance that such agreements provide adequate protection in the event of unauthorized use or disclosure of the Corporation's trade secrets, know-how or other proprietary information.

Additional Funding Requirements and Access to Capital

The Corporation may require substantial additional funds for further research and development, scheduled clinical testing, regulatory approvals and the commercialization of its products. Neptune may seek additional funding for these purposes through public or private equity or debt financing, collaborative arrangements with other biopharmaceutical companies and/or from other sources. There can be no assurance that additional funding will be available on acceptable terms to permit successful commercialization of the Corporation's products. Should the Corporation fail to obtain the necessary capital, it may be required to delay, reduce or eliminate one or more of its various research programs or seek financial support from one of its corporate partners or from third-parties who may require that the company waive significant rights regarding protection of its proprietary technologies or offer it financial support on less favourable terms than those normally acceptable to the Corporation.

Environmental Matters

The Corporation's research and development processes involve the use of certain regulated materials. The Corporation is subject to federal, provincial, state and local laws and regulations governing the use, manufacture, storage, handling

and disposal of such materials. The Corporation believes that its safety procedures comply with such regulatory requirements, and that it has sufficient insurance coverage in place against this risk; however, the risk of accidental contamination or injury cannot be completely eliminated. In the event of an accident, the Corporation could be held liable for damages, which could exceed the resources of the Corporation. Although the Corporation believes that it complies in all material respects with the applicable environmental legislation and regulations, and currently has no immediate plans for major capital expenditures in respect of environmental protection installations, there can be no assurance that the Corporation will not be required to incur significant costs to comply with regulatory requirements in the future, or that the operations, business or assets of the Corporation will not be materially adversely affected by current or future legislative or regulatory requirements.

Availability and Sources of Raw Materials

The Corporation depends on third parties for the sourcing of components for its various products. The Corporation believes that alternative sources of supply for its various raw materials exist. However, any change in the Corporation's suppliers could have a significant impact on the Corporation's capacity to complete certain of its current research and development projects and, accordingly, would affect its projected commercial and financial growth. While other potential alternative suppliers of raw material have been identified, they must first pass intensive validation tests to ensure their compliance with product specifications. No assurance can be given regarding the successful outcomes of such tests or the ability of Neptune to secure alternate sources of supply at competitive pricing, and upon fair and reasonable contractual terms and conditions.

We are dependent on a limited number of customers

We expect to continue to depend upon a relatively small number of customers for a significant percentage of our revenue. During fiscal 2010, two customers each represented more than 10% of our total 2010 revenue, or 37.3% in the aggregate, (2009 three customers each represented more than 10% of our total revenue, or 48.6% of revenue; 2008 two customers represented 31.4% of revenue). A decline in revenue from these customers or a loss of a large customer could have a material adverse affect on our financial condition and results of operations. To reduce this reliance, we have been targeting new customers and new business opportunities. In addition, if any of our customers has insufficient liquidity, we could encounter significant delays or defaults in payments owed to us by customers, which could have a significant adverse impact on our financial condition and results of operations. Any deterioration in the financial condition of our customers will increase the risk of collecting receivables. The current global economic crisis could also impact our customers' ability to pay receivables or result in customers having financial difficulty or even going into bankruptcy or reorganization which could also impact our ability to collect our receivables.

Foreign Currency Fluctuations

The Corporation expects that most of its revenues will be in United States dollars and Canadian dollars. From time to time, the Company uses derivative financial instruments to reduce foreign exchange exposure. Significant fluctuations in the rate of exchange could adversely affect the Corporation's financial performance. There is a risk of loss arising from an eventual weakening of the United States dollar.

Value of Intangible Assets

The Corporation is required to review the carrying value of its intangible assets for impairment annually or when events or changes in circumstances indicate that the asset might be impaired. Intangible assets include the net book value of product rights, trademarks and process know-how covered by certain patented and non-patented information. Management reviews the carrying value based on projected future results. If events such as an increase in generic competition or inability to manufacture or obtain supply of products occur that may cause sales of the related products to decline, the Corporation adjusts the projected results accordingly. Any impairment in the carrying value results in a write-down of the intangible asset that is charged to income during the period in which the impairment is determined. The write-down of intangible assets may have a material adverse effect on the results of operations in the period in which the write-down occurs.

Litigation

Any unfavourable court judgment following the cases disclosed in this annual report or other cases could affect the Corporation's cash flow.

Risks related to Neptune's Industry

Biopharmaceutical Sector

The biopharmaceutical sector must contend with dramatic scientific and technological developments and regulatory requirements that may, within a relatively short timeframe, render the products and processes developed or planned by the Corporation less profitable or obsolete.

Rapid Technological Change

The Corporation operates in a sector that is subject to rapid and substantial change. There can be no assurance that products developed by others will not render the Corporation's products or technologies non-competitive or that the Corporation will be able to keep pace with technological developments. Competitors may have developed or may be in the process of developing technologies that could be the basis for competitive products. Some of these products may prove more effective and less costly than products developed by the Corporation.

Government Regulations

The development, production and commercialization of biopharmaceutical products is generally subject to comprehensive regulations under Health Canada's Therapeutic Products Program and various other national, regional and local regulatory bodies, including the Food and Drug Administration in the United States. No assurance can be given that the Corporation or its clients and partners will not encounter difficulties or will not incur excessive costs in obtaining the necessary approvals or permits, which could delay or prevent the commercialization and production of its products.

Distribution of the Corporation's products outside Canada and the United States is also subject to comprehensive government regulation. Regulations, specifically requirements in respect of product releases, the time involved in respect of regulatory assessment and the sanctions imposed in the event of infringement vary from country to country. No assurance can be given that the Corporation will obtain the requisite approvals in the relevant countries or that it will not incur significant expense in obtaining regulatory approvals or maintaining them in effect. Failure to obtain the necessary regulatory approvals, the suspension or revocation of current approvals or any failure to comply with regulatory requirements may have a material adverse effect on the Corporation's operations, its financial situation and its operating results.

Competition

Competition in the biopharmaceutical sector is intense. The Corporation competes with companies that produce similar or nearly identical biopharmaceutical products or that proposes different approaches to the separation or purification of components of krill. Certain of those companies have greater resources than the Corporation. Accordingly, no assurance can be given that products developed by these other companies or that their equivalent technology in the area of separation or purification of components of krill will not adversely affect the Corporation's competitiveness.

Uncertainty Regarding the Outcome of Clinical Studies

In most countries, the use and sale of therapeutic products is regulated by governmental or regulatory agencies to ensure their safety and efficacy. To obtain approval of such agencies for the use, distribution, marketing and sale of such products and to demonstrate their safety and efficacy, pre-clinical and clinical testing is required. There can be no assurance that any such study relating to any product will provide satisfactory results. If results are not satisfactory, the Corporation could abandon its commitment to the relevant product or research program.

Potential Product Liability

The development of human therapeutic products involves an inherent risk of product liability claims and associated adverse publicity. Product liability insurance is costly, often limited in scope, and could be unavailable or only available on terms unacceptable to the Corporation. There can be no assurance that the Corporation will be able to obtain or maintain insurance on reasonable terms or to otherwise protect itself against potential product liability claims that could impede or prevent commercialization of the Corporation's future products. A product liability claim against the Corporation or the withdrawal of a product from the market could have a materially adverse effect on the Corporation's business or its financial condition.

Uncertain Market

The Corporation believes that products based on its core technology will have numerous applications and that there is a growing market for the products that it has developed. However, there can be no assurance that these expectations are accurate, particularly considering competition from existing or new products and the uncertain commercial viability of certain of the Corporation's products.

Volatility of Share Price

Market prices for securities in general, and that of biopharmaceutical companies in particular, tend to fluctuate. Factors such as the announcement to the public, or in various scientific or industry forums, of technological innovations, new commercial products, patents, exclusive rights obtained by the Corporation or others, results of preclinical and clinical studies by the Corporation or others, a change of regulations, publications, financial results, public concerns over the risks of pharmaceutical products such as blood and plasma filtration products for the removal of pathogens or over the safety of blood collection systems, future sales of securities by the Corporation or its shareholders and many other factors could have considerable effects on the price of the Corporation's securities.

ITEM 4: INFORMATION ON THE COMPANY

A. *History and Development of the Company*

Neptune Technologies & Bioressources Inc. (the Company) is located at 225 Promenade du Centropolis, Laval, Québec H7T 0B3, phone: (450) 687-2262 or toll-free: 1-888-664-9166. The Company was incorporated under Part 1A of the Companies Act (Québec) in Québec, Canada on October 9, 1998.

Neptune's registered agent in the United States is CT Corporation System, 111 Eight Avenue, 13th floor, New York, NY, 10011.

The Company focuses on the research, development and commercialization of products derived from marine biomasses for the nutraceutical, pharmaceutical and cosmetic industries. During the period ended February 28, 2009, the Company transferred certain rights to its subsidiaries, Acasti Pharma Inc. and NeuroBioPharm Inc., in order to develop pharmaceutical products in the fields of cardiovascular and neurological diseases, respectively.

The Company develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process Neptune OceanExtract. The Company continues to develop its extraction process and markets its marine oil Neptune Krill Oil - NK[®] as well as its protein concentrated Neptune Krill Aquatein - NKA.

During the nine-month fiscal period ended February 28, 2009, the Company granted an exclusive worldwide license to its majority-owned subsidiary, Acasti, to develop, validate health benefits by way of clinical studies and market new pharmaceutical products (OTC, medical food, Rx) that target the cardiovascular system using the Company's technology and intellectual property. Acasti will finance its research and development activities as well as its clinical studies. The products developed by Acasti are expected to require the approval from the U.S. Food and Drug Administration before clinical studies are conducted as well as the approval from similar regulatory organizations before sales are authorized.

The Company has established Acasti in order to segregate its cardiovascular pharmaceutical activities from its nutraceuticals activities, which in the opinion of Company's management will allow the financial community to differentiate Acasti's activities from the Company's core business and will also enable Neptune and Acasti to separately attract pharmaceutical and nutritional companies to enter into strategic alliances.

On July 17, 2008, the Company's Board of Directors declared a dividend to its shareholders. The Board of Directors approved a dividend of \$0.00025 CDN per share on the outstanding common shares of the Company for payment to shareholders of record at the close of business on July 28, 2008. This dividend was paid on August 11, 2008 by the issuance of an aggregate of 9,380,355 transferable, non-convertible notes, each note having a principal value of \$0.001, maturing two years after the date of issue, bearing interest from the first anniversary date of their issuance at a rate of ten percent (10%) per annum, and being redeemable at all times by the Company, either in cash or in kind (the Notes).

On August 21, 2008, the Company's and Acasti's Boards of Directors approved an Exchange offer to be offered by Acasti to all of the holders of Notes, to purchase the Notes at a price equal to the Notes' value, payable by the issuance by Acasti of a maximum of 9,380,355 units, each unit representing one Class A share and one Series 2 warrant of Acasti (Acasti Unit). On August 25, 2008, Acasti proceeded with the exchange offer to Neptune's Noteholders, and each Noteholder had until October 3, 2008 to accept the exchange of their Notes against Acasti units on a one for one basis. The approval for the Exchange offer by the Company's shareholders was obtained on September 25, 2008.

On November 27, 2008, Acasti issued to Noteholders 9,246,935 Acasti Units in consideration of 9,246,935 Notes to shareholders in the exchange offer as well as the outstanding notes prepayment. A total cash payment of \$149 was made to Noteholders not qualifying for the prepayment in securities due to regulatory issues.

On October 15, 2008, the Company granted an exclusive worldwide license to its renamed, on December 24, 2008, wholly-owned subsidiary NeuroBioPharm to develop, validate and commercialise new pharmaceutical products (OTC, medical food, Rx) that target cognitive and neurological pharmaceutical applications using the Company's technology and intellectual property. Each product will be developed and financed by NeuroBioPharm. The products developed by NeuroBioPharm are expected to require the approval of the U.S. Food and Drug Administration before clinical studies are conducted as well as the approval of similar regulatory organizations before sales are allowed.

During the nine-month fiscal period ended February 28, 2009, Neptune obtained \$6,500,000 in debt financing, of which \$3,500,000 was allocated to the repayment of outstanding long-term debts, allowing Neptune substantial savings on financial expenses, and \$3,000,000 was allocated to finance a 50% capacity increase in the production at its plant facilities. Neptune also obtained a credit facility of up to \$1,000,000.

The Company, upon acquisition of the Sherbrooke production plant in October 2006, also concluded long-term financing totalling \$1,254,750 in the form of two loans, the first with Desjardins, in the amount of \$855,000 (15 years at 7.7%), and the second with the seller of the plant in the amount of \$399,750 (5 years at 10.25%). The outstanding capital on both loans have since been repaid.

The Company continued to expand its customer base worldwide and is expecting revenue growth driven by repeat demand from existing customers and incoming demand from new customers from North America, Europe and Asia. Neptune also completed its plant expansion and the scaling up of its production capacity at its Sherbrooke plant during the first and second quarter of fiscal 2010, providing for more than a 50% increase of yearly output from 60,000 kilograms to close to 100,000 kilograms. The capacity increase of its Sherbrooke (Quebec, Canada) required a total investment of \$4,212,076 by Neptune of which \$3,000,000 was financed by debt and the excess has been financed by cash on hand. The integration of new technical equipment into the manufacturing line and the completion of the capacity expansion were completed on schedule, at the end of the first quarter. The ramp-up of the facility, which took place during the second quarter, impacted the financial results in the second quarter but the Company managed to catch up with the production in the third and fourth quarter to surpass 2009 annualized revenues. During the third quarter and fourth quarter, the production plant ran at a steady rate of over 100,000 kg annually. In order to respond to increased demand and deliver on its volume commitments, Neptune is currently working to further expand its production capacity from 100,000 kg to an estimated 120,000 to 130,000 kg annually. This additional expansion is expected to take place during the second and third quarters of fiscal 2011. This expansion should take place without production interruption and represents a marginal investment financed by cash flow from current operations. Neptune's additional industrial plant project discussions are on schedule, with the target for the new industrial plant realization to take place during the course of calendar 2012.

During the first quarter of fiscal 2010, the Company signed an agreement with Bayer Healthcare LLC for the commercialization of Neptune proprietary products in the United States. Also in the first quarter, Neptune entered into a new distribution agreement with Inno-Vite, a Canadian leader in innovative health products focusing on research-proven ingredients. Inno-Vite launched Neptune Krill Oil NKO® under the brand name Inno-Krill in health food stores across Canada. During the second quarter of fiscal 2010, Weifa, a leading pharmaceutical company also

launched NKO[®] for the first time in the Norwegian market in drug stores for women's health.

The Company presented novel innovative product opportunities customized for dietary supplements, functional and medical foods at Vitafoods International 2009. Neptune launched a new pipeline of novel formulations containing its proprietary marine omega-3 phospholipids enhanced with validated bioactive ingredients targeted to specific health applications. The Company is also testing the industry's reception of a new biomass extract generated from Neptune's research and development program targeting new vascular and affective health indications. The Company will also be presenting pilot commercial products for functional food applications including juice, fruit berries, fruit paste and protein bars.

The Company also sustained its clinical research initiatives. As a result, Neptune is able to leverage scientific results demonstrating health benefits specific to the proprietary composition of Neptune Krill Oil (NKO®) on prevalent human conditions, such as premenstrual syndrome, high cholesterol, inflammation, osteoarthritis and attention deficit hyperactivity disorder. Similarly, the clinical trials for functional food applications with the multinational corporations Nestlé and Yoplait are progressing in a satisfactory way.

During the second quarter of fiscal 2010, the Company received a complaint filed by Schiff Nutrition Group Inc. ("Schiff"), a former distributor of Neptune's products, in the United States District Court for the District of Utah, Central division, alleging that Neptune failed to meet certain delivery thresholds. As a result, Schiff is seeking monetary damages in the minimum amount of US \$1 million from Neptune.

After careful review of this complaint and having sought legal advice, the Company filed early in the third quarter a response and counterclaims to the Schiff complaint in federal district court in Utah. The Company denies all material allegations and the requested monetary compensation in the complaint and asserts federal and state law claims against Schiff, including that Schiff failed to pay the Company for shipments of NKO® accepted by Schiff, and that Schiff caused its contractor to encapsulate NKO® despite the Company's objections that the resulting product would not meet specifications after encapsulation by Schiff's contractor.

Despite the Company's warning to Schiff to cease directly and indirectly using the Company trademarks including NKO® and clinical support, Schiff continued to use the Company trademarks and claims, as it was seen on websites of multiple Schiff distributors.

No provision has been recorded by the Company as at February 28, 2010 for this matter because the outcome and the amount of loss, if any, is not determinable.

In the third quarter, the Company announced that convertible debentures with a fair value of \$2,250,000 were converted. Holders of \$84,000 of debenture capital converted capital and accumulated interest into Neptune units resulting in the issuance of 69,783 common shares and 34,891 warrants of Neptune. Neptune warrants are exercisable until October 9, 2011 at various prices ranging from \$2.05 to \$2.25 depending on the market price of Neptune shares at their date of conversion. Holders of \$2,166,000 of debenture capital chose to convert into Acasti units resulting in the transfer from Neptune to the former debenture holders of 9,455,867 Acasti shares and the issuance of 9,455,867 Acasti call options by Neptune. Acasti call options are exercisable at \$0.50 and expire one year after their issuance. At as February 28, 2010, \$496,000 of convertible debentures remains outstanding.

In the third quarter, Neptune also converted all of its 38,240,000 Acasti Class C shares into Acasti Class A shares as per the terms of the shares. After all conversions and transfers Neptune owned 28,784,133 Acasti Class A shares and 4,950,000 Acasti multi-voting Class B shares.

In regards to its intellectual property protection, the Company has always had a firm policy to protect its intellectual property rights including its patents, trademarks and trade secrets, with every legal means available. Recently, certain of Neptune's competitors have been marketing, advertising and selling their finished krill-based products claiming benefits based on Neptune's research or by infringing on patents for which Neptune has exclusive rights. Neptune, being determined to enforce its rights, has thus filed suits against some of those companies in order to protect its

intellectual property.

The Company has also decided to exercise its right to appeal the decision of the European Patent Office regarding the European composition of phospholipids and use patent. The Company does not agree with the decision that states that Neptune's Patent does not sufficiently disclose the invention. With the filing of an appeal, the decision to revoke the patent is suspended and the patent remains enforceable until appeal is heard.

In the third quarter, the Company also filed a patent infringement lawsuit against Aker Biomarine ASA, Jedwards International, Inc., and Virgin Antarctic LLC. The complaint, which was filed in the U.S. District Court for the District of Massachusetts, alleges infringement of U.S. Patent No. 6,800,299. The patent is directed to a method of extracting total lipid fractions from krill.

In the fourth quarter, the Company received a ruling on its appeal against the December 2008 ruling against the company's Intellectual Property purchase option. In this new ruling, the Court of Appeal confirmed Neptune's right to exercise its purchase option related to its Intellectual Property at a purchase price of \$275 plus interest. The court also confirmed that Neptune had exercised its option on August 18, 2004 and rejected all royalty claims with the exception of \$36 plus interest.

ABOUT THE SUBSIDIARIES

Acasti Pharma Inc.

The status of Acasti's new pharmaceutical products, over-the-counter (OTC) prescription medical foods, and prescription drug products, is as follows:

During 2010 fiscal year, Acasti has continued making significant progress in its scientific research and development programs and has achieved several value-creating milestones within the OTC, medical food and prescription drug programs (Rx). Acasti negotiated a deal with a non-disclosable partner to commercialize an OTC product in the USA, Brazil and Canada. Furthermore, the selection process of potential partners for co-development of Rx, OTC and medical foods is completed and Acasti has implemented its operational plans towards the execution of pre-marketing and commercialization.

Acasti announced publicly its significant pre-clinical study results in prestigious and international conferences. The preclinical study results were presented at the council for Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2010 Scientific Sessions Meeting of the American Heart Association in San Francisco, CA. The results of the study entitled "CaPre , an Omega-3: Phospholipid, Managing Dyslipidemia in Three Murine Phenotypes" were presented by Dr. Steven J. Adelman, Ph.D., FAHA, CEO/Founder of Vascular Strategies LLC. This study, conducted in collaboration with Professor Daniel Rader, University of Pennsylvania School of Medicine, and Dr. Steven J. Adelman, evaluates the mechanism of action of Acasti's prescription drug candidate (omega-3 phospholipid CaPre) for the treatment of dyslipidemia and cardio-metabolic disorders. CaPre was shown to be effective in beneficially modulating the lipid profile of healthy and diseased mice with high cholesterol, obesity and diabetes. CaPre significantly reduced triglycerides (60%) and bad cholesterol - LDL (28%) while simultaneously increasing good cholesterol - HDL (25%).

The efficacy of CaPre was evaluated in Zucker Diabetic Fatty (ZDF) model, with which, as previously reported, CaPre demonstrated significant anti-dyslipidemic effects associated with substantial elevations of High-density lipoprotein-Cholesterol (HDL-C) or good cholesterol . CaPre was administered for 3 months at a daily human equivalent dose of 500mg and 2,500mg in both ZDF diabetic (established, severe, type 2 diabetes) and normal healthy rats. Both rat phenotypes were subjected to oral glucose tolerance tests (OGTT). In medical practice the OGTT is commonly used to test for diabetes and insulin resistance. It involves the oral administration of high amounts of glucose in order to determine how quickly it is cleared from the blood. The test may be performed as part of a panel of tests, such as the comprehensive metabolic panel. Treatment of severely diabetic rats with CaPre was shown to significantly reduce impaired glucose tolerance within 1 month of treatment, with the higher dose being only slightly

more effective than the lower dose. After 3 months, the ZDF rats had established a normal tolerance to glucose analogous to the healthy rats. Also, the healthy rats continued to tolerate glucose normally, indicating another safety parameter for CaPre .

Along with this endeavor Acasti received positive feedback from pre-IND (Investigational New Drug application) and pre-CTA (Clinical Trial Application) respectively from FDA and Health Canada to pursue the pharmaceutical development of CaPre . Acasti has now identified a GMP (Good Manufacturing Practice) manufacturing site to comply with the regulations of pharmaceutical development.

From a business development perspective, Acasti showcased its platform and product to a variety of pharmaceutical companies through international business perspective development meeting (Annual Alliance Management congress and Annual Combination Drug Therapies Conference, both organized by the Cambridge Healthtech Institute (CHI) and the BioPharmaceutical Strategy Series). Acasti presented its strong positioning in the field of Cardiometabolic disorders and its action plan for successful collaboration with worldwide pharmaceutical industry leaders and its strategy for implementation. Acasti intensified its position on its corporate strategy in seeking alliances for its new product lines, while providing opportunities for in/out licensing agreements. Acasti is establishing itself with international and strategic industrial partners who are seeking a product to manage the complexity of mixed dyslipidemia associated with the ever-increasing problems of obesity and diabetes.

NeuroBioPharm Inc. (NeuroBioPharm or NBP)

On October 15, 2008, the Company transferred an exclusive worldwide license to research and develop new active pharmaceutical ingredients (API) based on Neptune s proprietary omega-3 phospholipid technology and intellectual property (the License). To further product development, NeuroBioPharm initiated IND-enabling research aiming towards IND/CTA allowance by the US-FDA and Health Canada in order to further validate the safety and effectiveness of its APIs for the prevention and treatment of neurological conditions in Phase I and IIA/b clinical studies. NeuroBioPharm s new pharmaceutical products are prepared for licensing to potential pharmaceutical alliances as OTC, prescription medical food and drug products. Each product will be developed and financed by NeuroBioPharm. The products developed by NeuroBioPharm are expected to require the approval of the U.S. Food and Drug Administration before clinical studies are conducted and approval of similar regulatory organizations before sales are allowed.

The Company is using NeuroBioPharm in order to segregate its neurological pharmaceuticals activities from its nutraceuticals activities, which in the opinion of Company s management will allow the financial community to differentiate the NeuroBioPharm neurological pharmaceutical applications activities from the Company s core nutraceuticals business and will also enable the Company and NeuroBioPharm to separately attract nutraceutical and pharmaceutical companies to enter into strategic alliances.

Also, on October 15, 2008, the Company transferred to NeuroBioPharm the development project and clinical study conducted under an agreement with a multinational company. NeuroBioPharm has assumed Neptune s role and responsibilities under this agreement which was signed at the end of August 2008 and covers the development of a medical food targeting a prevalent medical condition. The results of this clinical study should be known during the summer of 2010.

On December 24, 2008, the Company proceeded with a distribution having a nominal value of less than \$1 to Neptune employees and insiders dedicated to the subsidiary of the Company resulting in the grant of 3,800,000 series 4 Warrants of NeuroBioPharm to insiders and 1,280,000 series 4 Warrants of NeuroBioPharm to employees. The Warrants will be liberated subject to applicable regulatory approval and/or compliance with other conditions, if required.

Exploratory pre-clinical studies were completed evaluating the potential effects of the NBP pipeline on neurodevelopmental and cognitive function in comparison to the industry gold standards; the results are encouraging and indicative of neurobioactivity in frontal and temporal lobes.

The clinical trial evaluating the effect of the medical food in early stage Alzheimer disease is still progressing and was almost completed. The trial is done in multiple sites in different provinces in Canada. Under the prescription drug products, preclinical studies evaluating the toxicity, pharmacokinetics and mechanism of action of the prescription drug are designed. NBP was active in developing the OTC product (NKPL72 and NKPL43) and is still validating the process at large scale. Finally, NBP attempts to sign a license or rights of first refusal for OTC monotherapy and/or fixed dose combination treatments with at least one partner is still strongly on-going.

B. Business Overview

Neptune is a biotechnology company that researches and develops novel extraction technologies, potent biological therapeutics agents and intellectual property for highly prevalent chronic conditions still lacking safe and definitive treatment solutions. The main focus of the Company is:

- To identify marine biomass that is pure of toxins, abundant and underexploited;
- To develop novel technology for the extraction and stabilization of potent marine biological therapeutic agents; and
- To develop safe and effective compounds for highly prevalent atherosclerotic conditions like cardiovascular diseases as well as for neurodegenerative and inflammation-related conditions.

Neptune is pursuing market opportunities in the nutraceutical market (including dietary supplements and functional foods) and, through its two subsidiaries Acasti Pharma and NeuroBioPharm, the pharmaceutical market (including medical food, over-the-counter and prescription drugs) for all its products.

Neptune generates revenues from research contracts (2010:\$58,875; 2009 (9 months):\$124,791; 2008:\$0) and sales. Virtually all revenues are derived from sales of NKO[®] product, which are geographically distributed as follows:

	2010	2009	2008
	\$	(9 months)	\$
	\$	\$	\$
Canada	151,762	\$888,375	\$984,551
United States	7,877,542	6,280,838	5,764,579
Europe	2,790,004	1,200,107	1,727,013
Asia / Oceania	1,786,279	95,161	1,787,682
Total	12,605,587	8,464,481	10,263,825

NutraceuticalOverview

Neptune's products are currently sold in the nutraceutical market. The nutraceutical market encompasses functional foods and dietary supplements, the latter of which include a wide range of nutrients such as vitamins, minerals, fatty acids, amino acids and herbal supplements. Functional food is a growing field in food and medical science and includes foods designed with health benefits beyond their usual nutritional value and which may be enriched with health promoting additives such as vitamins, probiotics or omega-3.

The nutraceutical market is growing rapidly driven by the health demands of an aging population. Within the next twenty years, the number of Americans 65 and older will double from 35 million to 70 million and is expected to then represent 20% of the population.¹ Similar demographical changes can be observed in other countries, resulting in a global trend. Beyond weight management, issues such as cholesterol, heart health, cognitive function and joint health are driving the market expansion. Functional foods such as probiotic yogurt and yogurt drinks, cereals bars and soya milk are experiencing substantial growth.²

Other additional factors have been identified as growth drivers in the nutraceutical markets including:

- Improved understanding and scientific knowledge of the contribution of diet in health and disease prevention;

¹ Demographic Trends in the 20th Century. Census 2000 Special Reports. November 2002.

² Baby Boomers and the U.S. Food and Beverage Industry: Packaged Facts, 12/1/2005.

- Increased consumer demand for products that maintain vitality and prevent disease;
- Increased health care costs and the trend towards self-treatment with a focus on natural products; and
- Technical advances and innovation in the food industry.

Dietary Supplements

The world retail market for dietary supplements is highly fragmented, composed of a large numbers of products and many small manufacturers and estimated at more than \$50 billion in annual sales.³ United States dietary annual supplement sales amount to approximately \$23 billion.⁴ Europe represents approximately one third of this market with sales in excess of \$15 billion. In Japan, dietary supplement sales of \$6 billion have been reported.⁵ We expect that specialty supplements such as probiotics and omega-3 will be experiencing the most sales growth over the next five years and that issues such as cholesterol, heart health and mental health will engender a major impact.

Functional Food

The main functional food categories include dairy products, confectionary products, various cereal products and functional beverages. It is difficult to estimate the potential size of the functional food market but there is reason to believe that the market size may be underestimated. The total U.S. retail food market amounted to \$457 billion in 2004.⁶ If approximately 25% of this food market could be used, in the future, for nutraceutical reasons, the functional food market may amount to more than \$100 billion in the US alone. Assuming a similar market size in Europe, total combined market potential could reach \$200 billion, an enormous foundation for the functional food market.

Calcium, probiotics and omega-3 products are getting significant attention and are expected to play a major role in the expanding dairy product category projected to reach \$15 billion by 2010 in the US.⁷ Omega-3 is also playing a major role in the \$23-billion breakfast cereal segment⁸ and heart-healthy products command about \$19 billion in sales today.⁹

Poly-Unsaturated Fatty Acids (PUFA)

The polyunsaturated fatty acid (PUFA) market, which includes predominantly omega-3 and 6 fatty acids, is growing at a fast pace and the most predominant omega-3 fatty acids are docosahexaenoic (DHA) and eicosapentaenoic acid (EPA) derived from plant and marine sources. Omega-3 sourced from marine oils is one of the fastest-growing sectors in the PUFA ingredient market, which is a direct result of the media attention pertaining to omega-3 health benefits and the growing need for alternative treatment for a variety of chronic disorders including the heart and the brain.

Extensive research, including Neptune s clinical trial work, has demonstrated their clinical benefits. Omega-3 fatty acids reduce inflammation and prevent risk factors associated with chronic diseases such as heart disease and arthritis and appear to be particularly important for cognitive (memory and concentration) and behavioural function.

Neptune s omega-3 s are sourced from krill, a zooplankton, with the advantage that the omega-3 fatty acids are carried by phospholipids and not triglycerides such as in fish oil. Phospholipids, a major component of biological membranes and are more easily digested resulting in a higher bioavailability of Neptune s products.

³ Industry Canada. International Market Research: Dietary Supplements.

⁴ Idem 3.

⁵ R.D. Kathman et al., Identification Manual to the Mysidacea and Euphausiacea of the Northeast Pacific , Canadian Special Publication and Aquatic Sciences 93, 1986, p. 269.

⁶ Progressive Grocers 72nd Annual Report of the Grocery Industry.

⁷ Cultured Dairy Products in the U.S. Packaged Facts, Oct 1, 2006.

- ⁸ Euromonitor. http://www.euromonitor.com/Cereal_Partners_Worldwide_exploits_developing_markets
⁹ <http://www.marketresearch.com/map/prod/1164892.html>

The market space is growing with the FDA having issued a qualified heart health claim enabling manufacturers to label products containing omega-3 EPA and DHA as being heart healthy. The market is waiting for additional health claims such as effects on high blood cholesterol and high blood pressure.

Omega-3 ingredient sales continue to increase, driven by increasing demand in dietary supplements, functional foods and beverages and pharmaceutical applications. Based on the trends reported in the 2005 Frost & Sullivan market report,¹⁰ the worldwide omega-3 market will reach more than \$1.4 billion in annual sales within the next five years. Higher quality and higher performance products providing concentrated amounts of omega-3 are gaining a larger market share of the marine oils industry in terms of revenues, because of their improved safety and health benefits. Omega-3 fortified food launches more than doubled in 2006 to 250 from 120 in 2005, according to Mintel.¹¹ Most product introductions have been in beverages, spreads, dairy products (i.e., yogurt), eggs, nutrition bars and baked goods.

Nutricosmeceutical and beauty from within Trend

Nutricosmeceuticals are defined as oral nutritional supplements with cosmetic applications and are commercialized in foods, beverages and dietary supplements. This beauty from within trend is spreading into the American and European markets. For example, Nestlé® and L'Oréal, the world's largest companies in food and cosmetics, respectively, created Innéov®, a developer of nutritional supplements with cosmetic applications. Coca-Cola® commercializes a milk-based beverage for evening use to promote beauty during sleep. New and scientifically-validated ingredients are entering the market and consumer uptake is being driven by the demand to turn back the negative physiological processes associated with aging.

Pharmaceutical

Acasti and NeuroBioPharm were formed to develop and commercialize the Company's products in the pharmaceutical market. The company has licensed specific application rights to these two subsidiaries.

Cardiovascular Disease

Cardiovascular disease includes a wide range of conditions and treatment is focused on both reducing cardiovascular risk factors to prevent an acute cardiovascular event and on preventing or delaying the onset of chronic cardiovascular disease. Important risk factors for cardiovascular disease are abnormal levels of lipids and/or lipoproteins such as triglycerides and cholesterol. Increased serum levels of low density lipoprotein (LDL - bad cholesterol) and low levels of high density lipoprotein (HDL - good cholesterol), the latter being recognized as the most important risk factor for the development of cardiovascular disease, are known as dyslipidemia. Dyslipidemia leads to plaque formation and narrowing of the arteries (atherosclerosis), leading to myocardial infarction (heart attack), stroke and peripheral vascular and neurodegenerative disease. Over 750,000 Americans die every year due to atherosclerosis related cardiovascular complications.¹² Statins, including medications such as Lipitor®, Zocor® and Crestor®,¹³ are used to decrease LDL, but are ineffective at raising HDL, creating an unmet treatment gap. It is estimated that over 100 million American adults have total blood cholesterol values considered borderline-high (200 to 240 mg/dL) or high (above 240 mg/dL) and are potentially eligible for a cholesterol lowering agent.¹⁴ Even though statins are widely prescribed, creating a worldwide \$30 billion market, they have less effect than fibrates or niacin in reducing triglycerides and raising HDL-cholesterol (good cholesterol¹⁵). This unmet medical need creates a growing billion dollar market space for safe monotherapies as well as combination products containing a statin and an HDL raising agent.

¹⁰ End-user Analysis of the Global Omega-3 PUFA Market, FO23-88. Frost & Sullivan.

¹¹ Mintel: www.marketresearch.com

- ¹² Atherosclerosis Research Unit. University of Southern California. http://www.usc.edu/schools/medicine/research/centers_programs/aru/elite.html
- ¹³ CNN Money. <http://money.cnn.com/2005/09/19/news/fortune500/cancerdrugs/index.htm>
- ¹⁴ Centers for disease control and prevention, CDC. <http://www.cdc.gov/nccdphp/publications/AAG/dhdsp.htm>
- ¹⁵ Nature Reviews Drug Discovery 5, 813-814 (October 2006) | doi:10.1038/nrd2156. Life after statin patent expiries. Jane Kidd

Cognitive Dysfunction and Neurodegenerative Disease

Neurodegenerative disease includes a large number of disorders such as Alzheimer's disease, Parkinson disease and Multiple Sclerosis. Deteriorating nerve cells are responsible for the loss of brain function and today few therapies are available for the wide range of neurodegenerative diseases, creating an immense unmet medical need. In the United States, over 5 million patients are suffering from Alzheimer's disease and 1.5 million patients from Parkinson disease.¹⁶ Worldwide, it is estimated that over 24 million people have dementia due to Alzheimer's disease.⁷ The neurodegenerative market is estimated at 15 billion dollars and growing at a double-digit rate.¹⁸

Attention-deficit hyperactivity disorder is a cognitive dysfunction caused mainly by the malfunction of the dopamine transporter system. The most commonly used medication is methylphenidate such as Ritalin[®], Ritalin-SR[®], Ritalin LA[®] or Concerta[®] and Metadate[®]. Annual sales of Novartis' Ritalin[®] product family amounted to \$US 440 million in 2008 and are growing at a rate of approximately 17% per year.¹⁹

Chronic Inflammation and Arthritis

Many forms of arthritis, such as osteoarthritis and rheumatoid arthritis, are inflammatory disorders; patients suffer from pain, stiffness, swelling and functional impairment. Osteoarthritis is the most common form of arthritis affecting over 20 million people in the United States.²⁰ It is caused by the breakdown and eventual loss of the cartilage between the bones of the joints.²¹ Non-surgical treatment options for osteoarthritis include analgesic and anti-inflammatory pain medications, nutritional supplementation, physical therapy, exercise, and weight loss. Common types of medications used to reduce pain in osteoarthritis include acetaminophen (Tylenol[®]) and non-steroidal anti-inflammatory drugs (e.g. Motrin[®], Advil[®], Aleve[®]). It is estimated that in the U.S. medical expenditures (direct costs) for arthritis and other rheumatic conditions in 2003 were 80.8 billion dollars.²²

NKO[®] Functional Food Grade

In 2010, Neptune achieved major advancements in the research and development of Neptune Krill Oil (NKO[®]) suitable for incorporation into functional foods of different matrices by masking and/or eliminating the characteristic krill odour and taste of the original oil.

Neptune has started working with a new functional bars manufacturer to replace Weider Bars which were terminated due to Weider's affiliation with Schiff Nutrition. The new bars provide Neptune more flexibility and a better market positioning since they can be produced at lower minimum quantities and are produced with all natural ingredients and have no artificial additives. This is more in line with the product positioning Neptune is targeting. Three new excellent bar flavours were developed (Cherry Chocolate, Chocolate Nut Pie and Chewy Ginger).

- a) The new healthy functional bars including a full therapeutic dose of NKO[®] (300mg and 500mg) per bar were displayed in all the major industry international tradeshows that Neptune participated in during 2010.
- b) The expected shelf life stability of 5 months was exceeded and is being further evaluated to target a 9 month period.
- c) New options of functional fruit juices were also introduced along side the functional bars in all the tradeshows of 2010.

Both the bars and juice were successfully received with positive comments on both color and taste by the hundreds of tradeshow participants who visited Neptune's booth.

Institute for Neurodegenerative Disease, IND, University of California.
<http://ind.universityofcalifornia.edu/diseases/>

17 Alzheimer s Disease International. <http://www.alz.co.uk/media/dementia.html>

18 Arrowhead Publishers. Leaders in Business Intelligence and Market Research.
<http://www.arrowheadpublishers.com/news/archives/2007/02/new-website.php>

19 Novartis Annual Report 2008.

20 <http://www.medicinenet.com/osteoarthritis/article.htm>

21 National Center for Chronic Disease Prevention and Health Promotion. USA.

22 Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. MMWR 2007;
56(01):4-7.

OPA³ - Optimal for Life

In 2009, Neptune continued the marketing of the new OPA³ brand and established it as the trademark for the Company's growing family of products. This new brand represents three essential elements (omega-3s, phospholipids and antioxidants) and effectively illustrates Neptune's product portfolio strategy and positioning of its initial product - NKO[®]. This unique combination allows long-term stability while it delivers increased bioavailability ensuring improved effectiveness in smaller doses. The OPA³ brand will allow Neptune to better communicate its distinct advantage and to create a new class of ingredients for the functional food and biopharmaceutical markets. NKO[®] and two new formulations of the OPA³ brand were evaluated and proven effective for neurological disorders in animal models.

NKO[®]- Neptune Krill Oil

A marine oil extracted from Antarctic Krill (*Euphausia Superba*) that provides a unique blend of nutritional elements was the first product in the OPA³ family to be developed and commercialized. Its elevated content in phospholipids, rich in omega-3 and omega-9 and antioxidants such as astaxanthin, vitamin A, vitamin E and flavonoid, offer a proprietary, safe and effective product free of preservatives with exceptional health benefits and superior stability. In 2009, NKO[®] further distinguished itself by proving its superior bioavailability in a clinical study comparing its product against the most known format of omega-3 on the market.

NKA - Neptune Krill Aquatein

Neptune Krill Aquatein (krill protein concentrate) is a product that features the complete range of marine amino acids, including the eight essential amino acids. This protein concentrate contains pre-digested proteins that are an important source of short-chain amino acids in the form of peptides that facilitate digestion by more effective assimilation. New market trends searching for a new and unique amino acid profile increased the potential value of NKA. More complete analyses of the composition of NKA were performed and different methods for improving quality and efficiency of production were also investigated. NKA is being positioned to be sold for both human and animal nutrition.

Research and Product Development Programs

- **Pharmaceutical drug development:** In fiscal year 2010 the Company completed the experimental phase of the drug precursor required for the development of prescription medical foods and drugs. Acasti Pharma completed the non-GLP (Good Laboratory Practice) phase of research and development of NKPL65 and NKPL53, the first two cardiovascular drugs. IND-enabling (Investigational New Drug) preclinical studies were initiated with CaPre as scheduled.
 - NKPL65 and NKPL53 are new generation cardiovascular products in the Acasti pipeline in preparation for investigational new drug application (IND) and FDA review in the U.S. aimed at the development of prescription drug and medical foods that safely and effectively increases HDL.
 - NPK80 and NKPL90 are new products in the research and development pipeline of NeuroBioPharm in preparation for investigational new drug applications (IND) in the U.S. for the development of prescription drugs and medical foods for the safe and effective management of cognitive, behavioural and neurodegenerative disorders.

Internal Research, Subcontracted Research or Alliance Research

Neptune-Funded Internal Research

- NKPL53: a series of preclinical tests were initiated in the nine-month fiscal period ended February 28, 2009. Preliminary results from initial toxicity testing are promising and justify continuation with lower functional daily doses for toxicity and effectiveness biomarkers.
- NKPL65: non-GLP development and analytical testing in multiple batches has been completed successfully within the allowed standardization of active pharmaceutical ingredients. GLP production has been initiated. Some preclinical testing was completed within our last fiscal year and others are scheduled to be completed within the current fiscal year.
- NKPL80 and NKPL90 non-GLP development and chemical analysis was initiated in the nine-month fiscal period ended February 28, 2009. Initial NKPL80 batches were standardized within allowed deviation limits. Some preclinical testing began in early fiscal 2010 and others are still ongoing.
- NPK-D organoleptic management of NKO[®] for implementation of NKO[®] in daily functional food and specialized medical food.
- Acasti completed preclinical research designed to evaluate the safety and efficacy of its first Active Pharmaceutical Ingredient (API) drug candidate, CaPre . The efficacy of CaPre on dyslipidemia was evaluated on Zucker Diabetic Fatty, a diseased rat phenotype, characterized with established type 2 diabetes, glucose intolerance and severe dyslipidemia, particularly elevated triglycerides and cholesterol. After 4, 8 and 12 weeks of chronic daily treatment with human equivalent daily dosing of 500mg and 2,500mg, CaPre was shown to significantly increase High Density Lipoprotein Cholesterol (HDL-C or good cholesterol) by 40% at the lower dose and by up to 61% at higher dose after 3 months treatment in those severely affected rats. These results show that CaPre could be effectively used in patients with metabolic syndrome and /or lipid disorders which remain a currently unmet medical need.
- Additional Acasti preclinical research designed to further evaluate the potentially broader spectrum of therapeutic efficacy of its first drug candidate, CaPre was completed. The efficacy of CaPre was evaluated in the same animal model, the Zucker Diabetic Fatty (ZDF) model, with which, as previously reported, CaPre demonstrated significant anti-dyslipidemic effects associated with substantial elevations of HDL-C or good cholesterol . CaPre was administered for 3 months at a daily human equivalent dose of 500mg and 2,500mg in both ZDF diabetic (established, severe, type 2 diabetes) and normal healthy rats. Both rat phenotypes were subjected to oral glucose tolerance tests (OGTT). In medical practice the OGTT is commonly used to test for diabetes and insulin resistance. It involves the oral administration of high amounts of glucose in order determine how quickly it is cleared from the blood. The test may be performed as part of a panel of tests, such as the comprehensive metabolic panel. Treatment of severely diabetic rats with CaPre was shown to significantly reduce impaired glucose tolerance within 1 month of treatment, with the higher dose being only slightly more effective than the lower dose. After 3 months, the ZDF rats had established a normal tolerance to glucose analogous to the healthy rats. Also, the healthy rats continued to tolerate glucose normally, indicating another safety parameter for CaPre .

Neptune-Funded Subcontracted Research

- NKO[®] (NPK-40) bioavailability testing was completed.
- NPK-D organoleptic management for implementation of NKO[®] in daily functional food and specialized medical food.
- Acasti has worked with a team of world renowned experts dedicated to functional testing and development of therapeutic candidates for arresting and reversing atherosclerosis through modulation of HDL, Reverse Cholesterol Transport (RCT), and Immune Mediators. The first of a series of experiments was undertaken by VascularStrategies LLC, Pennsylvania, to unravel the mechanism of action of the active pharmaceutical ingredients (API) which was conducted in three (3) mouse models reflecting healthy state and moderate to severe dyslipidemia has been completed. After only 6 weeks of treatment at very low doses ranging from 0.5g

to 2.0g, Acasti API achieved a statistically significant increase of HDL and reduction of LDL while achieving up to a 60% reduction of triglycerides; a considerably better effect than prescription omega-3 esters.

- NeuroBiopharm (NBP) completed a pre-clinical study in collaboration with NeuroCode AG, (Wetzlar, Germany), a team of recognized experts dedicated to specific profiling of active pharmaceutical ingredients by means of electroencephalographic (EEG) power spectra of conscious free moving rats. The objectives of the trial were a) to determine the nature and extent of effect of the new NBP medical food candidate NKPL on the electrical activity of the brain, and b) to characterize the EEG effects in relation to standard central nervous system (CNS) drugs. At the lowest daily dose of 250mg, NKPL showed a significant effect strongly resembling (by 80% and 100%) the activity of methylphenidate or Ritalin®, a drug recognized as the gold standard for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This data provides evidence that NKPL, a highly concentrated phospholipid extract, may be an effective treatment for children with ADHD and a safe alternative to Ritalin®. NBP will be advancing its research towards the development of a readily available product aimed to improve the cognitive and emotional health of children and adults, in the near future.

Alliance Funded Research

- Research on indications proving compliance with the European Food Safety Associations Medical Health Claim criteria and regulations.
- NKPL53 efficacy testing in preparation for IND submission approval.

Completed Clinical Studies

Neptune is continuously investing in medical research aimed at demonstrating the benefits of its products on human health. In 2009, Neptune completed a clinical trial entitled Evaluation of the bioavailability and steady state assessment of EPA and DHA of Neptune Krill Oil compared to pharmaceutical grade EPA & DHA esters, combination of bioactives simulating NKO® and fish oil .

- This study was completed September 2008 and final results were submitted by the CRO (Clinical Research Organizations) in February 2009. Preliminary results were presented in the Supply Side West trade show and conference in Las Vegas (October 2008) and Health Ingredients Congress in Paris (November 2009).

In 2008, Neptune instigated a clinical trial relating to the evaluation of the effects of Neptune Krill Oil and superior effect of NKO® over fish oil on global cognitive function in patients with mild to moderate neurodegenerative disease. The study is entitled Multi-center, doubled-blind, placebo-controlled, monotherapy study of NKO in early stage of Alzheimer's disease (The Mnemosyne trial) .

- The clinical study protocol was finalized and approved by ethics. Study sites have been selected, audited and recruited. Recruitment has commenced with more than one third of the patients recruited in 2009. The trial is projected to be completed before the fall 2010.

1. Skin Cancer

The results of a pre-clinical animal study on the effects of NKO® on the prevention of skin cancer caused by UV radiation indicate that NKO® may prevent skin damage caused by chronic exposure to UV radiation.

2. Premenstrual Syndrome

The results of a double blind clinical study on the effects of NKO® on the management of premenstrual syndrome (PMS) published in May 2003 in a medical journal - the Alternative Medicine Review (Sampalis et al., 2003; 8(2): 171-179) demonstrate, with a high degree of certainty, that NKO® can significantly reduce both the physical and emotional symptoms associated with PMS (premenstrual syndrome), and that it is significantly more effective than fish oil (omega-3 18:12) in the management of physical and emotional dysmenorrheal symptoms.

3. *Hyperlipidemia*

The results of a double blind clinical study on the effects of NKO[®] on hyperlipidemia (high cholesterol) demonstrate with a high degree of certainty that:

- NKO[®] is safe and effective in controlling hyperlipidemia by significantly reducing total cholesterol levels, LDL (bad cholesterol) and triglycerides, while increasing HDL (good cholesterol) to as yet unmatched levels without adverse effects. These effects were evaluated on patients who are resistant to statins, who failed to attain their target LDL levels after at least six months of low dose statin treatment.
- NKO[®] (1 - 1.5 g/day) was shown to be safe and significantly more effective than fish oil in the management of hyperlipidemia. In the same study, NKO[®] was shown to achieve a significantly greater reduction of LDL levels and increase of HDL levels as compared to fish oil (3g/day). These results were generated among statin-resistant patients, who failed to attain the target LDL levels after at least six months of low dose statin treatment.

Cardiovascular Risk Modification Analysis

- The results of an independent risk modification analysis of the hyperlipidemia study data based on the Framingham model have shown that patients treated with NKO[®] can achieve a significantly reduced risk for cardiovascular events and significantly higher chance to prevent cardiovascular events over a 10-year period when compared to those treated with fish oil or for the statin resistant patients treated with low dose statin.

Health Economics Analysis

- An independent health economics analysis of the hyperlipidemia data showed that NKO[®] monotherapy as well as NKO[®] co-administered with a low dose statin was significantly more cost-effective than all other interventions studied for all types of cardiovascular events aggregated.
- From a cost-benefit perspective, NKO[®] was shown to be the most favorable treatment alternative for angina, congestive heart failure, stroke, myocardial infarction, Percutaneous Transluminal Coronary Angioplasty (PTCA), fatal myocardial infarction and coronary artery bypass graft surgery (CABG); NKO[®] has a negative cost-benefit indicating that the cost of acquisition is less than the benefits derived from the intervention.
- With respect to death and cardiac arrests that are rare events, the cost-benefit ratio is positive indicating the acquisition cost is higher than the benefits derived. However, NKO[®] remained the least expensive alternative for these rare events.

4. *Chronic Inflammation and Osteoarthritis*

A Phase II clinical study on the effects of NKO[®] on conditions relating to chronic inflammation and osteoarthritis, published in May 2007 in the peer-reviewed medical journal - Journal of the American College of Nutrition - demonstrated that NKO[®] within a short treatment period can significantly reduce the C-reactive protein and osteoarthritic symptoms in patients diagnosed with a chronic inflammatory disease.

5. *Attention Deficit Hyperactivity Disorder (ADHD)*

The clinical results obtained during an open label pilot study demonstrated that NKO[®] may significantly improve cognitive function (among others concentration, planning skills and focus) of adults suffering from ADHD. The recorded observations were indicative of the neurological advantages of using Neptune Krill Oil over a controlled period of time. These results corroborate the short-term direction of the Company in terms of its clinical research initiatives.

Raw Material

Krill is a generic term of Norwegian origin designating 85 species of deep and cold water pelagic marine planktonic animal (zooplankton) constituent of the global marine biomass.²³

Krill looks like miniature shrimp. The smallest species of krill, found in the Pacific Ocean, measures approximately 1 cm.²⁴ The larger Antarctic krill can grow up to 6cm. Krill is the most abundant animal biomass on the planet and is found in schools that can sometimes cover several square kilometres of ocean.²⁵

There are two primary ocean regions where krill is harvested: the Southern Ocean (Antarctic krill) and the North Pacific Ocean (Pacific krill, mainly off the coasts of Japan and Canada). The total quantity of krill in these two oceans is conservatively estimated to be at least 500,000,000 metric tonnes (mt). From these two oceans, a total of some 150-189,000 mt of both krill species is harvested annually.²⁶ Of that total from 1997/98 until 2007/08, 90-129,000 mt originated from the Southern Ocean (Antarctic krill or *Euphausia superba*)²⁷ and an average annual catch of 60,000 mt from the Pacific (Pacific krill or *Euphausia pacifica*).²⁸ The catches represent less than 0.1% of the existing resource. In 2008/2009 the main countries that harvest krill are China, Japan, Norway, Poland, Russia and South Korea. From 2005/06 to 2007/08, annual quotas for Antarctic Krill have increased by 34%.²⁹ Annual quotas of 6,555 million tons 2010/09 are the same as for 2008/09. The data leads us to believe that: the resource is abundant, accessible and has a potential for long-term sustainable exploitation with adequate traceability measures. The average market price for whole frozen krill is around \$1,000/mt. Neptune maintained successful negotiations with major krill suppliers to ensure long-term supply, quality and competitive prices. Whole frozen krill prices can be volatile as they are affected by, among other factors, the amount of krill fished in any single year; however prices have been relatively consistent in recent years.

The Company sources its krill used in the manufacturing of its products from three suppliers. The Company considers that its relationship with its suppliers is good and that it is not dependent upon these suppliers, as alternative sources of supply are available.

Sales Distribution

Neptune manufactures its products at its Sherbrooke plant and sells NKO[®] in bulk oil or in capsules to its distributors, who commercialize it under their private labels in multiple market segments, including health food stores, mass markets (food and drug), direct sales (MLM, internet, catalogue, radio) and via healthcare professional recommendation. The NKO[®] encapsulation is subcontracted by third parties in Canada, USA and Europe. 100% of Neptune NKO[®] sales revenues during the year ended February 28, 2010 and the nine-month fiscal period ended February 28, 2009 were derived from independent companies.

²³ Tony J. Pitcher, Series Foreword, page vi in Inigo Everson editor, *Krill: biology, ecology, and fisheries*, Fish and aquatic resources series 6, Blackwell Science Ltd, 2000.

²⁴ R.D. Kathman et al., *Identification Manual to the Mysidacea and Euphausiacea of the Northeast Pacific*, Canadian Special Publication and Aquatic Sciences 93, 1986, p. 269.

²⁵ Stephen Nicol, *Time to Krill?*, Australian Antarctic Division, 1995, pages 2-3.

²⁶ World Health Organization (WHO), *Nutritional Value of Antarctic Krill*, 1995, Bulletin 73; S. Nicol & Y Endo. Krill fisheries: Development, management and ecosystem implications. *Aquatic Living Resources* 12(2), 105-120. 1999; R. Shotton, B17. Southern Ocean FAO Statistical Areas 48, 58 and 88, Review of the state of world marine fishery resources, FAO, Marine Resources Service, Fishery Resources Division, Fisheries Technical Paper 457, pp. 158-162, 2005. V. Siegel. Distribution and population dynamics of *Euphausia superba*: summary of recent findings. *Polar Biology* 29: 1-22, 2005.

Commission for the Conservation of Antarctic Marine Living Resources / CCAMLR, *Understanding CCAMLR's Approach to Management*, May 15, 2000; SC-CCAMLR-XXV Report of the twenty-fifth meeting of the Scientific Committee, October 2006; CCAMLR. Schedule of conservation measures in force 2008/09, 2008. CCAMLR, Statistical Bulletin, Volume 20 (1998-2007) CCAMLR-SB/0820, 2008; T. Ichii, Krill Arvesting, 9.3 Japanese northeastern coastal waters *Euphausia pacifica* Chapter 9, in *Krill: Biology, Ecology and Fisheries*, Fish and aquatic resources series 6, Blackwell Science Ltd, 2000

²⁸ CCAMLR op. cit.

²⁹ World Health Organization (WHO), *Nutritional Value of Antarctic Krill*, 1995, Bulletin 73; S. Nicol & Y Endo. Krill fisheries: Development, management and ecosystem implications. *Aquatic Living Resources* 12(2), 105-120. 1999; R. Shotton, B17. Southern Ocean FAO Statistical Areas 48, 58 and 88, Review of the state of world marine fishery resources, FAO, Marine Resources Service, Fishery Resources Division, Fisheries Technical Paper 457, pp. 158-162, 2005. V. Siegel. Distribution and population dynamics of *Euphausia superba*: summary of recent findings. *Polar Biology* 29: 1-22, 2005.

During the fiscal year ended February 28, 2010, more than 98% of the Company's sales were made to customers based outside Canada. The Company enters into hedging instruments from time to time to partly offset currency risks.

The Company's primary lines of business are not subject to any significant seasonal fluctuations.

Licenses / Intangibles

Though the Company uses, for its production, its own process technology, which is protected by trade secrets, the Company also strategically exploits, within its intellectual property portfolio, an exclusive, irrevocable worldwide license on a patent related to an extraction process belonging to the University of Sherbrooke (the University). The License Agreement applies to the process of oil extracted from krill and from other marine and/or aquatic biomasses. In consideration for the grant of such license, the University is entitled to receive from the Company, until a buyout of the patent by the Company, royalties of 4% of the net sales of krill oil extracted using the University's process, by the Company, by any sublicensee or by any person associated with the Company or any sublicensee.

The License Agreement stipulates that the Company shall remain the sole owner of any improvement and/or modification and/or enhancement of the extraction process done and/or paid for the Company. The License Agreement also stipulates that the University shall remain the sole owner of any improvement and/or modification and/or enhancement of the extraction process done and/or paid for the University. Thus, the Company, for a period of 24 months following any such improvement and/or modification and/or enhancement by the University, has the right to enter into an exclusive license agreement with the University with respect to any such improvement and/or modification and/or enhancement. No such improvement and/or modification and/or enhancement has been reported to the Company by the University.

The License Agreement may be terminated (i) by way of agreement between the University and the Company; (ii) in the event of a default by the Company or the University; (iii) in the event of the insolvency or bankruptcy of the Company; or (iv) if the Company ceases to carry on its activities in the normal course of business.

The Company also benefits from a right of first refusal with respect to any research project for the development of a process to extract and purify oils originating from marine and freshwater biomasses and from an option to purchase the intellectual property rights with respect to the results of the related research conducted by the University. The exercise price for this purchase option has been set at \$275,000 by mutual agreement between the University and the Company. This price was contested by the researcher but will remain the same based on the decision of the appeal court rendered in 2009 (see Item 8A: Legal Proceedings).

On August 18, 2004, the Company notified the University of its intention to exercise its \$275,000 purchase option relating to the intellectual property. As per the licensing agreement between the University and the Company, the terms of payment are as follows: \$100,000 on the transfer date of the intellectual property, \$50,000 on the first anniversary date of the transfer, \$50,000 on the second anniversary and \$75,000 on the third anniversary.

The Company is no longer dependent on the license agreement mentioned above, as the Company has developed and now manufactures its products with its own proprietary technology process platform Neptune Ocean Extract.

Brand Names and Trademarks

Neptune has registered the trademarks OPA³ and NKO[®] in over thirty countries. Neptune OceanExtract[™] and NKA are other trademarks of Neptune.

- NKO[®] distributors apply private labels while including the NKO[®] logo; private label names are pre-approved by Neptune.

- Licenses: Neptune has licensed worldwide commercialization rights for NKO[®] in functional food for specific food categories and health indications to Nestle and Yoplait. It has also signed an agreement with Bayer Healthcare for the commercialization of Neptune proprietary products in the United States. The Company is in negotiations to further expand the functional food market with strategic alliances with other large well-known food companies.

- Acasti has applied for worldwide trademark protection of CaPre (name given to its prescription drug candidate).

Patents

Neptune has the following patent portfolio:

Category	Description	Countries	
		Issued	Pending
Novel Phospholipid/ Flavonoid	Composition of Matter	25	6
Cardiovascular Neurological health	Method of Use	24	6
Health Applications	Method of Use	-	30
Process	Process	34	1

Acasti has initiated its patent portfolio with its first application as a USA provisional company of a composition use patent.

Trade Secrets

Neptune protects its optimization and extraction processes through industrial trade secrets. Regulatory approvals Neptune has obtained the following regulatory approvals, permits and authorizations:

- European Food Safety Authority (EFSA) has approved NKO[®] as PARNUTS for commercialization in the European Union.
- European Food Safety Authority (EFSA) has approved NKO[®] as a Novel Food for commercialization in the European Union.
- NKO[®] has received US-FDA GRAS (Generally Recognized as Safe) notification as a human food ingredient in the United States.
- NKO[®] has obtained approval as a Complementary Medicine from the Therapeutic Goods Administration (TGA) in Australia.
- NKO[®] has a natural product number (NPN) issued by Health Canada.
- Neptune production plant in Sherbrooke accredited as a nutraceutical GMP (Good Manufacturing Practices) following an audit performed by Health Canada, Natural Health Product Directorate (NHPD).

The development, production and commercialization of biopharmaceutical products is generally subject to comprehensive regulations under Health Canada's Therapeutic Products Program and various other national, regional and local regulatory bodies, including the Food and Drug Administration in the United States. Distribution of the Corporation's products outside Canada and the United States is also subject to comprehensive government regulation. Regulations, specifically requirements in respect of product releases, the time involved in respect of regulatory assessment and the sanctions imposed in the event of infringement vary from country to country.

C. Organizational Structure

Neptune has two wholly-owned subsidiaries, NeuroBioPharm Inc. and Neptune Technologies & Bioresources USA Inc. (Neptune USA) and one majority-owned subsidiary Acasti Pharma Inc. (Acasti).

Acasti was incorporated on February 1, 2002 pursuant to a certificate of incorporation issued under Part IA of the *Companies Act* (Québec), under the name 9113-0310 Québec Inc.

Neptune USA was incorporated on June 1, 2006 under the laws of the State of Delaware. Neptune USA does not carry on business at this time.

NeuroBioPharm was incorporated on October 15, 2008 pursuant to a certificate of incorporation issued under Part 1A of the *Companies Act* (Québec), under the name NEUROVIMER PHARMA INC.

Corporate Structure Diagram

Neptune owns 28,784,133 Class A shares, representing 60.4% of all Class A shares issued and outstanding of Acasti Pharma. Acasti Pharma Class A shares are voting with no par value.

Neptune owns 4,950,000 Class B shares, representing 99% of all Class B shares issued and outstanding of Acasti Pharma. Acasti Pharma Class B shares are voting (ten votes per share), non-participating, with no par value and bear a maximum annual non-cumulative dividend of 5%. Acasti Pharma Class B shares are exchangeable, at the holder's discretion, for Class A shares, on a one-for-one basis. Acasti Class B shares are also redeemable at the holder's discretion at 0.80\$ per share, subject to certain conditions. Neptune controls 80.2% of Acasti Pharma voting rights.

D. Property Plant and Equipment

Neptune owns a 14,887 square-foot laboratory and production facility in Sherbrooke, Québec, Canada. Neptune owns a full complement of equipment used in all aspects of its research, development and manufacturing work. Neptune believes that its facilities are adequate for its current needs and that additional space, when required, would be available on commercially reasonable terms. Neptune's head office is located in Laval, Quebec in a 5,007 square-foot leased office space. The lease agreement expires December 21st 2013. Neptune, through its subsidiary Acasti, also operates animal clinical trials in a 295 square-foot leased facility located in Montréal, Québec. This lease agreement expires September 15th, 2011.

ITEM 4A: UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 5: OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion of our financial condition and results of operations is based upon and should be read in conjunction with our financial statements included as Exhibit F-1 to this annual report. Our financial statements have been prepared in accordance with Canadian GAAP, and therefore differ from financial statements prepared in

accordance with U.S. GAAP. For a further discussion of these differences, see note 27 to our 2010 audited consolidated financial statements included as Exhibit F-1 in this annual report.

For a discussion of our foreign exchange risk and related hedging risk programs, see Item 11: Quantitative and Qualitative Disclosure About Market Risk .

A. Operating Results and B. Liquidity and Capital Resources
Management Analysis of The Financial Situation and Operating Results/Management Discussion and Analysis

This analysis is presented in order to provide the reader with an overview of the changes to the consolidated financial position and operating results of Neptune Technologies & Bioresources Inc. (Neptune or the Company) including its subsidiaries, Acasti Pharma Inc. (Acasti) and NeuroBioPharm Inc. (NeuroBioPharm). This analysis explains the material variations in the audited consolidated statements of earnings, financial position and cash flows of Neptune for the year ended February 28, 2010, as well as for the nine-month period ended February 28, 2009. During the fiscal period ended February 28, 2009, the Company changed its fiscal year-end to February 28 from May 31. For comparative purposes, the Company has explained the variations between the twelve month period ended February 28, 2010 and the unaudited twelve-month period ended February 28, 2009 as well as between the nine-month period ended February 28, 2009 and the unaudited nine-month period ended February 28, 2008.

This analysis must be read in conjunction with the Company s audited and consolidated financial statements as at and for the period ended February 28, 2010 which are prepared in accordance with Canadian Generally Accepted Accounting Principles (GAAP). Additional information o the Company as well as is Annual Report and its Annual Information Form can be found on the SEDAR website at www.sedar.com or on the Securities and Exchange Commission s EDGAR website at www.sec.gov. For a reconciliation to United States GAAP, as well as the information required for the presentation of the financial statements according to US GAAP by virtue of the Securities and Exchange Commission rules and regulations, see Item 8, note 27 to our 2010 audited consolidated financial statements included in Exhibit F 1 to this annual report.

All dollar amounts in this document, with the exception of per-share amounts or unless otherwise noted, are in thousands of Canadian dollars.

OVERVIEW

As a result of a reorganization of activities during fiscal 2009, the Company has three reportable operating segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune), the second is the development and commercialization of pharmaceutical applications for cardiovascular diseases (Acasti Pharma) and the third is the development and commercialization of pharmaceutical applications for neurological diseases (NeuroBioPharm).

NEPTUNE

The Company continues to expand its customer base worldwide and is expecting revenue growth driven by repeat demand from existing customers and incoming demand from new customers from North America, Europe and Asia. Neptune also completed its plant expansion and the scaling up of production capacity at its Sherbrooke plant during the first and second quarter providing for more than a 50% increase of yearly output from 60,000 kilograms to close to 100,000 kilograms. The integration of new technical equipment into the manufacturing line and the completion of the capacity expansion were completed on schedule, at the end of the first quarter. The ramp-up of the facility, which took place during the second quarter, impacted the financial results in the second quarter but the Company has managed to catch up with the production in the third and fourth quarter to surpass last year annualized revenues. During the third quarter and fourth quarter, the production plant ran at a steady rate of over 100,000 kg annually. In order to respond to increased demand and deliver on its volume commitments, Neptune is currently working to further expand its production capacity from 100,000 kg to an estimated 120,000 to 130,000 kg annually. This additional expansion is expected to take place during the first two quarters of fiscal 2011. This expansion should take place without production interruption and represents a marginal investment financed by cash flow from current operations. Neptune s

additional industrial plant project discussions are on schedule, with the target for the new industrial plant realization to take place during the course of calendar 2012.

During the first quarter of fiscal 2010, the Company signed an agreement with Bayer Healthcare LLC for the commercialization of Neptune proprietary products in the United States. Also in the first quarter, Neptune entered into a new distribution agreement with Inno-Vite, a Canadian leader in innovative health products focusing on research-proven ingredients. Inno-Vite launched Neptune Krill Oil - NKO® under the brand name Inno-Krill in health food stores across Canada. During the second quarter, Weifa, a leading pharmaceutical company also launched NKO® for the first time in the Norwegian market in drug stores for women's health.

The Company presented novel innovative product opportunities customized for dietary supplements, functional and medical foods at Vitafoods International 2009. Neptune launched a new pipeline of novel formulations containing its proprietary marine omega-3 phospholipids enhanced with validated bioactive ingredients targeted to specific health applications. The Company is also testing the industry's reception of a new biomass extract generated from Neptune's research and development program targeting new vascular and affective health indications. The Company will also be presenting pilot commercial products for functional food applications including juice, fruit berries, fruit paste and protein bars.

The Company also sustained its clinical research initiatives. As a result, Neptune is able to leverage scientific results demonstrating health benefits specific to the proprietary composition of Neptune Krill Oil - NKO® on prevalent human conditions, such as premenstrual syndrome, high cholesterol, inflammation, osteoarthritis and attention deficit hyperactivity disorder. Similarly, the clinical trials for functional/medical food applications with the multinational corporations Yoplait and Nestlé are progressing in a satisfactory way.

During the second quarter, the Company received a complaint filed by Schiff Nutrition Group Inc. ("Schiff"), a former distributor of Neptune's products, in the United States District Court for the District of Utah, Central division, alleging that Neptune failed to meet certain delivery thresholds. As a result, Schiff is seeking monetary damages in the amount of at least US \$1 million from Neptune.

After careful review of this complaint and having sought legal advice, the Company filed a response and counterclaims early in the third quarter to the Schiff complaint in federal district court in Utah. The Company denies all material allegations and the requested monetary compensation in the complaint and asserts federal and state law claims against Schiff, including that Schiff failed to pay the Company for shipments of NKO® accepted by Schiff, and that Schiff caused its contractor to encapsulate NKO® despite the Company's objections that the resulting product would not meet specifications after encapsulation by Schiff's contractor.

Despite the Company's warning to Schiff Nutrition Group Inc. to cease directly and indirectly using the Company trademarks including NKO® and clinical support, Schiff Nutrition Group Inc. continued to use the Company trademarks and claims, as it was seen on websites of multiple Schiff Nutrition Group Inc. distributors.

No provision has been recorded by the Company as at February 28, 2010 for this matter because the outcome and the amount of loss, if any, is not determinable.

In the third quarter, the Company announced that convertible debentures with a principal value of \$2,250 had been converted. Holders of \$84 of debenture capital converted capital and accumulated interest into Neptune units resulting in the issuance of 69,783 common shares and 34,891 warrants of Neptune. Neptune warrants are exercisable until October 9, 2011 at various prices ranging from \$2.05 to \$2.25 depending on the market price of Neptune shares at their date of conversion. Holders of \$2,166 of debenture capital chose to convert into Acasti Pharma Inc. units resulting in the transfer from Neptune to the former debenture holders of 9,455,867 Acasti Class A shares and the issuance of 9,455,867 Acasti call options by Neptune. Acasti call options are exercisable at \$0.50 and expire one year after their issuance. As at February 28, 2010, \$496 of convertible debentures remains outstanding.

In the third quarter, Neptune also converted all of its 38,240,000 Acasti Class C shares into Acasti Class A shares as per the terms of the shares. After all conversions and transfers Neptune owns 28,784,133 Acasti Class A shares and

4,950,000 Acasti multi-voting Class B shares.

In regards to its intellectual property protection, the Company has always had a firm policy to protect its intellectual property rights including its patents, trademarks and trade secrets, with every legal means available. Recently, certain of Neptune's competitors have been marketing, advertising and selling their finished krill-based products claiming benefits based on Neptune's research or by infringing on patents for which Neptune has exclusive rights. Neptune, being determined to enforce its rights, has thus filed suits against some of those companies in order to protect its intellectual property.

The Company has also decided to exercise its right to appeal the decision of the European Patent Office regarding the European composition of phospholipids and use patent. The Company does not agree with the decision that states that Neptune's Patent does not sufficiently disclose the invention. With the filing of an appeal, the decision to revoke the patent is suspended and the patent remains enforceable until appeal is heard.

In the third quarter, the Company also filed a patent infringement lawsuit against Aker Biomarine ASA, Jedwards International, Inc., and Virgin Antarctic LLC. The complaint, which was filed in the U.S. District Court for the District of Massachusetts, alleges infringement of U.S. Patent No. 6,800,299. The patent is directed to a method of extracting total lipid fractions from krill.

In the fourth quarter, the Company received a ruling on its appeal against the December 2008 ruling against the Company's Intellectual Property purchase option. In this new ruling, the Court of Appeal confirmed Neptune's right to exercise its purchase option related to its Intellectual Property at a purchase price of \$275 plus interest. The court also confirmed that Neptune had exercised its option on August 18, 2004 and rejected all royalty claims with the exception of \$36 plus interest.

ABOUT THE SUBSIDIARIES

Acasti Pharma Inc. (Acasti)

During the fiscal period ended February 28, 2009, the Company transferred an exclusive worldwide license to its subsidiary, Acasti, to research and develop new active pharmaceutical ingredients (API) based on Neptune's proprietary omega-3 phospholipid technology and intellectual property (the License). To further product development Acasti initiated IND-enabling research aiming towards IND/CTA allowance by the US-FDA and Health Canada in order to further validate the safety and effectiveness of its APIs for the prevention and treatment of cardiovascular conditions in Phase I and II a/b clinical studies. Acasti's new pharmaceutical products are prepared for licensing to potential pharmaceutical alliances as OTC, prescription medical food and drug products. In consideration for the license, Acasti issued 5,000,000 class B shares, 26,000,000 class C shares and 8,000,000 series 1 warrants to Neptune. Acasti will finance its research and development activities as well as its clinical studies. The products developed by Acasti are expected to require the approval of the U.S. Food and Drug Administration before clinical studies are conducted and approval of similar regulatory organizations before sales are allowed.

The Company uses Acasti to segregate its cardiovascular pharmaceuticals activities from its nutraceuticals activities, which in the opinion of Company's management will allow the financial community to differentiate Acasti's cardiovascular pharmaceutical activities from the Company's core nutraceuticals business and will also enable the Company and Acasti to separately attract nutraceutical and pharmaceutical companies to enter into strategic alliances.

On July 17, 2008, the Company's Board of Directors declared a dividend to its shareholders. The Board of Directors approved a dividend of \$0.00025 per share on the outstanding common shares of the Company for payment to shareholders on record at the close of business on July 28, 2008. This dividend was paid on August 11, 2008 by the issuance of an aggregate of 9,380,355 transferable, non-convertible notes (the Notes), each note having a principal value of \$0.001, maturing two years after the date of issue, bearing interest from the first anniversary date of their issuance at a rate of ten percent (10%) per annum, and being redeemable at all times by the Company, either in cash or in kind.

On August 21, 2008, the Company's and Acasti's Boards of Directors approved an exchange offer to be offered by Acasti to all of the holders of Notes, to purchase the Notes at a price equal to the Notes' value, payable by the issuance by Acasti of a maximum of 9,380,355 of its Class A shares and of 9,380,355 of its Series 2 warrants (Acasti Units). At the same date, Acasti adopted a stock option plan and granted 3,175,000 options to its directors, officers and employees effective October 8, 2008. The Acasti stock option plan and the granting of the options are subject to applicable regulatory approval and/or compliance with other conditions, if required.

On August 25, 2008, Acasti proceeded with the exchange offer to Neptune's Noteholders. Each Noteholder had until October 3, 2008 to accept or refuse to exchange their Note against an Acasti unit. The approval for the exchange offer by the Company's shareholders was obtained on September 25, 2008.

On October 8, 2008, Acasti exchanged its 8,000,000 series 1 warrants issued in connection with the licence transfer mentioned previously for 6,000,000 series 4 warrants and 2,000,000 series 5 warrants. After the exchange, the Company proceeded with a distribution having a nominal value of less than \$1 to Neptune stock option holders who did not benefit from the Acasti exchange offer and resulting in the grant of 4,045,000 series 4 Warrants of Acasti to insiders dedicated to the subsidiary of the Company and 1,280,000 series 4 Warrants of Acasti to the employees dedicated to the subsidiary of the Company. The Warrants will be liberated subject to applicable regulatory approval and/or compliance with other conditions, if required.

On October 9, 2008, the Company completed a private placement of \$2,750,000 by the issuance of convertible debentures in tranches of \$1,000, bearing interest at 8% per annum, payable annually in cash or in kind and expiring on October 9, 2011. Several financial instruments were attached to the debenture and various choices are offered to the debenture holders with respect to conversion in share capital of Neptune or Acasti (see note 14 to the consolidated financial statements).

On November 27, 2008, Acasti had issued to Neptune's shareholders 9,246,935 units in consideration of 9,246,935 Notes payable by the Company following the choice by the shareholders on the exchange offer as well as the outstanding notes prepayment. For the foreign shareholders for whom the Company could not proceed with the prepayment for regulation issues, a cash payment of \$149 was made.

The status of Acasti's new pharmaceutical products, over-the-counter (OTC), prescription medical foods, and prescription drug products, is as follows:

During 2010 fiscal year, Acasti made significant progress in its scientific research and development programs and has achieved several value-creating milestones within the OTC, medical food and prescription drug programs (Rx). Acasti negotiated a deal with a non-disclosable partner to commercialize an OTC product in the USA, Brazil and Canada. Furthermore, the selection process of potential partners for co-development of Rx, OTC and medical foods is completed and Acasti has implemented its operational plans towards the execution of pre-marketing and commercialization.

Acasti announced publicly its significant pre-clinical results in prestigious and international conferences. The preclinical study results were presented at the council for Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2010 Scientific Sessions Meeting of the American Heart Association in San Francisco, CA. The results of the study entitled "CaPre, an Omega-3: Phospholipid, Managing Dyslipidemia in Three Murine Phenotypes" were presented by Dr. Steven J. Adelman, Ph.D., FAHA, CEO/Founder of Vascular Strategies LLC. This study, conducted in collaboration with Professor Daniel Rader, University of Pennsylvania School of Medicine, and Dr. Steven J. Adelman, evaluates the mechanism of action of Acasti's prescription drug candidate (omega-3 phospholipid CaPre) for the treatment of dyslipidemia and cardio-metabolic disorders. CaPre was shown to be effective in beneficially modulating the lipid profile of healthy and diseased mice with high cholesterol, obesity and diabetes. CaPre significantly reduced triglycerides (60%) and bad cholesterol - LDL (28%) while simultaneously increasing good cholesterol - HDL (25%).

The efficacy of CaPre was evaluated in Zucker Diabetic Fatty (ZDF) model, with which, as previously reported, CaPre demonstrated significant anti-dyslipidemic effects associated with substantial elevations of High-density lipoprotein-Cholesterol (HDL-C) or good cholesterol. CaPre was administered for 3 months at a daily human equivalent dose of 500mg and 2,500mg in both ZDF diabetic (established, severe, type 2 diabetes) and normal healthy rats. Both rat phenotypes were subjected to oral glucose tolerance tests (OGTT). In medical practice the OGTT is commonly used to test for diabetes and insulin resistance. It involves the oral administration of high amounts of

glucose in order determine how quickly it is cleared from the blood. The test may be performed as part of a panel of tests, such as the comprehensive metabolic panel. Treatment of severely diabetic rats with CaPre was shown to significantly reduce impaired glucose tolerance within 1 month of treatment, with the higher dose being only slightly more effective than the lower dose. After 3 months, the ZDF rats had established a normal tolerance to glucose analogous to the healthy rats. Also, the healthy rats continued to tolerate glucose normally, indicating another safety parameter for CaPre .

Along with this endeavor Acasti received positive feedback from pre-IND and pre-CTA respectively from FDA and Health Canada to pursue the pharmaceutical development of CaPre . Acasti has now identified a GMP manufacturing site to comply with the regulations of pharmaceutical development.

From a business development perspective, Acasti showcased its platform and product to a variety of pharmaceutical companies through international business development meetings (Annual Alliance Management congress and Annual Combination Drug Therapies Conference, both organized by the Cambridge Healthtech Institute (CHI) and the BioPharmaceutical Strategy Series). Acasti presented its strong positioning in the field of Cardiometabolic disorders and its action plan for successful collaboration with worldwide pharmaceutical industry leaders and its strategy for implementation. Acasti intensified its position on its corporate strategy in seeking alliances for its new product lines, while providing opportunities for in/out licensing agreements. Acasti is establishing itself with international and strategic industrial partners who are seeking a product to manage the complexity of mixed dyslipidemia associated with the ever-increasing problems of obesity and diabetes.

NeuroBioPharm Inc. (NeuroBioPharm or NBP)

On October 15, 2008, the Company transferred an exclusive worldwide license to research and develop new active pharmaceutical ingredients (API) based on Neptune s proprietary omega-3 phospholipid technology and intellectual property (the License). To further product development, NeuroBioPharm initiated IND-enabling research aiming towards IND/CTA allowance by the US-FDA and Health Canada in order to further validate the safety and effectiveness of its APIs for the prevention and treatment of neurological conditions in Phase I and IIa/b clinical studies. NeuroBioPharm s new pharmaceutical products are prepared for licensing to potential pharmaceutical alliances as OTC, prescription medical food and drug products. Each product will be developed and financed by NeuroBioPharm. The products developed by NeuroBioPharm are expected to require the approval of the U.S. Food and Drug Administration before clinical studies are conducted and approval of similar regulatory organizations before sales are allowed.

The Company is using NeuroBioPharm in order to segregate its neurological pharmaceuticals activities from its nutraceuticals activities, which in the opinion of Company s management will allow the financial community to differentiate the NeuroBioPharm neurological pharmaceutical applications activities from the Company s core nutraceuticals business and will also enable the Company and NeuroBioPharm to separately attract nutraceutical and pharmaceutical companies to enter into strategic alliances.

Also, on October 15, 2008, the Company transferred to NeuroBioPharm the development project and clinical study conducted under an agreement with a multinational company. NeuroBioPharm has assumed Neptune s role and responsibilities under this agreement which was signed at the end of August 2008 and covers the development of a medical food targeting a prevalent medical condition. The results of this clinical study should be known during the summer of 2010.

On December 24, 2008, the Company proceeded with a distribution having a nominal value of less than \$1 to Neptune employees and insiders dedicated to the subsidiary of the Company resulting in the grant of 3,800,000 series 4 Warrants of NeuroBioPharm to insiders and 1,280,000 series 4 Warrants of NeuroBioPharm to employees. The Warrants will be liberated subject to applicable regulatory approval and/or compliance with other conditions, if required.

Exploratory pre-clinical studies were completed evaluating the potential effects of the NBP pipeline on neurodevelopmental and cognitive function in comparison to the industry gold standards; the results are encouraging and indicative of neurobioactivity in frontal and temporal lobes.

The clinical trial evaluating the effect of the medical food in early stage Alzheimer disease is still progressing and is almost completed. The trial is done in multiple sites in different provinces in Canada. Under the prescription drug products, preclinical studies evaluating the toxicity, pharmacokinetics and mechanism of action of the prescription drug are designed. NBP was active in developing the OTC product (NKPL72 and NKPL43) and is still validating the process at large scale. Finally, NBP attempts to sign a license or rights of first refusal for OTC monotherapy and/or fixed dose combination treatments with at least one partner is still strongly on-going.

PRINCIPAL CONSOLIDATED FINANCIAL INFORMATION

(In thousands of dollars, except per share data)

	Twelve-month period ended February 28		Nine-month period ended February 28	
	2010 (Audited)	2009 (Unaudited)	2009 (Audited) recast ⁴	2008 (Unaudited)
	\$	\$	\$	\$
Sales and research contracts	12,664	11,724	8,589	7,129
EBITDA ¹	(1,190)	598	328	750
Net loss	(1,535)	(3,167)	(1,885)	(3,500)
Net loss per share and diluted loss per share	(0.040)	(0.084)	(0.050)	(0.095)
Total assets	17,566	18,154	18,154	14,106
Working capital ²	4,497	7,936	7,936	6,718
Shareholder equity	7,996	9,002	9,002	8,056
Book value per common share ³	0.209	0.239	0.239	0.215
Long term debt	6,275	5,731	5,731	2,676

¹ The EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by Canadian GAAP, the results may not be comparable to similar measurements presented by other public companies. Neptune obtains its EBITDA measurement by adding to net earnings, financial expenses, amortizations, income taxes and gains and losses on foreign exchange incurred during the fiscal year. Neptune also excludes the effects of non-monetary transactions recorded, such as share-based compensation and gain on dilution for its EBITDA calculation.

² The working capital is presented for information purposes only and represents a measurement of the Company's short-term financial health mostly used in financial circles. The working capital is calculated by subtracting current liabilities from current assets. Because there is no standard method endorsed by Canadian GAAP, the results may not be comparable to similar measurements presented by other public companies.

³ The book value per share is presented for information purposes only and is obtained by dividing the book value of shareholders equity by the number of outstanding common shares at the end of the fiscal year. Because there is no standard method endorsed by Canadian GAAP, the results may not be comparable to similar measurements presented by other public companies.

⁴ Giving effect to the adoption of new accounting standards related to intangible assets on March 1, 2009. See note 2(a) of the consolidated financial statements.

RECONCILIATION OF THE CONSOLIDATED EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (EBITDA)

A reconciliation of this non-GAAP financial information is presented in the table below. The Company uses non-GAAP measures to assess its operating performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than GAAP do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Company uses EBITDA to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating

performance, and because the Company believes it provides meaningful information on the Company financial condition and operating results.

Neptune obtains its Consolidated EBITDA measurement by adding to net earnings (net loss), financial expenses, amortizations, income taxes and losses on foreign exchange incurred during the fiscal year. Neptune also excludes the effects of non-monetary transactions recorded, such as share-based compensation and gain on dilution, for its Consolidated EBITDA calculation. The Company believes it is useful to exclude these items as they are either non-cash expenses, items that cannot be influenced by management in the short term, or items that do not impact core operating performance. Excluding these items does not imply they are necessarily nonrecurring.

RECONCILIATION OF NON-GAAP FINANCIAL INFORMATION

(Expressed in thousands, except per share amounts)

	Twelve-month period ended February 28		Nine-month period ended February 28	
	2010 (Audited)	2009 (Unaudited)	2009 (Audited) recast ¹	2008 (Unaudited)
	\$	\$	\$	\$
Net loss	(1,535)	(3,167)	(1,885)	(3,500)
Add (deduct):				
Amortization	768	685	531	441
Financial expenses	678	597	519	391
Stock-based compensation	485	3,479	2,172	3,184
Foreign exchange loss (gain)	636	(987)	(1,000)	234
Gain on dilution	(2,222)	(9)	(9)	-
EBITDA	(1,190)	598	328	750

¹ Giving effect to the adoption of new accounting standards related to intangible assets on March 1, 2009. See note 2(a) of the consolidated financial statements.

SELECTED CONSOLIDATED QUARTERLY FINANCIAL DATA

Fiscal year ended February 28, 2010

	Total	First Quarter	Second Quarter ¹	Third Quarter	Fourth Quarter
	\$	\$	\$	\$	\$
Sales and research contracts	12,664	2,878	1,371	3,758	4,657
EBITDA ²	(1,190)	(284)	(1,634)	440	288
Net income (loss)	(1,535)	(1,407)	(2,112)	2,023	(39)
Basic earnings (loss) per share	(0.04)	(0.037)	(0.056)	0.053	(0.001)
Diluted earnings (loss) per share	(0.04)	(0.037)	(0.056)	0.050	(0.001)

Nine-month period ended February 28, 2009 (Recast³)

	Total	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
	\$	\$	\$	\$	\$
Sales and research contracts	8,589	n/a ⁴	2,366	2,451	3,772
EBITDA ²	328	n/a ⁴	157	(708)	879
Net income (loss)	(1,885)	n/a ⁴	(598)	(1,360)	73
Earnings (loss) per share basic and diluted	(0.05)	n/a ⁴	(0.016)	(0.036)	0.002

Fiscal year ended May 31, 2008

	Total	First	Second	Third	Fourth
	\$	Quarter	Quarter	Quarter	Quarter
	\$	\$	\$	\$	\$
Sales and research contracts	10,264	2,085	2,169	2,876	3,134
EBITDA ²	1,020	332	70	348	270
Net loss	(4,779)	(1,051)	(1,563)	(886)	(1,279)
Loss per share basic and diluted	(0.130)	(0.029)	(0.042)	(0.024)	(0.035)

¹ Impact of first quarter plant shut down during second quarter of fiscal 2010.

² The EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by Canadian GAAP requirements, the results may not be comparable to similar measurements presented by other public companies. Neptune obtains its EBITDA measurement by adding to net earnings, financial expenses, amortization, income taxes and losses on foreign exchange incurred during the fiscal year minus gains on settlement of debentures. Neptune also excludes the effects of non-monetary transactions, such as share-based compensation and gain on dilution for its EBITDA calculation.

³ Giving effect to the adoption of new accounting standards related to intangible assets on March 1, 2009. See note 2(a) of the consolidated financial statements.

⁴ The Company changed its year end from May 31 to February 28 during fiscal 2009.

SEGMENT DISCLOSURES

The Company has three reportable operating segment structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune), the second is the development and commercialization of pharmaceutical applications for cardiovascular diseases (Acasti Pharma) and the third is the development and commercialization of pharmaceutical applications for neurological diseases (NeuroBioPharm).

For the fiscal year ended February 28, 2010 all revenues were generated by the nutraceutical segment with the exception of small revenue from research contracts in NeuroBioPharm. The continuity of all operations of the consolidated group are presently supported by Neptune revenues; Acasti Pharma and NeuroBioPharm operations are limited to product development in the OTC, prescription medical foods and prescription drug products as well as pre-clinical research.

NKO[®] is currently the only product sold in the nutraceutical market by Neptune. NKO[®] presently generates a gross margin that varies between 40% and 50% depending on the country and the market where it is sold. In the case of Acasti and NeuroBioPharm, several products have been developed but none is presently generating revenue. Acasti and NeuroBioPharm have adopted the same development strategy as Neptune, which is to generate short term revenue with OTC and prescription medical food products. It is impossible to evaluate a precise timeline for the launch of any of Acasti or NeuroBioPharm products as negotiations, are ongoing with potential partners.

The consolidated treasury flows are explained in the following section. Except as described below, significant consolidated cash flows are consistent with those of the nutraceutical segment. In regards to the cardiovascular segment, Acasti's operating activities generated a decrease in liquidities of \$1,999 mostly related to its operating loss as well as the changes in operating assets and liabilities. Acasti's investing activities generated liquidities of \$2,002 mostly related to the maturity of short-term investments. Acasti's financing activities generated an increase in liquidities of \$81 all related to the issuance of shares on exercise of warrants. Therefore, Acasti's cash position increased by \$84 for the year ended February 28, 2010.

The following table show selected financial information by segments :

Year ended February 28, 2010				
(Expressed in thousands)	Nutraceutical \$	Cardiovascular \$	Neurological \$	Total \$
Sales and research contracts	12 605	-	59	12 664
EBITDA	688	(1 559)	(319)	(1 190)
Net income (loss)	340	(1 556)	(319)	(1 535)
Total assets	16 653	913	-	17 566
Working capital	3 966	574	(43)	4 497
EBITDA calculation				
Net income (loss)	340	(1 556)	(319)	(1 535)
add (deduct)				
Amortization	759	9	-	768
Financial expenses	678	-	-	678
Stock-based compensation	485	-	-	485
Foreign exchange loss (gain)	648	(12)	-	636
Gain on dilution	(2 222)	-	-	(2 222)
EBITDA	688	(1 559)	(319)	(1 190)

COMMENTS RELATIVE TO THE SIGNIFICANT VARIATIONS BETWEEN THE THREE-MONTH AND TWELVE-MONTH PERIODS ENDED FEBRUARY 28, 2010 (AUDITED) AND THE THREE-MONTH AND TWELVE-MONTH PERIODS ENDED FEBRUARY 28, 2009 (UNAUDITED)**Revenue**

Revenue for the last quarter continued to increase to attain a record high of \$4,657 for the three-month period ended February 28, 2010, representing an increase of 24% compared to the three-month period ended February 28, 2009. Revenue for the twelve-month period ended February 28, 2010 increased to reach \$12,664, representing an increase of 8% compared to the twelve-month period ending February 28, 2009. This increase in the Company's revenue is mainly attributable to the aggressive penetration of the American, European and Australian markets due to the increasing awareness and recognition of NKO®.

Virtually all of the Company's sales are derived from the nutraceutical segments. In fiscal 2010, two customers accounted for 37.3% of total revenues.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

EBITDA decreased by \$591 for the three-month period ended February 28, 2010 to \$288, compared to \$879 for the three-month period ending February 28, 2009, a decrease of 67% over the corresponding quarter in 2009. EBITDA decreased by \$1,788 for the twelve-month period ended February 28, 2010 to \$(1,190), compared to \$598 for the twelve-month period ended February 28, 2009. The reason for the twelve-month period decrease is mainly due to the research and development expenditures incurred in Acasti and NeuroBioPharm for approximately \$1,000, and increases in litigation-related costs for approximately \$650.

Net Income (Loss)

The Company realized a consolidated net loss for the three-month period ended February 28, 2010 of \$39 or \$0.001 per share compared to a net income of \$73 or \$0.002 per share for the three-month period ended February 28, 2009. The net loss for the twelve-month period ended February 28, 2010 amounts to \$1,535 or \$0.04 per share, compared to a net loss of \$3,167 or \$0.084 per share for the twelve-month period ended February 28, 2009, an improvement of 52% from last year's corresponding period. These results are attributable to the decrease in the stock-based compensation charge by \$2,994 as well as the gain on dilution realized on the debenture conversion for an amount of \$2,222. These favorable variances were offset by an increase in research and development expenses mainly attributable to the two subsidiaries, Acasti and NeuroBioPharm, for an amount of approximately \$1,000 as well as a foreign exchange loss of \$636 for the twelve-month period ended February 28, 2010, compared to a foreign exchange gain of \$987 for the twelve-month period ended February 28, 2009.

COMMENTS RELATIVE TO THE SIGNIFICANT VARIATIONS BETWEEN THE THREE-MONTH AND NINE-MONTH PERIOD ENDED FEBRUARY 28, 2009 (AUDITED) AND THE THREE-MONTH AND NINE-MONTH PERIOD ENDED FEBRUARY 28, 2008 (UNAUDITED)

Revenue

Revenue for the last quarter continued to increase to attain \$3,772 for the three-month period ended February 28, 2009, representing an increase of 31% compared to the three-month period ended February 29, 2008. Revenue for the nine-month period ended February 28, 2009 increased to reach \$8,589 representing an increase of 20% compared to the nine-month period ended February 29, 2008. This increase in the Company's revenue is mainly attributable to the aggressive penetration of the American market due to the increasing awareness and recognition of NKO® as well as a favorable exchange rate on the American dollar.

Virtually all of the Company's sales are derived from the nutraceutical segments. In fiscal 2009, three customers accounted for 48.6% of total revenues.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

EBITDA increased by \$531 for the three-month period ended February 28, 2009 to \$879 compared to \$348 for the three-month period ended February 29, 2008, an increase of 155% over the corresponding quarter in 2008. EBITDA decreased by \$422 for the nine-month period ended February 28, 2009 to \$328 compared to \$750 for the nine-month period ended February 29, 2008, a decrease of 55%. The reason for the nine-month period decrease is mainly due to the research and development expenditures incurred in Acasti and NeuroBioPharm. On a comparative basis, EBITDA for the nutraceutical business for the nine-month period ended February 28, 2009 compared to the corresponding period in 2008 increased by 65% from \$750 to \$1,238 primarily due to increased sales and margins.

Net Income (Loss)

The Company realized for the first time on a consolidated basis a net profit for the three-month period ending February 28, 2009 of \$73 or \$0.002 per share compared to a net loss of \$886 or \$0.024 per share for the three-month period ended February 29, 2008, an increase in absolute dollars of \$957 from last year's corresponding quarter. The net loss for the nine-month period ended February 28, 2009 amounts to \$1,885 or \$0.05 per share, compared to a net loss of \$3,500 or \$0.095 per share for the nine-month period ended February 29, 2008, an improvement of 46% from last year's corresponding period. These results are due to the improvement in productivity as well as an increase of the gross margin reflected in the cost of sales and operating expenses. It is also attributable to the decrease in the stock-based compensation charge by \$1,012 in the quarter and \$2,320 for the nine-month period. The Company also realised a gain on foreign exchange for a total amount of \$1,000 compared to a foreign exchange loss of \$235 for the last year's corresponding period primarily due to the strengthening of the U.S. dollar relative to the Canadian dollar.

These favourable variances were offset by an increase in research and development expenses mainly attributable to the two subsidiaries Acasti and NeuroBioPharm for an amount of \$903.

TREASURY FLOW AND FINANCIAL SITUATION BETWEEN THE TWELVE-MONTH PERIOD ENDED FEBRUARY 28, 2010 (AUDITED) AND THE TWELVE-MONTH PERIOD ENDED FEBRUARY 28, 2009 (UNAUDITED)

Operating Activities

During the twelve-month period ended February 28, 2010, the operating activities generated a decrease in liquidities of \$506, compared to a decrease of \$488 for the corresponding twelve-month period ended February 28, 2009. The change in liquidities derived from operating activities from the twelve-month period ended February 28, 2009 to the twelve-month period ended February 28, 2010 is mainly attributable to the higher loss from operations which excludes the gain on dilution for an amount of \$2,222 and a net increase in operating assets and liabilities for an amount of \$1,380, primarily due to lower investment in accounts receivable and research tax credits and higher investments in inventories.

Investing Activities

During the twelve-month period ended February 28, 2010, the investing activities generated a decrease in liquidities of \$1,340. This decrease is mainly due to investments in property, plant and equipment for an amount of \$3,581. These investments are mainly comprised of investments in the plant expansion, which has been financed by our long term financing facility (see note 16 to the consolidated financial statements). In addition, the Company invested in its intangible assets for an amount of \$77. In order to finance these and other projects the Company decreased its short-term investments by \$2,317.

Financing Activities

During the twelve-month period ended February 28, 2010, the financing activities generated an increase in liquidities of \$2,474. This increase is mainly attributable to the increase of the long term debt by \$3,000 in order to finance the plant expansion, less repayments, amounting to \$761. The Company also increased its liquidities by issuing shares following warrants and options exercised for a total amount of \$235.

Overall, as a result of cash flows from all activities, the Company increased its cash by \$257 for the twelve-month period ended February 28, 2010.

TREASURY FLOW AND FINANCIAL SITUATION BETWEEN THE NINE-MONTH PERIOD ENDED FEBRUARY 28, 2009 (AUDITED) AND THE NINE-MONTH PERIOD ENDED FEBRUARY 28, 2008 (UNAUDITED)

Operating Activities

During the nine-month period ended February 28, 2009, the operating activities generated a decrease in liquidities of \$290, compared to a decrease of \$592 for the corresponding nine-month period ended February 29, 2008. The positive change in liquidities derived from operating activities from the nine-month period ended February 29, 2008 compared to the nine-month period ended February 28, 2009 is mainly attributable to the improved results. The variation in working capital items from the nine-month period ended February 28, 2009 compared to the nine-month ended February 29, 2008 represents an increase of \$466, primarily due to increases in inventories and research tax credits receivable. The change in working capital items for the nine-month period ended February 28, 2009 includes an increase in accounts receivable for an amount of \$480, an increase in research tax credits for an amount of \$462, an increase in inventory for an amount of \$390 and an increase in accounts payable and accrued liabilities for an amount of \$192.

Investing Activities

During the nine-month period ended February 28, 2009, the investing activities generated a decrease in liquidities of \$2,292. This decrease is mainly due to investments in property, plant and equipment for an amount of \$904. These investments are mainly comprised of investments in the plant expansion, which will all be financed by our long term financing facility. In addition, the Company invested in its intangible assets for an amount of \$254 mainly attributable to charges for the novel food regulation. In order to finance these and other projects the Company decreased its short-term deposits by \$1,104.

Financing Activities

During the nine-month period ended February 28, 2009, the financing activities generated an increase in liquidities of \$2,831. This increase is mainly attributable to the debenture financing for \$2,720 net of the financing fees. As explained in note 16 to the audited consolidated financial statements, the Company also refinanced its long-term debt in 2009. The Company entered into a debt agreement totaling \$6,500 of which \$3,453 was disbursed in 2009. The Company used these amounts to reimburse its long term debt of \$3,397.

Overall, as a result of cash flows from all activities, the Company increased its cash by \$290 for the nine-month period ended February 28, 2009.

At February 28, 2010, the Company's liquidity position, consisting of cash and short-term investments, was \$2,094.

Also, At February 28, 2010, the Company had an authorized operating line of credit \$1,000, all of which was available, as well as an additional \$200 for foreign exchange contract, all of which was also available.

The Company believes that its available cash and term deposits, expected interest income, research collaborations and licensing agreements, research tax credits, and access to capital markets should be sufficient to finance the Company's operations and capital needs during the ensuing fiscal year. However, in light of the uncertainties associated with the regulatory approval process, clinical trial results, commercialization of nutraceutical products and the Company's ability to secure additional licensing, partnership and/or other agreements, further financing may be required to support the Company's operations in the future. See "Subsequent Events".

FINANCIAL POSITION

The Company's objective in managing capital is to ensure sufficient liquidity to develop its technologies and commercialize its products, finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection, its overall capital expenditures and those related to its debt reimbursement. The Company is not exposed to external requirements by regulatory agencies regarding its capital.

As explained in note 16 to our 2010 audited consolidated financial statements, the Company is subject to certain financial covenants under its mortgage loan.

Since inception, the Company has financed its liquidity needs primarily through a public offering of common shares, private placements with or without warrants and issuance of long-term debt and convertible debentures. The Company optimizes its liquidity needs using non-dilutive sources whenever possible, including research tax credits, grants, interest income and revenues from strategic partnerships and collaboration agreements. Nevertheless, the Company's most important source of liquidity remains its operating cash flows which are attributable to and generated from its ongoing sales.

The Company defines "capital" to include total shareholders equity, long-term debt and convertible debentures.

The Company's capital management objectives remain the same as for the previous fiscal period.

The Company's policy is to maintain a minimal level of debt. In 2009, the Company successfully renegotiated the refinancing of its debt, reduced its financial expenses and increased its production capacity to be able to face the increasing demand for its products (for more details see note 16 to the 2010 audited consolidated financial statements). At February 28, 2009, the Company had an authorized operating line of credit \$1,000,000, of which an amount of \$1,000,000 was available.

At February 28, 2010, cash amounted to \$1,093,194, term deposits amounted to \$1,001,011 and tax credit receivable amounted to \$664,131, for a total of \$2,758,336.

The following table details the important changes to the balance sheet at February 28, 2010 compared to February 28, 2009:

Accounts	Increase (Reduction) (In Thousands of dollars)	Comments
Cash	257	See cash flows statement
Short term investments	(2,317)	Conversion to cash to fund operations
Receivables	(1,717)	Improvement in collection terms
Inventory	872	Increase of purchases of raw material
Property, plant and equipment	2,376	Plant expansion project and amortization
Accounts payable and accrued liabilities	(125)	Improvement in suppliers credit terms
Convertible debenture	(1,699)	Conversion of debentures and interest and accretion expenses
Long-term debt	2,243	Plant expansion financing

PRIMARY ANNUAL FINANCIAL RATIOS

	2010	2009	2008
Working Capital Ratio (current assets/current liabilities) ¹	2.05	2.98	3.17
Solvency Ratio (Debt Capital / Shareholders' Equity) ²	0.78	0.63	0.43

* including convertible debentures for 2009 and 2010.

¹ The Working Capital Ratio is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by Canadian GAAP, the results may not be comparable to similar measurements presented by other public companies.

² The Solvency Ratio is presented for information purposes only and represents a financial performance measurement tool mostly used in financial circles. Because there is no standard method endorsed by Canadian GAAP, the results may not be comparable to similar measurements presented by other public companies.

Most of the Company's financial ratios deteriorated or were maintained during the period ended February 28, 2010 compared to the period ended February 28, 2009 mainly due to decrease in accounts receivables and short-term investments. The Company's solvency ratio deteriorated during the period ended February 28, 2010 compared to the period ended February 28, 2009 mainly due to the second tranche mortgage loan used to finance the plant expansion and the effects of the plant shutdown on the operating results.

CONTRACTUAL OBLIGATIONS

The Company's contractual obligations, including payments due during the next five reporting periods and thereafter, are presented in the following table:

REQUIRED PAYMENTS PER PERIODS

Contractual Obligations	Total	Less than one period	2 to 3 periods	4 to 5 periods	More than 5 periods
	\$	\$	\$	\$	\$
Long-term debt	5,780	967	1,920	1,868	1,025
Interest on long-term debt	758	230	332	169	27
Loans guaranteed by investments in lease contracts*	74	47	27	-	-
Research and development contract	1,062	1,062	-	-	-
Other lease contracts	727	245	345	137	-
Total liabilities	8,401	2,551	2,624	2,174	1,052

* Including interest fees.

OFF-BALANCE SHEET ARRANGEMENTS

The Company off-balance sheet arrangements consist of the following commitments:

The Company has entered into a licensing agreement, which calls for semi-annual payments of royalties based on the net realized sales of licensed products, according to the following conditions:

	Rate	Minimum royalty
To a Canadian university as of June 1, 2002 (for the term of the patents or until the Company exercised its option) ¹	4%	\$5

To a company controlled by an officer and director
as of June 1, 2002 (for an unlimited period)

1%

¹ The Company has a \$275 purchase option relating to the intellectual property currently held by a Canadian university.

In the normal course of business, the Company has signed agreements with various partners and suppliers relating to the execution of research projects to produce and market certain products. The Company has reserved certain rights relating to these projects. During the first quarter 2009, the Company initiated a clinical trial to be realized over the following next 30 months for an amount of \$775. As at February 28, 2010, payments of \$459 have been made towards the total amount of the contract. In addition, during the first quarter 2010, the Company initiated another clinical trial to be realized over the following 20 months for an amount of \$345 (€240). As at February 28, 2010, payment of \$144 (€100) has been made toward the total amount of the contract. The Company initiated another research project during 2010 to be realized over the following 12 months for an amount of \$583. As at February 28, 2010, an accrual of \$38 is included in accrued liabilities.

The Company has also entered into long-term lease agreements, which call for payments of \$727 for the rental of premises. Minimum lease payments for the next years are \$245 in 2011, \$174 in 2012, \$171 in 2013 and \$137 in 2014.

RELATED PARTY TRANSACTIONS

Under the terms of an agreement entered into with a shareholder (a company controlled by an officer and director), the Company is committed to pay royalties of 1% of its revenues related to its nutraceutical segment in semi-annual installments, for an unlimited period. The annual amount disbursed in cash cannot exceed net earnings before interest, taxes and amortization of Neptune on a non-consolidated basis. For the year ended February 28, 2010, total royalties paid or payable to this party amounted to \$120 (nine-month period ended February 28, 2009 - \$222, including royalties on the transfer of licenses to the subsidiaries of \$137). As at February 28, 2010, the balance payable to this shareholder under this agreement amounts to \$175 (February 28, 2009 - \$222). This amount is presented in the

balance sheet under accounts payable and accrued liabilities.

These transactions are measured at the exchange amount, which is the amount of consideration determined and accepted by the parties involved.

CHANGE TO ACCOUNTING POLICIES

New accounting policies adopted in fiscal 2010:

On March 1, 2009, the Company adopted the following accounting standards issued by the Canadian Institute of Chartered Accountants ("CICA").

Goodwill and Intangible Assets:

The CICA issued Section 3064, *Goodwill and Intangible Assets*, which replaced Section 3062, *Goodwill and Other Intangible Assets*, and Section 3450, *Research and Development Costs*. The new standard provides guidance on the recognition of intangible assets in accordance with the definition of an asset and the criteria for asset recognition as well as clarifying the application of the concept of matching revenues and expenses, whether these assets are separately acquired or internally developed.

As a result of this standard, direct costs incurred to secure patents related to internally-generated assets in the research phase will no longer be capitalized by the Company. The Company applied this standard on a retrospective basis. The impact of adopting this standard was to increase the opening deficit and reduce intangible assets, as at June 1, 2008 and March 1, 2009, by \$151 and \$147, respectively, for such assets capitalized prior to the date of commercialization, May 31, 2002. The impact of the adjustment on the net loss in 2009 is not significant.

Financial Instruments:

Effective September 1, 2009, the Company adopted an amendment to CICA Section 3862, *Financial Instruments - Disclosures*, which requires additional disclosures about fair value and liquidity risk. The amendments introduce a "fair value hierarchy" for disclosures which intends to provide information to financial statement users about the relative reliability of fair value measurements. The new standard relates to disclosure only and did not impact the financial results of the Company. See note 22 (d).

Presentation of unrealized gains and losses on foreign exchange:

The Company restated the consolidated statement of cash flows for the nine-month period ended February 28, 2009 in order to present the effects of unrealized gains and losses on foreign exchange, as was required by CICA Handbook Section 1540, *Cash Flow Statements*. As a result of the correction, cash flows from operating activities (foreign exchange gain (loss) on cash and short-term investments) decreased by \$193, cash flows from investing activities (maturity (purchases) of short-term investments) increased by \$47 and the foreign exchange gain (loss) on cash held in foreign currencies was added, in the amount of \$146.

Future accounting changes:

Business Combinations:

Section 1582, *Business Combinations*, replaces Section 1581, *Business Combinations*. The Section establishes standards for the accounting for a business combination. It provides the Canadian equivalent to the IFRS standard, IFRS 3 (Revised), *Business Combinations*. The Section applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2011.

Consolidated Financial Statements:

Section 1601, *Consolidated Financial Statements*, and Section 1602, *Non-Controlling Interests*, together replace Section 1600, *Consolidated Financial Statements*. Section 1601 establishes standards for the preparation of consolidated financial statements. Section 1602 establishes standards for accounting for a non-controlling interest in a subsidiary in consolidated financial statements subsequent to a business combination. It is equivalent to the corresponding provisions of IFRS Standard, IAS 27 (Revised), *Consolidated and Separate Financial Statements*.

The Sections apply to interim and annual consolidated financial statements relating to fiscal years beginning on or after January 1, 2011. Earlier adoption is permitted as of the beginning of a fiscal year. The Company does not anticipate that it will ever adopt these new sections because they become effective only when the Company is expecting to adopt the International Financial Reporting Standards.

International Financial Reporting Standards:

In February 2008, Canadian Accounting Standards Board (AcSB) confirmed that Canadian GAAP, as used by publicly accountable enterprises, would be replaced by International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"). The changeover date is for interim and annual financial statements relating to fiscal years beginning on or after January 1, 2011 with comparative figures for previous period. Therefore, the Company will be required to report under IFRS for its 2012 interim and annual financial statements. The Company will convert to these new standards according to the timetable set within these new rules. The Company has not yet assessed the impact these new standards will have on its financial statements. The Company has performed an initial high-level analysis of the key accounting areas that may be impacted by the transition to IFRS, but has not yet performed a detailed assessment of the impact these new standards will have on its financial statements.

USE OF ESTIMATES

The preparation of financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the recorded amount of assets and liabilities and the reported amount of contingent assets and liabilities at the date of the financial statements and the recorded amounts of income and expenses during the year. Actual results may differ from those estimates. Significant areas requiring the use of management estimates include estimating the useful life and recoverability of long-lived assets, including property, plant and equipment and intangible assets, determining the fair value of financial instruments and estimating the fair value of stock-option awards as well as assessing the recoverability of research tax credit receivable and future income tax assets. Consequently, actual results could differ from those estimates.

SUBSEQUENT EVENTS

- (a) On April 30, 2010, 1,068,000 Debenture Warrants were exercised for total proceeds of \$1,335 and 1,086 Debenture Call-Options for total proceeds of \$271.
- (b) The Company held a special and annual shareholders' meeting on June 22, 2010 (the "Meeting"). At the Meeting, a majority of shareholders approved, among other things, an amendment to the Company's stock option plan and adopted the Shareholder Rights Plan (the "SRP"), each of which had been previously approved by the Board of Directors of the Company.
 - (i) The Company's stock option plan now allows the Company to issue a number of incentive stock options not in excess of 15% of the number of shares issued and outstanding on the date of the Meeting. As at the date of the Meeting, the total number of common shares of the Company issued and outstanding was 40,172,744.
 - (ii) The Board determined that the establishment of a SRP was in the best interest of the Company's shareholders, because it allows them to have more time to consider any significant takeover bid for the Company without undue pressure, it allows the Board to propose, if appropriate, other alternatives to maximize shareholder value and it allows additional time for competing bids to emerge. The rights issue pursuant to the SRP required the approval of a majority of shareholders, which was obtained at the Meeting.

The SRP allows holders of common shares to purchase from the Company, for each common share held, an amount of common shares worth twice the market price on the date a triggering event occurs, at a price per common share equal to half the market price on the date of such triggering event. As defined in the SRP, a triggering event consists in a transaction that results in the acquisition by a person or group of persons (the "Acquirer") of 20% or more of the outstanding common shares of the Company through a transaction that is not considered a permitted bid. The Acquirer would not be entitled to exercise any right it may hold through such transaction.

The rights under the SRP are not triggered by the purchase of shares made pursuant to a permitted bid. A permitted bid is one that is open for not less than 60 days and that is made to all shareholders by way of a take-over circular prepared in compliance with applicable securities laws. It must also comply with certain other conditions set out in the agreement signed with Computershare Services Inc., acting as registrar and transfer agent for the Company, to implement the SRP.

The Board retains discretion on the continuation of the SRP until its scheduled termination in three years, and on the waiving of dilutive effects of the provisions on triggering events for acquirers. A copy of the SRP is available on SEDAR and EDGAR under the Company's filings.

- (c) On July 13, 2010, the Board of Directors of the Company decided, after nearly 2 years without a general incentive option grant to employees and management, to grant a total of 790,000 incentive stock options of the Company, 695,000 rights on Acasti series 4 warrants held by the Company and 760,000 rights on Neurobiopharm series 4 warrants held by the Company to insiders and employees. The Company's incentive stock options have an exercise price of \$1.50 and a 3-year maturity. Rights on Acasti series 4 warrants and rights on Neurobiopharm series 4 warrants have an aggregate exercise price of \$0.50 and \$0.25 and maturities of October 9, 2013 and December 24, 2013, respectively, and are subject to shareholder approval.

CRITICAL ACCOUNTING POLICIES

In preparing the Company's consolidated financial statements in conformity with GAAP, Management is required to make certain estimates, judgements and assumptions that the Company believes are reasonable based upon the information available at the time. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The accounting policies which the Company considers to be critical are those that require the most difficult, subjective, or complex judgments and that are the most important to aid in fully understanding and evaluating its consolidated financial statements. These accounting policies are discussed in the following paragraphs.

Property, Plant and Equipment and Intangible Assets are started at cost and amortized on a straight-line or declining balance basis. The Company regularly reviews property, plant and equipment and intangible assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets exceeds the sum of the expected cash flows from its uses and disposal. Management's judgment regarding the existence of impairment indicators is based on legal factors, market conditions and operating performances. Future events could cause management to conclude that impairment indicators exist and that the carrying values of the Company's capital assets or intangible assets are impaired. Any resulting impairment loss could have a material adverse impact on the Company's financial position and results of operations.

Income Taxes are accounted for under the asset and liability method. In the Company's case, recurrent operating losses during the development years create tax assets that may reduce future taxable earnings, if any. In assessing whether future tax assets may be realized, management provides valuation allowances by considering the likelihood that some portion or all of the tax assets is dependant upon the generation of future taxable income. Given the Company's history of losses, management has determined that the criteria for the recognition of tax assets were not met at February 28, 2010.

Research and Development consist of direct and indirect expenditures, including a reasonable allocation of overhead expenses, associated with the Company's various research and development programs. Research costs are expensed as incurred. Development costs are expensed as incurred unless a development project meets generally accepted accounting criteria for deferral and amortization. Overhead expenses comprise general and administrative support provided to the research and development programs and involve costs associated with support activities such as facility maintenance, utilities, office services, information technology.

Refundable Research and Development tax credits are recorded based on our estimates of amounts expected to be recovered and are subject to audit by the taxation authorities and, accordingly, these amounts may vary materially.

Stock-based Compensation represents the accounting cost of stock options awarded to employees and directors under the corporation's stock option plan. The value of these options is estimated by using the Black-Scholes option-pricing model that was developed to estimate the fair value of freely-tradable, fully transferable options without vesting restrictions. The use of this model requires highly subjective assumptions, especially the assumption relating to future stock price volatility, which greatly affects the computed values.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

During the period ended February 28, 2010, the CEO and the CFO evaluated whether there were any material changes in internal control over financial reporting pursuant to MI 52-109. They individually concluded that there was no change during the year ended February 28, 2010 that affected materially the Company's internal controls over financial reporting and disclosure controls and procedures.

RISK FACTORS

The information contained in this annual report for the year ended February 28, 2010 should be read in conjunction with all the Company's public documentation and in particular the risk factors section in the Annual Information Form filed on SEDAR and Item 3D of this document. This information does not represent an exhaustive list of all risks related to an investment decision in the Company.

Credit risk:

Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations, and arises primarily from the Company's trade receivables. The Company may also have credit risk relating to cash, which it manages by dealing only with highly-rated Canadian institutions. The carrying amount of financial assets, as disclosed in the consolidated balance sheet, represents the Company's credit exposure at the reporting date, including trade receivables. The Company's trade receivables and credit exposure fluctuate throughout the year. The Company's average trade receivables and credit exposure during the year may be higher than the balance at the end of that reporting period.

The Company's credit risk for trade receivables is concentrated, as the majority of its sales are to a relatively small group of distributors. As at February 28, 2010, the Company had twenty trade debtors. Most sales' payment terms are set in accordance with industry practice. Three customers represent 56% (two customers represented 41% as at February 28, 2009) of total trade accounts included in accounts receivable. Most of the Company's clients are distributors for a given territory and are privately-held enterprises. The profile and credit quality of the Company's retail customers vary significantly. Adverse changes in a customer's financial position could cause us to limit or discontinue conducting business with that customer, require us to assume more credit risk relating to that customer's future purchases or result in uncollectible accounts receivable from that customer. Such changes could have a material adverse effect on our business, consolidated results of operations, financial condition and cash flows.

The Company's extension of credit to customers involves considerable judgment and is based on an evaluation of each customer's financial condition and payment history. The Company has established various internal controls designed to mitigate credit risk, including a credit analysis by the insurer which recommends customers' credit limits and payment terms that are reviewed and approved by the Company. The Company reviews periodically the insurer's maximum credit quotation for each of its clients. New clients are subject to the same process as regular clients. The Company has also established procedures to obtain approval by senior management to release goods for shipments when customers have fully-utilized approved insurers credit limits. From time to time, the Company will temporarily transact with customers on a prepayment basis where circumstances warrant. While the Company's credit controls and

processes have been effective in mitigating credit risk, these controls cannot eliminate credit risk and there can be no assurance that these controls will continue to be effective, or that the Company's low credit loss experience will continue. Customers do not provide collateral in exchange for credit, except in unusual circumstances. Receivables from selected customers are covered by credit insurance, with amounts usually up to 100% of the invoicing, with the exception of some customers under specific terms. The information available through the insurers is the main element in the decision process to determine the credit limits assigned to customers. The Company provides for trade receivable accounts to their expected realizable value as soon as the account is determined not to be fully collectable, with such write-offs charged to consolidated earnings unless the loss has been provided for in prior periods, in which case the write-off is applied to reduce the allowance for doubtful accounts. The Company updates its estimate of the allowance for doubtful accounts, based on individual customer evaluations of the collectability of trade receivable balances at each balance sheet reporting date, taking into account amounts which are past due, and any available information indicating that a customer could be experiencing liquidity or going concern problems.

Foreign exchange risk:

The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Company's business transactions denominated in currencies other than the Canadian dollar. From time to time, the Company uses derivative financial instruments to reduce its foreign exchange exposure. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Company's operating results. Approximately 89% of the Company's revenues are in US dollars. A small portion of the purchases, except for the purchase of raw materials, are made in foreign currencies. There is a financial risk involved related to the fluctuation in the value of the US dollar in relation to the Canadian dollar. The Company enters into currency forwards to purchase or sell amounts of foreign currency in the future at predetermined exchange rates. The purpose of these currency forwards is to fix the risk of fluctuations in future exchange rates.

Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates. The risk that the Company will realize a loss as a result of the decline in the fair value of its term deposits is limited because these investments have short-term maturities and are generally held to maturity. An assumed 0.5% interest rate increase during the year ended February 28, 2010 would have decreased net earnings by \$27, with an equal opposite effect for an assumed 0.5% decrease. The capacity of the Company to reinvest the short-term amounts with equivalent returns will be impacted by variations in short-term fixed interest rates available in the market.

Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Audit Committee and the Board of Directors review and approve the Company's operating budgets, and review the most important material transactions outside the normal course of business.

Financial risks:

Until each entity is independently financed, the success of the Company is dependent on its ability to support the development of its two subsidiaries and its ability to bring their products to market, obtain the necessary approvals, and achieve future profitable operations. This is dependent on the Company's ability to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs nor the Company's ability, nor its subsidiaries ability, to fund these programs going forward.

Management intends to continue the careful management of risks relating to exports, foreign exchange, interest rates and sale prices for its merchandise.

Product Liability:

The Company has secured a \$5,000 product liability insurance policy, renewable on an annual basis, to cover civil liability relating to its products. The Company also maintains a quality-assurance process that is QMP certified by the Canadian Food Inspection Agency (CFIA). Additionally, the Company has obtained *Good Manufacturing Practices* accreditation from Health Canada.

C. *Research and Development*

Neptune R&D policies are targeted at the development of proprietary natural health ingredients for the nutraceutical, medical food and pharmaceutical markets. Neptune's products are all subject to trademark and patent rights directly owned by or exclusively licensed to Neptune.

Since its foundation, Neptune envisioned the development of clinically validated safe and effective ingredients for dietary supplements, functional food, medical food, over the counter and prescription therapeutics. During the first years Neptune developed Neptune Krill Oil (NKO®), a proprietary marine extract rich in omega-3 functionalized on phospholipids and potent antioxidants clinically proven safe and effective for the management of cholesterol and arthritic disorders. NKO® is now patented, trademarked and commercialized in North America, Europe and Australasia.

During the last two years, Neptune's research and development efforts have focused on enhancing the composition of NKO® and eliminating or masking the inherent seafood odor and taste of the product. In order to achieve its target, the company is collaborating with public and private research institutions, as well as strategic partners in the food industry such as Nestle and Yoplait, among others. This research has resulted in the development of various functional foods, such as health bars, fruit juice, vegetable juice, berry nuggets and fruit paste, with stable and pleasant odor and taste throughout the standard shelf-life of each product.

Neptune has licensed the pharmaceutical rights to its two subsidiaries, Acasti Pharma Inc. and NeuroBioPharm Inc., for the respective development of cardiovascular and neurological medical food, OTC and prescription drugs.

Acasti has completed the product development and is finalizing IND-enabling studies preparing for the first IND submission for its prescription drug by the end of this year. NeuroBioPharm is presently conducting a clinical study evaluating the effect of its medical food on Alzheimer's. The study is expected to be completed by June 2011.

R&D spending by project for the last three fiscal periods was as follows:

Fiscal period ended	Sniff ⁽¹⁾ \$	Pharmaceutical Applications \$	Project Improvement of NKO® \$	NKA \$	Total \$
February 28, 2010	117,873	1,698,395	850,249	77,002	2,743,519
February 28, 2009	233,807	501,102	542,053	0	1,276,962
May 31, 2008	344,047	0	120,632	19,844	484,524

(1) Solutions for NKO® in functional food.

The amounts spent on research and development for the last three years are summarized in note 6 to our 2010 audited consolidated financial statements. The Company expenses all research and development costs related to research projects. We manage our ongoing research and development projects and programs in a dynamic, flexible manner. Our researchers, staff and management are typically involved in more than one of our research and development projects and the percentage of time an employee may be involved in a project varies according to the changing needs and progress of that project. As well, a significant portion of the Company's research and development expenses, such as laboratory supplies, travel, information systems and services and facilities costs, benefit multiple projects and are not necessarily individually tracked or allocated to a specific project when incurred.

D. *Trend Information*

Other than those discussed under Item 4B: Business Overview, the Company does not know of any significant trends that would be material to its operations since the latest financial year.

E. Off-Balance Sheet Arrangements

With the exception of lease commitments in the amount of \$727,000 and commitments disclosed below and in **F. Tabular disclosure of contractual obligations** they are no off-Balance Sheet Arrangements. In the normal course of business, the company has signed agreements with various partners and suppliers relating to the execution of research projects to produce market certain products. The company has reserved certain rights to these projects. During the first quarter 2009, the company initiated a clinical trial that will be realized during the next 30 months for an amount of \$775,000. As at February 28 2010, payments of \$459,000 have been made towards the total amount of the contract. In addition, during the first quarter 2010, the company initiated another clinical trial that will be realized during 20 months for an amount of \$345,000 (€240,000). As at February 28 2010, payment of \$144,000 (€100,000) has been made toward the total amount of the contract. The company initiated another research project during 2010 that will be realized during 12 months for an amount \$583,000. As at February 28 2010, an accrual of \$38,000 is included in accrued liabilities..

F. Tabular Disclosure of Contractual Obligations

Contractual Obligations in thousands	Total \$	Less than one year \$	2 to 3 years \$	4 to 5 years \$	More than 5 years \$
Long-term debt	5,780	967	1,920	1,868	1,025
Interest in long-term debt	758	230	332	169	27
Loans guaranteed by investments in lease contracts*	74	47	27	-	-
Research and development contract	1,062	1,062	-	-	-
Other lease contracts	727	245	345	137	-
Total liabilities	8,401	2,551	2,624	2,174	1,052

* Including interest fees.

The Company has commitments under various agreements as follows:

(a) License agreement:

The Company has entered into a licensing agreements, which call for semi-annual payments of royalties based on the net realized sales of licensed products for the term of the patents, according to the following conditions:

	Rate	Minimum royalty
To a Canadian university as of June 1, 2002 ⁽ⁱ⁾	4%	\$ 5,000
To a company controlled by an officer and director as of June 1, 2002	1%	

⁽ⁱ⁾ The Company has a \$275,000 purchase option relating to the intellectual property currently held by this Canadian university.

As for the exclusive License/Option, on August 18, 2004, the Company notified the Canadian University of its intention to exercise its \$275,000 purchase option relating to the intellectual property (see section 2.9.1. hereof entitled Exclusive License/Option). As per the licensing agreement reached between the Canadian university and the Company, the terms of payment are as follows: \$100,000 on the transfer date of the intellectual property, \$50,000 on the first anniversary date of the transfer, \$50,000 on the second anniversary and \$75,000 on the third anniversary.

On August 23, 2004, university researchers filed an injunction against the Company and the Canadian University demanding cancellation of the purchase option of the intellectual property granted to the Company by the Canadian university.

(b) Research and development agreements:

In the normal course of business, the Company has signed agreements with various partners and suppliers relating to the execution of research projects to produce and market certain products. The Company has reserved certain rights relating to these projects. The execution of research projects call for payment of \$1,062,000 within less than one year.

(c) Rental agreements:

The Company has entered into long-term lease agreements, which call for payments of \$727,000 for the rental of premises.

G. Safe Harbor

See above Statement Regarding Forward-Looking Information

ITEM 6: DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES**A. Directors and Senior Management**

Name and Province and Country of Residence	Principal Occupation	Position Within the Corporation	Year of Nomination as a Director or employee of the Company
Henri Harland ⁽⁴⁾⁽⁵⁾ Québec, Canada	President and Chief Executive Officer of the Company	Director, President and Chief Executive Officer of the Company	1998
Ronald Denis ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾ Québec, Canada	Chief of Surgery at Hôpital du Sacré-Coeur, Montréal	Director and Chairman of the Board of the Company	2000
Daniel Perry ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾ France	General Manager of Société du Vivier des Landes	Director of the Company	2000
Jean-Claude Debard ⁽¹⁾⁽²⁾ France	President of Hyundai Automobile	Director of the Company	2009
Michel Chartrand ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾ Québec, Canada	President of Groupe PharmaEссор Inc.	Director of the Company	2006
Tina Sampalis ⁽⁵⁾ Québec, Canada	Chief Scientific Officer of the Company and President of Acasti	Chief Scientific Officer of the Company	2001
André Godin ⁽⁵⁾ Québec, Canada	Vice-President, Administration and Finance of the Company	Vice-President, Administration and Finance of the Company	2003

⁽¹⁾ Member of the Audit Committee

⁽²⁾ Member of the Compensation Committee

⁽³⁾ Member of the Corporate Governance Committee

⁽⁴⁾ Director of Acasti Pharma and NeuroBioPharm

⁽⁵⁾ Officer of Acasti Pharma and NeuroBioPharm

As of May 18, 2010, the directors and executive officers, as a group, beneficially owned or exercised control or direction over approximately 3,663,694 (9.32%) of the outstanding common shares of Neptune.

In Neptune's Management Proxy Circular dated May 26, 2010, all of the above listed directors were nominated by management for election and all were elected.

Following are brief biographies of Neptune's directors and executive officers:

Mr. Henri Harland

Mr. Henri Harland has been a director and the President and Chief Executive Officer of the Company since its incorporation on October 9, 1998. He is the Founder of the Company and has been involved in the krill research project since 1991. For ten years he has held the position of President and Chief Executive Officer of Groupe Conseil Harland Inc., a financial engineering group. Previously, he acted as an independent financial consultant guiding companies from different industrial sectors in both North America and Europe in their capital restructure, financing and business development.

Dr. Ronald Denis

Dr. Ronald Denis is currently Chief of Surgery and Co-Director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal. Also, since 1987, Dr. Denis has been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Mr. Daniel Perry

Since March 1993, Mr. Perry is General Manager of a company operating a recreation/tourism complex in France. Also, Mr. Perry is a specialist and consultant in the marketing of new products on the European continent.

Mr. Michel Chartrand

Since July 2009, Michel Chartrand is the Vice-President of Retail Partner Solutions at McKesson Canada. From 2004 to 2009, Mr. Michel Chartrand was the President and Chief Executive Officer of Groupe PharmEssor inc. which regroups Gestion Santé Services Obonsoins inc. and Groupe Essaim inc., two important Quebec pharmacy franchisors. From 1998 to 2004, Mr. Chartrand was the Executive Vice-President of Gestion Santé Services Obonsoins inc.

Mr. Jean-Claude Debard

Mr. Debard has been President of Hyundai Automobile France and FEA Services as well as an officer of Frey Accessories and Parts since 1999 and most recently Executive President of Group Emil Frey France since 2008. Since 1999, Mr. Debard has sat on the Surveillance Committees of Holding (SERGESA), SsangYong France and Hyundai Finances.

Tina Sampalis M.D., Ph.D.

Dr. Tina Sampalis is an Oncology Surgeon, trained in Physiology at McGill University, Medicine at the University of Patras (Greece), Dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), Pediatric, General and Oncology Surgery at the University of Athens (Greece), graduate training (PhD) in Surgical Research at the University of Athens and a second PhD in Epidemiology and Experimental Surgery at McGill University. She has received several international scholarships and awards for her work on the clinical implementation of retinols skin and breast cancer and for her work on Scintimammography. U.S. and Canadian patent applications have been filed for the development and implementation of innovative micro-invasive and stereotactic robotic surgical techniques for breast cancer. Between May 2000 and June 2007, she has held the position of Vice-President of Research and Business Development and since June 2007 the position of Chief Scientific Officer of the Company.

Mr. André Godin

Mr. André Godin, C.A., has a Bachelor in Administration and has been a Member of the Canadian Institute of Chartered Accountants since 1988. He has more than 10 years experience in the Biotech/Pharma industry as former President of a Dietary Supplement Company and as a Corporate Controller for a pharmaceutical company in OTC products. Mr. Godin has been Vice-President, Administration and Finance for Neptune since 2003.

B. Compensation
Compensation of Directors

In fiscal 2010, other than the Company's CEO, all directors were independent and were remunerated by the Company in their capacity as directors. Henri Harland, President and CEO of the Company, received no remuneration as a director.

The compensation for the independent directors, other than the Chairman of the Board, is a combination of annual meeting fees and stock options. The meeting fees are further described in the chart below.

Summary Table Meeting Fees Payable to Directors

Detail	Compensation (\$)
Fee for Director of the Board per Board meeting attended	500
Fee for Chairman of the Board per Board meeting attended	1000
Fee for Board of Directors meeting attended by way of conference call	250
Fee for Chairman of the Board per Board meeting attended by way of conference call	250
Fee for Board of Directors Committee per meeting attended	500
Fee for Chairman of the Committee for Committee per meeting attended	750
External directors are paid an annual fixed compensation of \$10,000 and the Chairman of the Board is paid an annual fixed compensation of \$20,000.	

In 2008, each independent director of the Company received 25,000 stock options on August 21, 2008 upon this nomination or re-election to the Board of Directors. The exercise price of each option granted is \$2.50.

The total remuneration paid to independent directors during the fiscal year ended February 28, 2010, is set out in the following table:

Remuneration Paid to Independent Directors

Name	Fees earned (\$)	Option/warrant- based awards (\$)	All other compensation (\$)	Total ⁽¹⁾ (\$)
Ronald Denis	24,500	-	-	24,500
Michel Chartrand	13,750	-	-	13,750
Daniel Perry	11,250	-	-	11,250
Jean-Claude Debard	6,750	-	-	6,750

⁽¹⁾ The directors do not receive pension benefits, share-based awards, perquisites or other annual compensation.

Outstanding Director Option-Based Awards

The following table provides information on the number and value of each independent director's outstanding options as of July 7, 2010.

Neptune

Name / Grant Date	Number of securities underlying unexercised options	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options ⁽¹⁾ (\$)
Michel Chartrand				
July 13, 2010	25,000	1.50	July 13, 2013	-
August 21, 2008	25,000	2.50	August 21, 2011	-
June 09, 2006	25,000	2.60	June 9, 2011	-
Ronald Denis				
July 13, 2010	25,000	1.50	July 13, 2013	-
August 21, 2008	25,000	2.50	August 21, 2011	-
June 09, 2006	25,000	2.60	June 9, 2011	-
Daniel Perry				
July 13, 2010	25,000	1.50	July 13, 2013	-
August 21, 2008	25,000	2.50	August 21, 2011	-
June 09, 2006	25,000	2.60	June 9, 2011	-
Jean-Claude Debard				
July 13, 2010	25,000	1.50	July 13, 2013	-
July 14, 2009	25,000	2,50	July 14, 2012	-

⁽¹⁾ Calculation is based on the trading price of the Company's shares on the TSX-Venture of \$2.10 on February 28, 2010

Acasti

Acasti options and warrants, as well as NeuroBioPharm, have been granted to independent directors of the Company in remuneration for the additional responsibilities and amount of work attributable to the position they hold in Acasti without any further monetary compensation for the fiscal periods ending February 28, 2009 and February 28, 2010 or unless an until a financing is realized.

The following tables provide information on the number and value of each independent director's outstanding Acasti options and warrants at the end of the financial year ended February 28, 2010.

Option-Based Awards

Name / Grant Date	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options ⁽¹⁾ (\$)
Michel Chartrand				
October 8, 2008	25,000	0,25	October 8, 2018	5,500
Jean-Claude Debard ⁽²⁾				
July 14, 2009	25,000	0.25	July 14, 2019	5,500
Ronald Denis				
October 8, 2008	25,000	0.25	October 8, 2018	5,500
Daniel Perry				
October 8, 2008	25,000	0.25	October 8, 2018	5,500

Calculation is based on the estimated price of Acasti's shares of \$0.47 on February 28, 2010 given the absence of a market value for Acasti's shares.

The award of Acasti options to Mr. Jean-Claude Debard is subject to disinterested shareholder approval

Acasti options and warrants were transferred and granted to the independent directors of the Company on October 8, 2008. Both have an exercise price of \$0.25 and mature, respectively, on October 8, 2018 and October 8, 2013. NeuroBioPharm warrants, granted on December 24, 2008, have an exercise price of \$0.10 and mature on December 24, 2013.

Warrant-Based Awards

Name / Grant Date	Number of securities underlying unexercised warrants (#)	Warrants exercise price (\$)	Warrants expiration date	Value of unexercised in-the-money Warrants ⁽¹⁾ (\$)
Michel Chartrand				
July 7, 2010 ⁽³⁾	25,000	0.50	October 9, 2013	-
October 8, 2008	125,000	0.25	October 8, 2013	27,500
Jean-Claude Debard ⁽²⁾				
July 7, 2010 ⁽³⁾	25,000	0.50	October 9, 2013	-
July 14, 2009	100,000	0.25	October 8, 2013	22,000
Ronald Denis				
July 7, 2010 ⁽³⁾	25,000	0.50	October 9, 2013	-
October 8, 2008	175,000	0.25	October 8, 2013	38,500
Daniel Perry				
July 7, 2010 ⁽³⁾	25,000	0.50	October 9, 2013	-
October 8, 2008	100,000	0.25	October 8, 2013	22,000

Calculation is based on the estimated price of Acasti's shares of \$0.47 on February 28, 2010 given the absence of a market value for Acasti's shares.

The award of Acasti warrants to Mr. Jean-Claude Debard is subject to disinterested shareholder approval Subject to shareholder approval.

NeuroBioPharm

The following table provides information on the number and value of each independent director's outstanding NeuroBioPharm warrants at the end of the financial year ended February 28, 2010.

Warrant-Based Awards

Name / Grant Date	Number of securities underlying unexercised warrants (#)	Warrants exercise price (\$)	Warrants expiration date	Value of unexercised in-the-money Warrants ⁽¹⁾ (\$)
Michel Chartrand				
July 7, 2010 ⁽³⁾	25,000	0.25	December 24, 2013	-
October 8, 2008	100,000	0.10	December 24, 2013	-
Jean-Claude Debard ⁽²⁾				
July 7, 2010 ⁽³⁾	25,000	0.25	December 24, 2013	-
July 14, 2009	100,000	0.10	December 24, 2013	-
Ronald Denis				
July 7, 2010 ⁽³⁾	25,000	0.25	December 24, 2013	-
October 8, 2008	100,000	0.10	December 24, 2013	-
Daniel Perry				
July 7, 2010 ⁽³⁾	25,000	0.25	December 24, 2013	-
October 8, 2008	100,000	0.10	December 24, 2013	-

No calculation of the fair value of the NeuroBioPharm Shares was performed by the Company. Given the absence of a market value for the company's shares, no value was given to the NeuroBioPharm shares for the purpose of this annual report.

The award of NeuroBioPharm warrants to Mr. Jean-Claude Debard is subject to disinterested shareholder approval Subject to shareholder approval.

Option-based and Warrant-based Awards of the Company, Acasti and NeuroBioPharm to the Directors value vested during the financial year ended on February 28, 2010

None of the previously options-based and warrants-based awards of the Company, Acasti and NeuroBioPharm to the Directors that vested during the financial year ended on February, 28, 2010 were in-the-money at their respective vesting date.

COMPENSATION OF EXECUTIVE OFFICERS

The Company is required to communicate the compensation provided to the Chief Executive Officer of the Company, the Chief Financial Officer of the Company and each of the three most highly compensated executive officers, or the three most highly compensated individuals acting in a similar capacity, other than the CEO and CFO, at the end of the most recently completed financial year whose total compensation was, individually, more than \$150,000 for that financial year.

Henri Harland is the Company's Chief Executive Officer (CEO), André Godin is the Vice President Administration and Finance (CFO) and Tina Sampalis, Chief Scientific Officer (CSO), are the only executive of the Company that received a total annual compensation exceeding \$150,000 for the last fiscal year. Messrs. Harland and Godin and Ms. Sampalis are hereinafter collectively referred to as the Named Executive Officers).

Compensation Discussion and Analysis

Compensation of executive officers of the Company is recommended to the Board of Directors by the Compensation Committee. In its review process, the Compensation Committee relies on input from management on the assessment of executives and Company performance.

During the most recently completed financial year, the Compensation Committee was composed of Mr. Michel Chartrand, Mr. Ronald Denis, Mr. Jean-Claude Debard and Mr. Daniel Perry. The Compensation Committee establishes management compensation policies and oversees their general implementation.

Executive compensation is generally based on pay for performance and to be competitive with other firms of comparable size in similar fields.

The Chief Executive Officer makes recommendations to the Compensation Committee as to the compensation of the Company's executive officers, other than himself, for approval by the Board. The Compensation Committee makes recommendations to the Board of Directors as to the compensation of the Chief Executive Officer, for approval, in accordance with the same criteria upon which the compensation of other executive officers is based.

Executive compensation is comprised of a base salary and variable components in the form of an annual bonus opportunity and stock options. The annual bonus provides an opportunity for management and executive employees to earn an annual cash incentive based on the degree of achievement of objectives set by the Board of Directors, generally based on actual vs. budgeted results. Generally, new stock option grants do not take into account the previous grant of options-based awards when considering new grants.

The members of senior management are eligible for specific performance compensation bonuses representing a variable percentage of the revenues generated in the six years following the execution of major agreements with strategic partners. The amount to be allocated is determined by the President and Chief Executive Officer, after consultation of the Board of Directors and Compensation Committee members, among the individuals having played a key role in the strategic alliance and/or major agreements.

A new compensation plan for some of the Named Executive Officers is being established by the Compensation Committee covering resignation, retirement or any other termination, as well as any change of control and/or change of responsibilities.

Qualitative factors beyond the quantitative financial metrics are also key considerations in making a determination of individual executive compensation payments. How executives achieve their financial results and demonstrate leadership consistent with the Company's values are key to individual compensation decisions.

The President and Chief Executive Officer's salary is based on comparable market consideration and the Compensation Committee's assessment of his performance, with regard given to the Company's financial performance and progress in achieving strategic performance.

The Company's executive compensation program is intended to attract, motivate and retain high performing senior executives, encourage and reward superior performance and align the executives' interests with those of the Company by providing a compensation which is competitive with the compensation received by executives employed by comparable companies by ensuring that the achievement of annual objectives is rewarded through the payment of bonuses and providing executives with long-term incentives through the grant of stock options.

The Company retained the services of AON Groupe Conseil to assist in determining the compensation of the Named Executive Officers of the Company for its fiscal year ended May 31, 2006. The mandate given to the consultant was to review and report to the Compensation Committee on the compensation of Named Executive Officers of companies comparable to the Company as well as the terms and conditions of such compensation, including incentive based remuneration.

The results from AON Groupe Conseil were based on a specialized survey conducted among Canadian biotechnology companies, Aon general databases and the public information available on public companies. AON did not reveal the name of any specific company used nor the selection criteria retained in its report to the Company, which was not required at that time by the securities legislation.

The Company did not practice any other benchmarking during the fiscal year ended on February 28, 2010 to establish the Named Executive Officer remuneration. The remuneration was based on the results obtained in the AON report which will be updated during the next financial year of the Company ending on February 28, 2011. The Company shall then be able to provide a complete description of the benchmark and the selection criteria used by the Company.

Compensation Elements

Remuneration of executive officers is revised each year and has been structured to encourage and reward the executive officers on the bases of short-term and long-term corporate performance. In the context of the analysis of the remuneration, the four following components are examined:

- (i) base salary;
- (ii) annual incentive plan, consisting of a cash bonus;
- (iii) grant of stock options of the Company; and grant of warrants of its subsidiaries, Acasti and NeuroBioPharm;
and
- (iv) other elements of compensation, consisting of benefits,

Base Salary

The compensation of the Company's executive officers is determined by the Board of Directors upon recommendations made by the Compensation Committee. Executive compensation is generally based on pay for performance and to be competitive with other firms of comparable size in similar fields.

Annual Incentive Plan

The Company has a bonus plan for the executive officers, based on a percentage of their base annual salary, granted at the discretion of the Board of Directors upon the recommendation of the Compensation Committee. Henri Harland, President and CEO of the Company is eligible for up to a 50% bonus of his annual base salary, Tina Sampalis, Chief Scientific Officer, is eligible for up to a 30% bonus of her base annual salary, and André Godin, Vice President Administration and Finance is eligible for up to a 30% bonus of his base annual salary.

Stock Options

The grant of stock options to the Company's executives is aimed at recognizing and rewarding the impact of longer-term strategic actions undertaken by management, offering an added incentive for the retention of the Company's executives as well as aligning the interests of the Company's executives with that of its shareholders.

The Company's Compensation Committee is responsible for overseeing and managing the Company Stock Option Plan and the Acasti Stock Option Plan. Grants of options to executives are approved by the Company's Board of Directors.

In addition, the Compensation Committee has recommended that warrants of its subsidiaries Acasti and NeuroBioPharm held by the Company be awarded to the Named Executive Officers to compensate them for the additional responsibilities and workload resulting from their new duties in the subsidiaries and to align their interests with shareholders' interests in order to stimulate value creation in the subsidiaries.

The grant of options is part of the long-term incentive component of executive and director compensation and an essential part of compensation. The designated senior executives and directors may participate in the stock option plan, which is designed to encourage optionees to link their interests with those of shareholders, in order to promote an increase in shareholder value. Awards are made by the Board of Directors, after recommendation by the Compensation Committee. Awards are established, among other things, according to the role and responsibilities associated with the participant's position and his or her influence over appreciation in shareholder value. Previous awards may sometimes be taken into account when new awards are considered. The terms of the plan are described below under the heading "Company Stock Option Plan" of this annual report.

Outstanding Named Executive Officer Option-Based and Warrant-Based Awards

The following tables sets out all awards of stock options to each Named Executive Officer outstanding at the end of the most recently completed financial year. This includes awards granted before the beginning of the financial year ended on February 28, 2010. The Company has no equity incentive plan for share-based award.

Company

Name / Grant Date	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options ⁽¹⁾ (\$)
Henri Harland				
July 13, 2010	150,000	1.50	July 13, 2013	
August 21, 2008	85,000	2.50	August 21, 2011	-
June 09, 2006	275,000	2.60	June 09, 2011	-
January 19, 2006	150,000	1.00	January 19, 2011	160,500
André Godin				
July 13, 2010	100,000	1.50	July 13, 2013	
August 21, 2008	70,000	2.50	August 21, 2011	-
June 09, 2006	100,000	2.60	June 09, 2011	-
January 19, 2006	150,000	1.00	January 19, 2011	160,800
Tina Sampalis				
July 13, 2010	100,000	1.50	July 13, 2013	
August 21, 2008	70,000	2.50	August 21, 2011	-
June 09, 2006	100,000	2.60	June 09, 2011	-
January 19, 2006	150,000	1.00	January 19, 2011	160,500

(1) Calculation is based on the trading price of the Company's shares on the TSX-Venture of \$2.07 on February 28, 2010.

Acasti and NeuroBioPharm

Acasti warrants and options, as well as NeuroBioPharm warrants, have been granted to Named Executive Officers of the Company in remuneration for the additional responsibilities and amount of work attributable to the position they hold in Acasti without any further monetary compensation for the fiscal periods ending February 28, 2009 and February 28, 2010 or unless and until a financing is realized.

Acasti

The following tables provide information on the number and value of each Named Executive Officers' outstanding Acasti options and warrants at the end of the financial year ended February 28, 2010.

Option-Based Awards

Name / Grant Date	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option expiration date	Value of unexercised in-the-money options ⁽¹⁾ (\$)
Henri Harland				
October 8, 2008	200,000	0.25	October 8, 2018	44,000
André Godin				
October 8, 2008	100,000	0.25	October 8, 2018	22,000
Tina Sampalis				
October 8, 2008	200,000	0.25	October 8, 2018	44,000

⁽¹⁾ Calculation is based on the estimated price of Acasti's shares of \$0.47 on February 28, 2010 given the absence of a market value for Acasti's shares.

Warrant-Based Awards

Name / Grant Date	Number of securities underlying unexercised warrants (#)	Warrants exercise price (\$)	Warrants expiration date	Value of unexercised in-the-money Warrants ⁽¹⁾ (\$)
Henri Harland				
July 13, 2010	175,000	0.50	October 9, 2013	-
October 8, 2008	1,250,000	0.25	October 8, 2013	275,000
André Godin				
July 13, 2010	100,000	0.50	October 9, 2013	-
October 8, 2008	700,000	0.25	October 8, 2013	154,000
Tina Sampalis				
July 13, 2010	175,000	0.50	October 9, 2013	-
October 8, 2008	1,250,000	0.25	October 8, 2013	275,000

⁽¹⁾ Calculation is based on the estimated price of the Company's shares of \$0.47 on February 28, 2010 given the absence of a market value for the Company's shares.

NeuroBioPharm

The following table provides information on the number and value of each the Named Executive Officers' outstanding NeuroBioPharm warrants at the end of the financial year ended February 28, 2010.

Warrant-Based Awards

Name / Grant Date	Number of securities underlying unexercised warrants (#)	Warrants exercise price (\$)	Warrants expiration date	Value of unexercised in-the-money Warrants ⁽¹⁾ (\$)
Henri Harland				
July 13, 2010	175,000	0.25	December 24, 2013	-
October 8, 2008	1,250,000	0.10	December 24, 2013	-
André Godin				
July 13, 2010	100,000	0.25	December 24, 2013	-
October 8, 2008	725,000	0.10	December 24, 2013	-
Tina Sampalis				
July 13, 2010	175,000	0.25	December 24, 2013	-
October 8, 2008	1,250,000	0.10	December 24, 2013	-

⁽¹⁾ No calculation of the fair value of the NeuroBioPharm Shares was performed by the Company. Given the absence of a market value for the company's shares, no value was given to the NeuroBioPharm shares for the purpose of this annual report.

Option-based and Warrant-based Awards of the Company, Acasti and NeuroBioPharm to the Named Executive Officers' value vested during the financial year ended on February 28, 2010

None of the previously options-based and warrants-based awards of the Company, Acasti and NeuroBioPharm to the Named Executive Officers that vested during the financial year ended on February, 28, 2010 were in-the-money at their respective vesting date.

Other Forms of Compensation

The Company's executive employee benefit program includes life, medical, dental and disability insurance. These benefits and perquisites are designed to be competitive overall with equivalent positions in comparable organizations. The Company does not have any pension plan available for its executives or directors.

Summary Compensation Table

The following Summary Compensation Table sets forth the compensation information for the Named Executive Officers for services rendered during the financial year ended February 28, 2010 and the nine-month period ended February 28, 2009.

For compensation related to previous years, please refer to the Company's Management Proxy Circular attached as an exhibit to the Company's Form 6-K filed on May 28, 2010.

Summary Compensation Table Named Executive Officers

Name	Year ended on February 28,	Salary (\$)	Option/Warrant-based awards ⁽¹⁾⁽²⁾ (\$)	Annual incentive plans (\$)	All other compensation (\$) ⁽³⁾⁽⁴⁾	Total compensation (\$)
Henri Harland	2010	380,000	-	-	-	380,000
	2009	291,058	109,812	-	61,448	462,318
André Godin	2010	204,000	-	-	15,692	219,692
	2009	151,693	90,433	-	-	242,126
Tina Sampalis	2010	294,000	-	-	55,000	349,000
	2009	214,000	90,433	-	-	304,433

- (1) The Company has adopted CICA 3870 Stock-based Compensation and Other Stock-based Payments to account for the issuance of stock options to employees and non-employees. The fair value of stock options is estimated at the grant date using the Black-Scholes Option Pricing Model. This model requires the input of a number of parameters, including stock price, stock exercise price, expected dividend yields, expected stock price volatility, expected time until exercise and risk-free interest rates. Although the assumptions used reflect management's best estimates, they involve inherent uncertainties based on market conditions generally outside of the Company's control.
- (2) For the nine-month period ended on February 28, 2009, the value of the option-based awards of the Company is based on a fair value of \$1.10 per option. The value of Acasti and NeuroBioPharm option-based awards and warrant-based awards is based on a fair value of \$0 per option or warrant on the date of such awards.
- (3) The amounts stated in this column represent the paid vacations to the Named Executive Officer for each relevant period, except for Mr. Henri Harland, which such amount represents part of over years accumulated vacation paid to him during the nine-month fiscal period ended February 28, 2009.
- (4) The value of perquisites and other personal benefits received by these executives did not total an aggregate value of \$50,000 or more, and does not represent 10% or more of their total salary for the 2010 and 2009 fiscal period.

Acasti and NeuroBioPharm, two subsidiaries of the Company, as described in the following table, were imputed a portion of the salaries of the Named Executive Officers. 30% and 10% of Henri Harland's salary; 20% and 5% of André Godin's salary; and 60% and 20% of Tina Sampalis' salary are imputed to Acasti and NeuroBioPharm respectively. These percentages are in effect as of February 28, 2010. Percentages are subject to adjustments at the discretion of the Company's management.

Name	Year ended on February 28,	Total Salary (\$)	Portion of the Salary Imputed to Neptune (\$)	Portion of the Salary Imputed to Acasti (\$)	Portion of the Salary Imputed to NeuroBioPharm (\$)
Henri Harland	2010	380,000	228,000	114,000	38,000
André Godin	2010	204,000	153,000	40,800	10,200
Tina Sampalis	2010	294,000	58,800	176,400	58,800

Company Stock Option Plan

The Company's stock option plan (the Company Stock Option Plan) was adopted on May 10, 2001 and was modified on October 1, 2002, August 28, 2003, June 14, 2005, April 20, 2006, April 29, 2009 and May 6, 2010. The Company Stock Option Plan was adopted to allow certain employees, directors, officers and consultants of the Company, as designated by the Board of Directors, to acquire shares directly from the Company.

The Company Stock Option Plan provides that each option granted under the Acasti Stock Option Plan will reduce by one and each option cancelled under the Acasti Stock Option Plan will increase by one the number of shares available

for further issuance under the Company Stock Option Plan until the date on which the shares of Acasti qualify as exchange-traded securities under applicable securities legislation and subject to the prior approval of the TSX Venture Exchange, at which date the number of shares available under the Company Stock Option Plan will be increased by the number of options then granted under Acasti Stock Option Plan.

The Company Stock Option Plan is administered by the Board of Directors of the Company, which will determine, *inter alia*, the number of common shares covered by any stock option, and the exercise price, expiry date and vesting period of such stock option in accordance with the terms of the Company Stock Option Plan.

As at the date of this annual report, options for up to 6,850,000 common shares of the Company may be granted by the Board of Directors under the Company Stock Option Plan. Not more than 5% of shares issued by the Company may be granted to a person for any 12 month period (not more than 2% if such person is a consultant or an investor relations services employee). In addition, the Company Stock Option Plan, together with any other plan to be established or any options already granted, will not result in either (i) the number of shares reserved for issuance in connection with options granted to insiders representing more than 10% of the number of shares of the Company outstanding, or (ii) the issuance to insiders, during a 12 month period, of a number of options representing more than 10% of the number of shares of the Company outstanding.

Options granted under the Company Stock Option Plan are non-transferable and are subject to a minimum vesting period of 18 months, with gradual and equal vesting at least on no less than a quarterly basis. They are exercisable, subject to vesting, at a price equal to the closing price of the common shares on the TSX Venture Exchange on the day prior to the grant of such options, and expire after a period determined by the Board of Directors not exceeding five years from such grant. Options will also lapse upon termination of employment or the end of the business relationship with the Company except that they may be exercised for 60 days after termination or the end of the business relationship (30 days for investor relations services employees), to the extent that they will have vested on such date of termination of employment.

Subject to the approval of the relevant authorities (including the TSX Venture Exchange) and compliance with the conditions attached to such approval (including, in certain circumstances, approval by disinterested shareholders), if applicable, the Board of Directors of the Company has the right to amend or terminate the Company Stock Option Plan. However, unless options holders consent to in writing, the amendment or termination of the Company Stock Option Plan cannot affect the conditions of options that are already granted and not exercised under the Company Stock Option Plan.

The Board of Directors of the Company approved the amendment and restatement of the Company Stock Option Plan as of May 6, 2010. The amendment to the Company Stock Option Plan allows (i) the Company to grant Company's stock options to certain employees, directors, officers and consultants of Acasti and NeuroBioPharm, or of any other subsidiary that the Company may have from time to time; and (ii) subject to the approval of the TSX Venture Exchange and the Company's disinterested shareholders, reduced the limit of stock options the Board of Directors is allowed to grant under the Company Stock Option Plan from 20% down to a maximum of 15% of the common shares of the Company issued and outstanding on May 6, 2010.

Acasti Stock Option Plan

Acasti's stock option plan (the Acasti Stock Option Plan) was approved by the Board of Directors of Acasti on October 8, 2008 and amended and restated as of April 29, 2009.

The Acasti Stock Option Plan was adopted to ensure to Acasti and its shareholders the benefit from incentive participation through the holding of shares by directors, officers, employees and consultants of Acasti, as designated by the Board of Directors of Acasti.

The Acasti Stock Option Plan is administered by the Board of Directors of Acasti, which will determine, *inter alia*, the number of Class A shares covered by any stock option and the exercise price, expiry date and vesting period of such stock option in accordance with the terms of the Acasti Stock Option Plan.

Options for Class A shares of Acasti representing up to 10% of the issued shares of Acasti held by public shareholders then outstanding may be granted by the Board of Directors under the Acasti Stock Option Plan,

provided that at no time shall the number of Class A shares of Acasti issuable pursuant to the terms of the Acasti Stock Option Plan exceed an aggregate of 1,530,000 Class A shares.

The number of options granted to a consultant or a person the services of which are retained in investor relations shall not exceed, for any 12 month period, more than 2% of the outstanding issued shares of Acasti then outstanding. In addition, the Acasti Stock Option Plan, together with any other plan to be established by Acasti or any options already granted by Acasti, will not result, unless the requisite shareholder approval is obtained under applicable securities legislation, in (i) the number of securities, calculated on a fully diluted basis, reserved for issuance under options granted to (A) related persons, exceeds 10% of the outstanding securities of Acasti, or (B) a related person and the associates of the related person, exceeds 5% of the outstanding securities of Acasti, or (ii) the number of securities, calculated on a fully diluted basis, issued within 12 months to (A) related persons, exceeds 10% of the outstanding securities of Acasti, or (B) an insider, exceeds 5% of the outstanding securities of Acasti.

The exercise price of the options will be determined by the Board of Directors of Acasti, but may not be lower than (i) the price per share obtained by Acasti for shares sold in its last arm's length private placement within the last year, and (ii) the demonstration of value of the exercise price in any one of the following ways: (A) a formal valuation or appraisal prepared by independent, qualified parties, such as Chartered Business Valuators, (B) deferred expenditures (excluding general and administrative costs) incurred within the five previous years, as evidenced by audited financial statements or an audited statement of costs, which have contributed to or can reasonably be expected to contribute to the development of the product or technology for which Acasti intends to conduct a recommended research and development program in the next 12 months, (C) net tangible assets, (D) five times annual average cash flow, or (E) some other determination of value acceptable to a recognized stock exchange where the securities of the Company are listed.

Options granted under the Acasti Stock Option Plan are non-transferable and may be exercised during the period determined by the Board of Directors, such period beginning at the earliest on the date of the grant of such options and ending at the latest ten years after such grant. Options will also lapse upon termination of employment or the end of the business relationship with the Company or death of the holder, except that they may be exercised for 60 days after termination of employment or the end of the business relationship (30 days for investor relations services employees) and for one year after the death of a holder.

Subject to the approval of the relevant authorities (including the TSX Venture Exchange) if applicable and compliance with the conditions attached to such approval (including, in certain circumstances, approval by disinterested shareholders) also if applicable, the Board of Directors of Acasti has the right to amend or terminate the Acasti Stock Option Plan. However, unless options holders consent to in writing, the amendment or termination of the Acasti Stock Option Plan cannot affect the conditions (number and exercise price) of options that are already granted and not exercised under the Acasti Stock Option Plan.

The Acasti Stock Option Plan must be approved each year by disinterested shareholders of the Company at its annual general meeting. The disinterested shareholders of the Company will also be asked, at such meeting, to ratify the grants of options to purchase Class A shares of Acasti approved by the Board of Directors of Acasti over the preceding year under the Acasti Stock Option Plan.

Termination and Change of Control Benefits

The implementation of termination and change of control benefits for key officers is currently under discussion. As at February 28, 2010, there were no termination and change of control benefits applicable to the Named Executive Officers.

Performance Graph

On February 28, 2010, the closing price of the common shares of the Company on the TSX Venture Exchange was \$2.07 per share. The following graph shows the cumulative return of a \$100 investment in common shares of the Company, made on February 28, 2005 on the TSX Venture Exchange, compared with the total return of the S&P / CDNX Index for the period shown on this graph.

The Company's trend in executive compensation was neutral during the fiscal year ended on February 28, 2010 despite the positive financial performance of the Company. Furthermore, the Company, aware of the international general economic climate, even if it has not been affected by it, did not award any bonuses or stock options during the fiscal year ended February 28, 2010, nor grant any salary raises during that period.

C. Board Practices

The Board currently consists of five (5) directors. Each director will hold office until the next annual meeting of shareholders or until the election of his successor, unless he resigns or his office becomes vacant by removal, death or other cause. For details on members of the audit committee and compensation committee please refer to table in item 6A.

There are no director services contracts with the Company providing for benefits upon termination of employment. Neptune and its subsidiaries have no compensatory plan or arrangement in respect of compensation received or that may be received by the directors of the Company in its most recently completed or current financial year to compensate such directors in the event of termination as director (resignation or retirement) or in the event of a change in control. However, such arrangements are under negotiation with certain executive officers. Other than as disclosed herein, there is no compensation paid to outside directors other than stock-based compensation.

The Audit Committee is composed of four members of the Board of Directors: Mr. Ronald Denis, Mr. Daniel Perry, Mr. Michel Chartrand and Mr. Jean-Claude Debard. The audit committee is appointed annually by the directors of Neptune at the first meeting of the board held after Neptune's annual general meeting. The primary function of the audit committee is to review the financial statements of Neptune before they are submitted to the board for approval. The Committee is also available to assist the board if required with matters relating to the appointment of Neptune's auditor and the overall scope and results of the audit, internal financial controls, and financial information for publication for various purposes. Under Multilateral Instrument 52-110 *Audit Committees* (MI 52-110), a director of an Audit Committee is independent if he or she has no direct or indirect material relationship with the issuer, that is, a relationship which could, in the view of the Board of Directors, reasonably interfere with the exercise of the member's independent judgment. All Audit Committee members are independent under this standard.

Each director's biography in Item 6A describes the relevant education and experience of each member of the Audit Committee that provides him or her with (a) an understanding of the accounting principles used by the Corporation to

prepare its financial statements, (b) the ability to assess the general application of such accounting principles, (c) experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to those that can reasonably be expected to be raised

by the Corporation's financial statements or experience actively supervising one or more persons engaged in such activities and (d) an understanding of internal controls and procedures for financial reporting.

The Compensation Committee is composed of four members of the Board of Directors: Mr. Ronald Denis, Mr. Daniel Perry, Mr. Michel Chartrand and Mr. Jean-Claude Debard. The Compensation Committee has the responsibility of evaluating the compensation, performance incentives and benefits granted to the Company's upper management in accordance with their responsibilities and performance, as well as of recommending the necessary adjustments to the Board of Directors of the Company. This committee also reviews the amount and method of remuneration granted to the directors. The Compensation Committee may engage an external firm to assist it during the execution of its mandate. The Compensation Committee considers time commitment, comparative fees and responsibilities in determining remuneration.

D. Employees

As at February 28, 2010, Neptune, along with Acasti and NeuroBioPharm, had a total of 75 employees.

	Administration	Sales	R&D	Production	Total
February 2010	16	3	10	46	75
February 2009	10	4	10	46	75
May 2008	11	3	3	42	59

E. Share Ownership

Name	Common Shares Owned and Controlled	Percentage of Common Shares Owned	Number of Securities Underlying Unexercised Options (#)	Exercise Price	Expiry Date
Henri Harland	2,656,611	6.61%	150,000	1.50	July 13, 2013
			275,000	2.60	June 9, 2011
			150,000	1.00	January 19, 2011
Ronald Denis	185,000	*	25,000	1.50	July 13, 2013
			25,000	1.50	July 13, 2013
Michel Chartrand	30,000	*	25,000	2.50	August 21, 2011
			25,000	2.60	June 9, 2011
			25,000	1.50	July 13, 2013
Daniel Perry	133,333	*	25,000	2.50	August 21, 2011
			25,000	2.60	June 9, 2011
			25,000	2.50	July 14, 2012
Jean-Claude Debard	0	*	25,000	1.50	July 14, 2012
			25,000	2.50	July 13, 2013
André Godin	833,000	2.07%	100,000	1.50	July 13, 2010
			70,000	2.50	August 21, 2011
			100,000	2.60	June 9, 2011
Tina Sampalis	655,750	1.63%	150,000	1.00	January 19, 2011
			100,000	1.50	July 13, 2010
			70,000	2.50	August 21, 2011
			100,000	2.60	June 9, 2011
			150,000	1.00	January 19, 2011

* Denotes less than 1%

(1) All prices are in Canadian Dollars

(2) As at August 18, 2010

ITEM 7: MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS**A. Major Shareholders**

As at May 18, 2010, to the best knowledge of the Company, other than the companies mentioned below, none of the directors or executive officers of the Company or other person beneficially owns, or controls or directs, directly or indirectly, voting securities carrying 5% or more of the voting rights attached to the Company's common shares:

Name and address of Shareholder	Number of Common Shares held	% of Common Shares
Northern Rivers Capital Management Inc. Royal Bank Plaza North Tower, Suite 2000 200 Bay Street, P.O. Box 66 Toronto, Ontario M5J 2J2	7,188,065	18.29%
GFX Trust ⁽¹⁾ 139, Place Ducharme Rosemère, Québec J7A 4H8	3,549,000	9.03%
Henri Harland ⁽²⁾ 139, Place Ducharme Rosemère, Québec J7A 4H8	2,366,611	6.02%

(1) Mr. Henri Harland is one of four trustees in GFX Trust.

(2) 439,611 common shares of the Company are controlled by Mr. Henri Harland and 1,927,000 common shares of the Company are held by Gestion Harland Inc., a company controlled by Henri Harland, President, CEO and Director of the Company.

B. Related Party Transactions

Under the terms of an agreement entered into with a shareholder (a company controlled by an officer and director), the Company is committed to pay royalties of 1% of its revenues in semi-annual instalments, for an unlimited period. The annual amount disbursed cannot exceed net earnings before interest, taxes and amortization of Neptune on a non-consolidated basis. For the year ended February 28, 2010, total royalties paid or payable to this party amounted to \$120,328 (year ended February 28, 2009 - \$221,629), including royalties on the transfer of licenses to the subsidiaries of \$137,000. As at February 28, 2010, the balance due to this shareholder under this agreement amounts to \$175,177 (2009 - \$221,629). This amount is presented in the balance sheet under accounts payable and accrued liabilities.

C. Interests of Experts and Counsel

Not applicable.

ITEM 8: FINANCIAL INFORMATION**A. Consolidated Statements and Other Financial Information**

See our 2010 audited consolidated financial statements in Exhibit F-1.

Legal Proceedings

University of Sherbrooke

On August 23, 2004, university researchers filed an injunction against the Company and the University demanding cancellation of the purchase option of the intellectual property granted to the Company by the University.

In December 2008, a ruling was rendered against the Company. The judge determined that the Company had not exercised its option to purchase the intellectual property in August 2004, as claimed by the Company, and it had to pay additional royalties in the amount of \$1,031,134 in addition to \$145,000 in fees. The judge furthermore set the purchase price for the intellectual property at \$1,776,000, although it had been previously established at \$275,000. Under the judgment, the Company had 45 days to exercise its option and it had to pay \$275,000 immediately.

Following the December 2008 ruling, the Company appealed the ruling and requested an immediate stay of its execution. The Company did not agree with the findings of the ruling and believed that its own arguments were well founded.

In January 2010, the court of appeal ruled in favor of the Company, confirming in its ruling the Company's rights to exercise its purchase option relating to the intellectual property at a purchase price of \$275,000 plus interest of \$36,000, for a total of \$311,000. The court also confirmed that the Company had exercised its option in August 18, 2004 and rejected all royalty claims with the exception of \$36,000 plus interest of \$11,000, for a total of \$47,000.

Schiff

During the second quarter, the Company received a complaint filed by Schiff Nutrition Group Inc. ("Schiff"), a former distributor of Neptune's products, in the United States District Court for the District of Utah, Central division, alleging that Neptune failed to meet certain delivery thresholds. As a result, Schiff is seeking monetary damages in the minimum amount of US \$1 million from Neptune.

After careful review of this complaint and having sought legal advice, the Company filed, early in the third quarter, a response and counterclaims to the Schiff complaint in the federal district court in Utah. The Company denies all material allegations and the requested monetary compensation in the complaint and asserts federal and state law claims against Schiff, including that Schiff failed to pay the Company for shipments of NKO[®] accepted by Schiff, and that Schiff caused its contractor to encapsulate NKO[®] despite the Company's objections that the resulting product would not meet specifications after encapsulation by Schiff's contractor.

Despite the Company's warning to Schiff to cease directly and indirectly using the Company trademark it was including NKO[®] and clinical support, Schiff continued to use the Company trademarks and claims, as it was seen on websites of multiple Schiff distributors.

Other

Also in 2009, Neptune filed a patent infringement lawsuit against Aker BioMarine ASA, Jedwards International, Inc. and Virgin Antarctic LLC, in defence of its U.S. method of extraction of total lipids fractions from Krill.

In 2009, Valensa submitted a patent application and refused to add Neptune's name as co-owner of this patent. This was in breach of an agreement to file with Neptune for a joint patent protection. Furthermore, Valensa failed to submit its action plan and volume commitments on the agreed upon deadline. For those reasons, Neptune refused to send samples to Valensa until Valensa complies with the terms of the signed agreement. This led to Valensa unilaterally terminating the agreement.

Dividend Policy

The Company declared a dividend of \$9,380 on its outstanding common shares on July 28, 2009, which was paid on August 15, 2009. The Company did not pay any other dividends on its outstanding common shares and does not anticipate that it will do so in the foreseeable future.

B. Significant Changes

There are no significant changes of financial conditions since the most recent audited financial statements included within this Annual Report. Interim financial statements for the period ended May 31, 2010 are incorporated by reference into this annual report.

ITEM THE OFFER AND LISTING**9:****A. Offer and Listing Details**

The annual high and low market prices for each of the following periods are as follows:

(a) Five most recent years

Fiscal year ended	TSX-V (CDN\$)		NASDAQ (US\$)	
	High	Low	High	Low
February 28, 2010	2.74	0.79	2.52	0.58
February 28, 2009	3.45	0.37	2.76	0.28
May 31, 2008	7.14	2.76	6.09	2.76
May 31, 2007	8.48	2.30	-	-
May 31, 2006	4.00	0.19	-	-

(b) Financial quarters two recent years

Quarter ended	TSX-V (CDN\$)		NASDAQ (US\$)	
	High	Low	High	Low
May 31, 2010	2.29	1.68	2.35	1.51
February 28, 2010	2.55	2.03	2.40	1.88
November 30, 2009	2.55	1.79	2.40	1.67
August 31, 2009	2.74	1.76	2.52	1.52
May 31, 2009	1.89	0.74	2.10	0.58
February 28, 2009	0.94	0.40	0.82	0.34
November 30, 2008	2.08	0.37	2.00	0.28
August 31, 2008	3.45	1.75	3.44	1.61

(c) Most recent six months

Period	TSX-V (CDN\$)		NASDAQ (US\$)	
	High	Low	High	Low
July 2010	1.44	1.02	1.36	1.08
June 2010	1.85	1.20	1.72	1.14
May 2010	2.15	1.68	2.13	1.51
April 2010	2.29	2.02	2.35	2.01
March 2010	2.18	2.00	2.11	1.94
February 2010	2.16	2.04	2.07	1.92

B. Plan of Distribution

Not applicable.

C. Markets

Neptune's common shares are currently listed and posted for trading on the TSX Venture Exchange under the symbol "NTB" and on the NASDAQ under the symbol "NEPT". The Company's common shares began trading on NASDAQ on August 6, 2007.

D. Selling Shareholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issue

Not applicable

ITEM 10: ADDITIONAL INFORMATION

A. Share Capital

Not applicable.

B. Memorandum and Articles of Association

Bylaws and Articles of Association

We were incorporated, in Canada, under Part IA of the *Companies Act* (Quebec) (the *Companies Act*). The Company's Articles of Incorporation as amended, which we refer to as our articles of incorporation, are on file with the Quebec Enterprise Registrar under the Quebec Enterprise Number 1148070734. Our articles of incorporation do not include a stated purpose and do not place any restrictions on the business that the Company carries on.

Directors

(a) *Power to vote where material interest.* Directors must not have any material interest in any organization carrying on business with the Company, except as permitted by applicable laws. Under the *Civil Code of Quebec*, to which the Company is subject as a legal person incorporated under the *Companies Act* (Quebec), a director of the Company must immediately disclose to the Board of Company any situation that may place him in a conflict of interest. Any such declaration of interest is recorded in the minutes of proceeding of the Board of Directors of the Company. The director abstains, except if required, from the discussion and voting on the question. In addition, it is the policy of the Company that an interested director recuse himself or herself from the decision-making process pertaining to a contract or transaction in which he or she has an interest.

(b) *Power to vote on compensation in absence of independent quorum.* Neither the Company's articles nor its bylaws contain provisions with respect to directors' power, in the absence of an independent quorum, to determine their remuneration.

(c) *Borrowing powers.* Subject to any restriction which may from time to time be included in the Company's articles, by-laws, or Unanimous Shareholders' Agreement, and without limiting the powers granted to the Company under the *Company's Act* (Quebec), the directors of the Company are authorized at all times: i) to borrow money on the Company's credit for amounts and upon conditions as may be deemed appropriate by obtaining loans or advances; ii) to issue bonds or other securities of the Company; iii) to pledge or sell such bonds or other securities for money at a price that is deemed appropriate; iv) to hypothecate, pledge or otherwise guarantee all or a portion of the Company's real property, movable or immovable, its business, its rights, present or future, or any borrowed sum or any other obligation or undertaking, present or future, of the Company; v) to delegate to certain directors or officers of the Company all or a part of the powers listed above, to the extent and in the manner determined by the directors.

(d) *Retirement and age limit for directors.* Neither the Company's articles nor its by-laws contain any provision with respect to the retirement of directors under an age limit requirement.

(e) *Number of shares (if any) required for director's qualification.* Neither the Company's articles nor its by-laws contain any provision with respect to the number of shares, if any, required for the qualification of directors.

Rights, Preferences and Restrictions Attaching to each Class of Shares of the Company

Common Shares

The following is a brief description of the rights, privileges, conditions and restrictions attaching to the Common Shares of the Company:

(a) Dividends. Subject to the prior rights of the holders of Preferred Shares ranking before the Common Shares as to dividends, the holders of Common Shares are entitled to receive dividends as declared by the Board of Directors of the Company from the Company's funds that are duly available for the payment of dividends.

(b) Voting Rights. Each Common Share entitles its holder to receive notice of, and to attend and vote at, all annual or special meetings of the shareholders of the Company. Each Common Share entitles its holder to one vote at any meeting of the shareholders, other than meetings at which only the holders of a particular class or series of shares are entitled to vote due to statutory provisions or the specific attributes of this class or series.

(c) Rights to share in the Company's Profits. None, other than as provided in paragraph (a) above (the holders of our common shares are entitled to receive dividends as determined by our Board of Directors) and paragraph (d) below (the holders of our common shares are entitled to participation in our remaining property and assets available for distribution in the event of our liquidation, dissolution or reorganization).

(d) Liquidation. In the event of the Company's voluntary or involuntary winding-up or dissolution, or any other distribution of the Company's assets among its shareholders for the purposes of winding up its affairs, the holders of Common Shares shall be entitled to receive, after payment by the Company to the holders of Preferred Shares ranking prior to Common Shares regarding the distribution of the Company's assets in the case of winding-up or dissolution, share for share, the remainder of the property of the Company, with neither preference nor distinction.

(e) Redemption Provisions. None.

(f) Sinking Fund Provisions. None.

(g) Liability to Further Capital Calls by the Company. None.

(h) Provisions discriminating against existing or prospective holders of Common Shares as a result of such holder owning a substantial number of shares. None.

Preferred Shares

The following is a brief description of the rights, privileges, conditions and restrictions attaching to the Preferred Shares of the Company:

(a) Dividends. The shares in each series of Preferred Shares rank prior to the Common Shares of the Company with regard to payment of dividends. Series A Preferred Shares entitle holders thereof to a fixed, preferential and non-cumulative annual dividend of 5% of the amount paid for the said shares.

(b) Voting Rights. The holders of Preferred Shares shall not be entitled to receive notice of, or to attend or vote at the meetings of the shareholders, except: (i) in the event of a separate meeting or vote by class or by series as specified by law, (ii) where entitled to vote by class or series on amendments to the attributes attaching to the class or series, or (iii) where applicable, in the event of the Company's omission to pay the number of periodical dividends, whether consecutive or not, as applicable to any series.

(c) Rights to share in the Company's Profits. Other than as provided in paragraph (a) above and paragraph (d) below, none.

(d) Liquidation. The shares in each series of Preferred Shares rank prior to the Common Shares of the Company with regard to reimbursement of capital and division of assets in the event of the Company's winding-up or dissolution.

(e) *Redemption Provisions.* None.

(f) *Sinking Fund Provisions.* None.

(g) *Liability to Further Capital Calls by the Company.* None.

(h) *Provisions discriminating against existing or prospective holders of Preferred Shares as a result of such holder owning a substantial number of shares.* None.

Action Necessary to Change Rights of Shareholders

In order to change the rights of our shareholders, we would need to amend our articles of incorporation to effect the change. Such amendment would require the approval of holders of two-third of the shares cast at a duly called special meeting. For certain amendments such as those creating of a class of preferred shares, a shareholder is entitled to dissent in respect of such resolution amending our articles and, if the resolution is adopted and the Company implements such changes, demand payment of the faire value of its shares. These conditions are those required by law under the *Company s Act* (Québec).

Meetings of Shareholders

An annual meeting of shareholders is held each year for the purpose of considering the financial statements and reports, electing directors, appointing auditors and for the transaction of other business as may be brought before the meeting. The board of directors has the power to call a special meeting of shareholders at any time.

Notice of the time and place of each meeting of shareholders must be given not less than 21 days, nor more than 60 days, before the date of each meeting to each director, to the auditor and to each shareholder who at the close of business on the record date for notice is entered in the securities register as the holder of one or more shares carrying the right to vote at the meeting.

Notice of meeting of shareholders called for any other purpose other than consideration of the minutes of an earlier meeting, financial statements and auditor s report, election of directors and reappointment of the incumbent auditor, must state the nature of the business in sufficient detail to permit the shareholder to form a reasoned judgment on and must state the text of any special resolution or by-law to be submitted to the meeting.

The only persons entitled to be present at a meeting of shareholders are those entitled to vote, the directors of the Company and the auditor of the Company. Any other person may be admitted only on the invitation of the chairman of the meeting or with the consent of the meeting. In circumstances where a court orders a meeting of shareholders, the court may direct how the meeting may be held, including who may attend the meeting.

Limitations on Right to Own Securities

The *Investment Canada Act* requires non-Canadian (as defined in the *Investment Canada Act*) (Canada) individuals, governments, corporations and other entities who wish to acquire control of a Canadian business (as defined in the *Investment Canada Act* (Canada)) to file either an application for review (when certain asset value thresholds are met) or a post closing notification with the Director of Investments appointed under the *Investment Canada Act* (Canada), unless a specific exemption applies. The *Investment Canada Act* (Canada) requires that, when an acquisition of control of a Canadian business by a non-Canadian is subject to review, it must be approved by the Minister responsible for the *Investment Canada Act* (Canada) on the basis that the Minister is satisfied that the acquisition is likely to be of net benefit to Canada , having regard to criteria set forth in the *Investment Canada Act* (Canada).

Provisions that would have an Effect of Delaying, Deferring or Preventing Change of Control

None.

Ownership Threshold

None, other than thresholds required by law.

Applicable Laws

Not applicable.

Conditions Governing Changes in Capital

Not applicable.

C. Material Contracts

The Company adopted a Shareholder Rights Plan (SRP) on June 22, 2010. The Board of Directors of the Company determined that the establishment of a SRP was in the best interest of the Company's shareholders because it allows them to have more time to consider any significant takeover bid for the Company without undue pressure, it allows the Board to propose, if appropriate, other alternatives to maximize shareholder value and to allow additional time for competing bids to emerge. The rights issue pursuant to the SRP required the approval of a majority of shareholders, which was obtained on June 22, 2010.

The SRP allows holders of common shares to purchase from the Company, for each common share held, an amount of common shares worth twice the market price on the date a triggering event occurs, at a price per common share equal to half the market price on the date of such triggering event. As defined in the SRP, a triggering event consists of a transaction that results in the acquisition by a person or group of persons (the "Acquirer") of 20% or more of the outstanding common shares of the Company through a transaction that is not considered a permitted bid. The Acquirer would not be entitled to exercise any right it may hold through such transaction.

The rights under the SRP are not triggered by the purchase of shares made pursuant to a permitted bid. A permitted bid is one that is open for not less than 60 days and that is made to all shareholders by way of a take-over circular prepared in compliance with applicable securities laws. It must also comply with certain other conditions set out in the agreement signed with Computershare Services Inc., acting as registrar and transfer agent for the Company, to implement the SRP.

The Board retains discretion on the continuation of the SRP until its scheduled termination in three years, and on the waiving of dilutive effects of the provisions on triggering events for acquirers. A copy of the SRP is available on SEDAR and EDGAR under the Company's filings.

Other than the SRP the Company has not entered into any material contract, other than those entered into in the normal course of business, within its most recently completed financial year, or before its most recently completed financial year, which is still in effect except for Technology License Agreement with Acasti Pharma Inc. on August 7, 2008 and Technology License Agreement with NeuroBioPharm Inc. on October 15, 2008.

During the nine-month fiscal period ended February 28, 2009, the Company granted an exclusive worldwide license to its majority-owned subsidiary, Acasti, to develop, validate health benefits by way of clinical studies and market new pharmaceutical products (OTC, medical food, Rx) that target the cardiovascular system using the Company's technology and intellectual property. Acasti will finance its research and development activities as well as its clinical studies. The products developed by Acasti are expected to require the approval from the U.S. Food and Drug Administration before clinical studies are conducted as well as the approval from similar regulatory organizations before sales are allowed.

On October 15, 2008, the Company granted an exclusive worldwide license to its renamed, on December 24, 2008, wholly-owned subsidiary NeuroBioPharm to develop, validate and commercialise new pharmaceutical products (OTC, medical food, Rx) that target cognitive and neurological pharmaceutical applications using the Company's technology and intellectual property. Each product will be developed and financed by NeuroBioPharm. The products developed by NeuroBioPharm are expected to require the approval of the U.S. Food and Drug Administration before

clinical studies are conducted as well as the approval of similar regulatory organizations before sales are allowed.

D. Exchange Controls

There are currently no limitations imposed by Canadian laws, decrees or regulations that restrict the import or export of capital, including foreign exchange controls, or that affect the remittance of dividends, and interest or other payments to nonresident holders of the Company's securities, other than withholding tax requirements. See Taxation below.

There is no limitation imposed by the laws of Canada or by the charter or other constituent documents of the Company on the right of a non-resident to hold or vote the common shares, other than as provided in the Investment Canada Act (the Investment Act). The following discussion summarizes the material features of the Investment Act for a non-Canadian who proposes to acquire common shares of the Company.

It is general only and is not a substitute for independent advice from an investor's own advisor, and it does not anticipate statutory or regulatory amendments other than as set out below. (While the provisions of the Investment Act may be engaged where a non-Canadian acquires all or substantially all of the assets used by the Company in carrying on a business, this circumstance is not discussed below.)

The Investment Act generally prohibits implementation of a reviewable investment by an individual, government or agency thereof, corporation, partnership, trust or joint venture (each an entity) that is not a Canadian as defined in the Investment Act (a non-Canadian), unless the minister responsible for the Investment Act, on application of the non-Canadian acquiror, is satisfied or deemed to be satisfied that the investment is likely to be of net benefit to Canada.

The size and nature of a proposed transaction may render an investment reviewable. In general, an investment in the Company's common shares by a non-Canadian that is a WTO investor (as that term is defined in the Investment Act and which term includes entities which are controlled by nationals of member states of the World Trade Organization), would be reviewable under the Investment Act if it is considered under the Investment Act to be an investment to acquire control of the Company and the value of the Company's assets, as determined in accordance with the regulations promulgated under the Investment Act, was over Cdn. \$312 million (in 2009) at the relevant time, which figure is subject to change annually pursuant to a GDP escalator). A lower review threshold would apply if the non-Canadian acquiror is not a WTO investor (in circumstances where the Company is not controlled by WTO investors other than a Canadian) or if the Company were viewed to carry on a cultural business.

A non-Canadian would acquire control of the Company for the purposes of the Investment Act if the non-Canadian acquired a majority of the Company's common shares. The acquisition of less than a majority but one-third or more of such common shares would be presumed to be an acquisition of control of the Company unless it could be established that, on the acquisition, the Company would not be controlled in fact by the acquiror through the ownership of the common shares.

Certain transactions relating to the Company's common shares would be exempt from the net benefit to Canada review and approval mechanism under the Investment Act, including: (a) an acquisition of the common shares by a person in the ordinary course of that person's business as a trader or dealer in securities; (b) an acquisition of control of the Company in connection with the realization of security granted for a loan or other financial assistance and not for a purpose related to the provisions of the Investment Act; and (c) an acquisition of control of the Company by reason of an amalgamation, merger, consolidation or corporate reorganization following which the ultimate direct or indirect control in fact of the Company, through the ownership of the Company's common shares, remained unchanged.

Note that effective March 12, 2009, certain amendments were effected to the Investment Act that provide for changes to the aforementioned review threshold upon the coming into force of certain regulations under the Investment Act. Those regulations have not yet come into force but are anticipated to come into force in the near future. Generally speaking, the review threshold referred to above will be increased to \$600 million of enterprise value (increasing over

time). The phrase "enterprise value" will be defined in the regulations. In the case of acquisitions of control of public companies, enterprise value is expected to be based on adjusted market capitalization.

The acquisition by a non-Canadian of common shares of the Company would be reviewable at the discretion of the minister under the national security provisions of the Investment Act if the minister has reasonable grounds to believe that the acquisition could be injurious to national security. The right of any person, Canadian or non-Canadian, to acquire common shares of the Company is subject to compliance with the competition laws of Canada and of any other jurisdictions in which the Company carries on business.

E. Taxation

ALL PROSPECTIVE INVESTORS ARE ADVISED TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE SPECIFIC TAX CONSEQUENCES OF PURCHASING THE COMMON SHARES OF THE COMPANY.

Material Canadian Federal Income Tax Consequences for United States Residents

The following summarizes the material Canadian federal income tax consequences generally applicable to the holding and disposition of the Company's common shares by a holder (in this summary, a U.S. Holder) who, (a) for the purposes of the Income Tax Act (Canada) (the Tax Act), is not resident in Canada, deals at arm's length with the Company, holds the Company's common shares directly and, not through a fiscally transparent entity, and as capital property and does not use or hold such common shares in the course of carrying on, or otherwise in connection with, a business in Canada, and (b) for the purposes of the Canada-United States Income Tax Convention, 1980 (the Treaty), is a resident solely of the United States, has never been a resident of Canada, and has not held or used (and does not hold or use) the Company's common shares in connection with a permanent establishment or fixed base in Canada. This summary does not apply to traders or dealers in securities, limited liability companies, tax-exempt entities, insurers, financial institutions (including those to which the mark-to-market provisions of the Tax Act apply), or any other U.S. Holder to which special considerations apply.

This summary is based on the current provisions of the Tax Act including all regulations thereunder, the Treaty, all proposed amendments to the Tax Act, the regulations and the Treaty publicly announced by the Government of Canada to the date hereof, and the current administrative practices of the Canada Customs and Revenue Agency. It has been assumed that all currently proposed amendments will be enacted as proposed and that there will be no other relevant change in any governing law or administrative practice, although no assurances can be given in these respects. This summary does not take into account provincial, U.S., state or other foreign income tax law or practice. The tax consequences to any particular U.S. Holder will vary according to the status of that holder as an individual, trust, corporation, partnership or other entity, the jurisdictions in which that holder is subject to taxation, and generally according to that holder's particular circumstances. Accordingly, this summary is not, and is not to be construed as, Canadian tax advice to any particular U.S. Holder.

Dividends

Dividends paid or deemed to be paid to a U.S. Holder by the Company will be subject to Canadian withholding tax. Under the Treaty, the rate of withholding tax on dividends paid to a U.S. Holder is generally limited to 15% of the gross amount of the dividend (or 5% if the U.S. Holder is a corporation and beneficially owns at least 10% of the Company's voting shares). The Company will be required to withhold the applicable withholding tax from any such dividend and remit it to the Canadian government for the U.S. Holder's account.

Disposition

A U.S. Holder is not subject to tax under the Tax Act in respect of a capital gain realized on the disposition of a common share of the Company in the open market unless the share is taxable Canadian property to the holder thereof and the U.S. Holder is not entitled to relief under the Treaty. A common share will be taxable Canadian property to a U.S. Holder if, at any time during the 60 months preceding the disposition, the U.S. Holder or persons with whom the U.S. Holder did not deal at arm's length alone or together owned, or had rights to acquire, 25% or more of the

Company's issued shares of any class or series. If the common shares of the Company constitute taxable Canadian property to the holder, the holder may be subject to Canadian income tax on the gain. The taxpayer's taxable capital gain or loss from a disposition of the share is the amount, if any, by which the proceeds of disposition exceed (or are exceeded by) the aggregate of the adjusted cost base and reasonable expenses of disposition. One-half of the capital gain is included in income and one-half of the capital loss is deductible from capital gains realized in the same year. Unused capital losses may be carried back three taxation years or forward indefinitely and applied to reduce capital gains realized in those years. It should be noted that Canada requires a withholding tax on the gross proceeds of a sale of taxable Canadian property by a non-resident. The withholding tax may be reduced on completion of a Clearance Certificate Request. If the disposition of the share is subject to tax in Canada, the non-resident must also file a Canadian income tax return reporting the disposition.

A U.S. Holder whose common shares do constitute taxable Canadian property, and who might therefore be liable for Canadian income tax under the Tax Act, will generally be relieved from such liability under the Treaty unless the value of such shares at the time of disposition is derived principally from real property situated in Canada. The value of the Company's common shares is not currently derived principally from real property situated in Canada.

Certain U.S. Federal Income Tax Considerations

The following is a summary of certain material U.S. federal income tax consequences to a U.S. Holder (as defined below) arising from the acquisition, ownership, and disposition of our common shares. This summary assumes that holders will hold their common shares as capital assets within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended (the Code) (generally, assets held for investment purposes). This summary is for general information purposes only and does not purport to be a complete analysis of all potential U.S. federal income tax consequences that may apply to a U.S. Holder as a result of the acquisition, ownership, and disposition of common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder.

This summary is based on the Code, existing and proposed U.S. Treasury Regulations, administrative pronouncements and judicial decisions in effect as of the date hereof. Such authorities may be replaced, revoked or modified, possibly on a retroactive basis, so as to result in U.S. federal income tax consequences different from those discussed below. This summary is not binding on the U.S. Internal Revenue Service (the IRS) or the courts.

This summary does not address the U.S. state and local, U.S. federal estate and gift, or foreign tax consequences to U.S. Holders of the acquisition, ownership, and disposition of common shares. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal income, U.S. state and local, U.S. federal estate and gift and foreign tax consequences of the acquisition, ownership, and disposition of common shares.

This summary does not address the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares to holders that are subject to special provisions under the Code, including tax-exempt organizations, qualified retirement plans, individual retirement accounts, other tax-deferred accounts, financial institutions, insurance companies, real estate investment trusts, regulated investment companies, dealers in securities or currencies, traders in securities that elect to apply a mark-to-market accounting method, U.S. Holders (as defined below) that have a functional currency other than the U.S. dollar, holders that are liable for the alternative minimum tax under the Code, holders that own common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction, holders that acquired their common shares in a compensatory transaction, or holders that own (directly, indirectly, or constructively) 10% or more of the total combined voting power of our outstanding shares. U.S. Holders that are subject to special provisions under the Code, including any holders described immediately above, should consult their own tax advisors regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares.

For purposes of this summary, a U.S. Holder is a beneficial owner of common shares that is: (i) an individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate if the income of such estate is subject to U.S. federal income tax regardless of its source, or (iv) a trust if (a) the trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or (b) a U.S. court is able to exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of such trust.

If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) holds common shares, the U.S. federal income tax consequences to such partnership (or other entity) and its partners (or owners) generally will depend on the activities of the partnership (or other entity) and the status of such partners (or owners). Partners of partnerships (or owners of other entities) should consult their own tax advisors regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares.

Distributions on Common Shares

Except as discussed below under *Passive Foreign Investment Company Rules*, a U.S. Holder that receives a distribution with respect to the common shares will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld) to the extent of our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. To the extent that a distribution exceeds our current and accumulated earnings and profits, such a distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in the common shares, and thereafter as capital gain.

Subject to certain limitations, dividends paid to non-corporate U.S. Holders, including individuals, may be eligible for a reduced rate of taxation in taxable years beginning before January 1, 2011 if we are a qualified foreign corporation for U.S. federal income tax purposes and if certain holding period requirements are satisfied. A qualified foreign corporation includes a foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States that includes an exchange of information program and that the U.S. Treasury Department has determined is satisfactory for purposes of the qualified dividend provisions of the Code. The U.S. Treasury Department has determined that the Canada-United States Income Tax Convention (1980) (the *Convention*) is satisfactory for purposes of the qualified dividend provisions of the Code. A qualified foreign corporation does not include a foreign corporation that is a passive foreign investment company (PFIC) for the taxable year in which a dividend is paid or that was a PFIC for the preceding taxable year. As discussed below, we believe that we were not a PFIC for the taxable year ended February 28, 2010 and we do not expect to be a PFIC for the current taxable year ending February 28, 2011. Because this conclusion is a factual determination that is made annually and is subject to change, however, there can be no assurances that we will not be a PFIC for the current taxable year or any future taxable year. Distributions on the common shares should be eligible for the reduced rate of taxation described above as long as we are eligible for the benefits of the *Convention* and we are not a PFIC in the taxable year of such distribution or the prior taxable year.

Distributions will be includable in a U.S. Holder's gross income on the date actually or constructively received by the U.S. Holder in accordance with such U.S. Holder's regular method of accounting. These dividends will not be eligible for the dividends received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations.

The amount of a distribution paid to a U.S. Holder in Canadian dollars generally will be equal to the U.S. dollar value of such distribution based on the exchange rate applicable on the date of receipt. If the Canadian dollars are converted into U.S. dollars on the date of receipt of the distribution, a U.S. Holder's tax basis in the Canadian dollars will be equal to their U.S. dollar value on that date. As a result, the U.S. Holder generally will not be required to recognize any foreign currency gain or loss. If a U.S. Holder does not convert Canadian dollars received as a distribution into U.S. dollars on the date of receipt, the U.S. Holder's tax basis in the Canadian dollars will be equal to their U.S. dollar value on that date. Such a U.S. Holder generally will recognize gain or loss on the subsequent sale or other taxable disposition of the Canadian dollars (including an exchange for U.S. dollars). This gain or loss generally will be treated as ordinary income or loss and will be treated as U.S.-source income or loss for U.S. foreign tax credit limitation purposes.

A U.S. Holder may be entitled to claim a U.S. foreign tax credit for, or deduct, Canadian taxes that are withheld from distributions received by the U.S. Holder, subject to applicable limitations in the Code. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder

during a taxable year. Complex limitations apply to the U.S. foreign tax credit. Dividends that we pay will constitute foreign source income and will be categorized as passive category income, or in the case of certain U.S. Holders, general category income. Each U.S. Holder should consult its own tax advisor regarding the availability of the U.S. foreign tax credit in its particular circumstances.

Disposition of Common Shares

A U.S. Holder will recognize gain or loss on the sale or other taxable disposition of common shares in an amount equal to the difference, if any, between the amount of cash plus the fair market value of any property received and the U.S. Holder's tax basis in the common shares sold or otherwise disposed of. Except as discussed below under *Passive Foreign Investment Company Rules*, any such gain or loss generally will be capital gain or loss, and will be long-term capital gain or loss if the common shares have been held for more than one year. Net long-term capital gains of non-corporate U.S. Holders, including individuals, currently are eligible for reduced rates of taxation. Deductions for capital losses are subject to significant limitations under the Code. Gain or loss recognized by a U.S. Holder on the sale or other taxable disposition of common shares generally will be treated as U.S.-source income or loss for U.S. foreign tax credit limitation purposes.

Passive Foreign Investment Company Rules

We will be a PFIC if, for a taxable year, (i) 75% or more of our gross income for such taxable year is passive income or (ii) on average, 50% or more of our assets either produce passive income or are held for the production of passive income, based on the fair market value of such assets. Passive income includes dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. For purposes of the PFIC income test and asset test described above, in general, if we own, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, we will be treated as if we (a) hold a proportionate share of the assets of such other corporation and (b) receive directly a proportionate share of the income of such other corporation.

Based on the composition of our income and assets, we believe that we were not a PFIC for the taxable year ended February 28, 2010, and, based on the projected composition of our income and assets, we do not expect that we will be a PFIC for the current taxable year ending February 28, 2011. The determination of whether we were or will be a PFIC for any taxable year depends on the nature and composition of our income and assets throughout the taxable year and on the application of complex U.S. federal income tax rules which are subject to differing interpretations. In addition, this determination is a factual determination that is made at the close of the taxable year and is subject to change. Accordingly, there can be no assurance at this time that we will not be a PFIC for the current taxable year or any future taxable year. Each U.S. Holder should consult its own tax advisors regarding our potential classification as a PFIC during any taxable year during which the U.S. Holder holds common shares and the U.S. federal income tax consequences to such U.S. Holder.

If we were to become a PFIC, any gain recognized by a U.S. Holder on the sale or other taxable disposition of common shares, and any excess distribution received on the common shares, generally would be ratably allocated to each day in the U.S. Holder's holding period for the common shares. Excess distributions are amounts received by a U.S. Holder with respect to its common shares in any taxable year that exceed 125% of the average distributions received by the U.S. Holder in the shorter of either the three previous years or the U.S. Holder's holding period for the common shares before the current taxable year. The amount of any such gain or excess distribution allocated to prior years of the U.S. Holder's holding period for the common shares generally would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such prior year. A U.S. Holder would be required to pay interest on the resulting tax liability for each such prior year, calculated as if such tax liability had been due in each such prior year.

A U.S. person that holds stock of a PFIC generally may make a mark-to-market election to mitigate some of the adverse tax consequences of holding PFIC stock. If we were to become a PFIC, a U.S. Holder generally would be able to make a mark-to-market election as long as the common shares constituted marketable stock. Marketable stock is stock that is regularly traded (other than in de minimis quantities) on a U.S. or foreign exchange or other market that the U.S. Treasury Department determines has trading, listing, financial disclosure, and other rules adequate to carry out the purposes of the mark-to-market election. NASDAQ, on which our common shares are currently traded, is a

qualifying exchange for this purpose. A U.S. Holder that made a mark-to-market election would include as ordinary income, for each taxable year in which we were a PFIC, an amount equal to the excess, if any, of the fair market value of the common shares as of the close of such taxable year over the U.S. Holder's adjusted tax basis in such common shares. A U.S. Holder that made a mark-to-market election would have a deduction in an amount equal to the excess, if any, of such U.S. Holder's adjusted tax basis in the common shares over the fair market value of such common shares as of the close of such taxable year. However, such deductions are allowable only to the extent of any net mark-to-market gains on the common shares that the U.S. Holder has included in income for prior taxable years. The U.S. Holder's basis in the common shares will be adjusted to reflect any such income or loss amounts.

A U.S. person that holds stock of a PFIC generally may make a qualified electing fund (QEF) election with respect to stock of the PFIC if the PFIC agrees to provide the holder with certain information on an annual basis. We do not currently intend to provide U.S. Holders with the information necessary to make effective QEF elections if we become a PFIC.

The PFIC rules are complex, and each U.S. Holder should consult its own tax advisor regarding the application of the PFIC rules in its particular circumstances and the availability and advisability of making a mark-to-market election.

Information Reporting and Backup Withholding

In general, unless a U.S. Holder belongs to a category of certain exempt recipients (such as corporations), information reporting requirements will apply to distributions as well as proceeds of sales of common shares that are effected through the U.S. office of a broker or the non-U.S. office of a broker that has certain connections with the United States. Backup withholding may apply to these payments if a U.S. Holder fails to provide a correct taxpayer identification number or certification of exempt status, fails to report in full dividend and interest income or, in certain circumstances, fails to comply with applicable certification requirements. Any amounts withheld under the backup withholding rules will be allowed as a refund or credit against a U.S. Holder's U.S. federal income tax, provided the U.S. Holder furnishes the required information to the IRS in a timely manner.

F. Dividends and Paying Agents

Not applicable.

G. Statements by Experts

Not applicable.

H. Documents on Display

The Company's registration statement on Form 20-F and its annual and periodic reports filed with the U.S. Securities and Exchange Commission (the Commission) may be inspected and copied at the Commission's public reference facilities in Room 5080, 100 F Street, N.E., Washington, D.C., 20549 and at the regional offices of the Commission, or obtained by mail from the Commission at prescribed rates. The Commission may be reached at 1-800-SEC-0330 for further information on the public reference rooms. Reports furnished by the Company to the Commission since June 8, 2007 are also maintained electronically on the Commission's website, www.sec.gov, and the Company's Canadian filings are available at www.sedar.com.

I. Subsidiary Information

Not applicable.

ITEM 11: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This ITEM should be read in conjunction with ITEM 3D: Risk Factors of this annual report.

Some market-risk sensitive instruments are entered into for purposes other than trading. The following discusses risks arising from financial instruments, including credit risk, foreign, exchange risk, interest rate risk and liquidity risk.

1. *Credit risk:*

Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations, and arises primarily from the Company's trade receivables. The Company may also have credit risk relating to cash, which it manages by dealing only with highly-rated Canadian institutions. The carrying amount of financial assets, as disclosed in the consolidated balance sheet, represents the Company's credit exposure at the reporting date, including trade receivables. The Company's trade receivables and credit exposure fluctuate throughout the year. The Company's average trade receivables and credit exposure during the year may be higher than the balance at the end of that reporting period.

The Company's credit risk for trade receivables is concentrated, as the majority of its sales are to a relatively small group of distributors. As at February 28, 2010, the Company had twenty trade debtors. Most sales' payment terms are set in accordance with industry practice. Three customers represent 56% (two customers represented 41% as at February 28, 2009) of total trade accounts included in accounts receivable.

Most of the Company's clients are distributors for a given territory and are privately-held enterprises. The profile and credit quality of the Company's retail customers vary significantly. Adverse changes in a customer's financial position could cause us to limit or discontinue conducting business with that customer, require us to assume more credit risk relating to that customer's future purchases or result in uncollectible accounts receivable from that customer. Such changes could have a material adverse effect on our business, consolidated results of operations, financial condition and cash flows.

The Company's extension of credit to customers involves considerable judgment and is based on an evaluation of each customer's financial condition and payment history. The Company has established various internal controls designed to mitigate credit risk, including a credit analysis by the insurer which recommends customers' credit limits and payment terms that are reviewed and approved by the Company. The Company reviews periodically the insurer's maximum credit quotation for each of its clients. New clients are subject to the same process as regular clients. The Company has also established procedures to obtain approval by senior management to release goods for shipment when customers have fully-utilized approved insurers credit limits. From time to time, the Company will temporarily transact with customers on a prepayment basis where circumstances warrant.

While the Company's credit controls and processes have been effective in mitigating credit risk, these controls cannot eliminate credit risk and there can be no assurance that these controls will continue to be effective, or that the Company's low credit loss experience will continue.

Customers do not provide collateral in exchange for credit, except in unusual circumstances. Receivables from selected customers are covered by credit insurance, with amounts usually up to 100% of the invoicing, with the exception of some customers under specific terms. The information available through the insurers are the main element in the decision process to determine the credit limits assigned to customers.

The Company provides for trade receivable accounts to their expected realizable value as soon as the account is determined not to be fully collectable, with such write-offs charged to consolidated earnings unless the loss has been provided for in prior periods, in which case the write-off is applied to reduce the allowance for doubtful accounts. The Company updates its estimate of the allowance for doubtful accounts, based on evaluations of the collectibility of trade receivable balances at each balance sheet reporting date, taking into account amounts which are past due, and any available information indicating that a customer could be experiencing liquidity or going concern problems.

The aging of trade receivable balances as at February 28, 2010 was as follows:

Current	\$ 2,071,825
Past due 0-30 days	415,693
Past due 31-120 days	187,130
Past due 121-180 days	649,827
Trade receivables	3,324,475
Less allowance for doubtful accounts	

2. Foreign exchange risk:

The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Company's business transactions denominated in currencies other than the Canadian dollar. From time to time, the Company uses derivative financial instruments to reduce its foreign exchange exposure. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Company's operating results.

Approximately 89% of the Company's revenues are in US dollars. A small portion of the purchases, except for the purchase of raw materials, are made in foreign currencies. There is a financial risk involved related to the fluctuation in the value of the US dollar in relation to the Canadian dollar.

The following table provides an indication of the Company's significant foreign exchange currency exposures as at February 28, 2010:

CAD	US\$	EURO
Cash	\$ 1,013,044	\$ 283,185
Accounts receivable	3,104,792	219,718
Accounts payable and accrued liabilities	(429,894)	(170,826)
Advance payments		(593,051)
	\$ 3,687,942	\$ (260,974)

The following exchange rates applied during the year ended February 28, 2010:

	Average rate	Reporting date rate
US\$ per CAD	1.1107	1.0525
EURO per CAD	1.5616	1.4377

Based on the Company's foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar and Euro would have respectively decreased (increased) the net loss as follows, assuming that all other variables remained constant:

	US\$	EURO
Decrease (increase) in net loss	\$ 184,397	\$ (13,049)

An assumed 5% weakening of the foreign currency during the year ended February 28, 2010 would have had an equal but opposite effect on the basis that all other variables remained constant.

The Company enters into currency forwards to purchase or sell amounts of foreign currency in the future at predetermined exchange rates. The purpose of these currency forwards is to fix the risk of fluctuations in future exchange rates.

3. Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.

The Company's exposure to interest rate risk is as follows:

Cash	Short-term fixed interest rate
Short-term investments	Short-term fixed interest rate
Bank loan - operating line of credit	Short-term variable interest rate
Long-term debt	Variable and fixed interest rate
Convertible debentures	Fixed interest rate

The risk that the Company will realize a loss as a result of the decline in the fair value of its short-term investments is limited because these short-term investments have short-term maturities and are generally held to maturity.

An assumed 0.5% interest rate increase during the year ended February 28, 2010 would have decreased net earnings by \$27,399, with an equal opposite effect for an assumed 0.5% decrease.

The capacity of the Company to reinvest the short-term amounts with equivalent returns will be impacted by variations in short-term fixed interest rates available in the market.

4. Fair value of financial instruments:

The carrying amounts of the Company's short-term financial assets and liabilities approximate their fair value given that they will mature in the short-term.

The fair value of the variable interest rate mortgage loans is equivalent to the carrying amount as the loans bear interest at a rate which varies according to the market rate.

The fair value of obligations under capital leases, of the refundable contributions obtained under a federal grant program and of the government grant receivable, is determined by discounting future cash flows using rates that the Company can use for loans with similar terms, conditions and maturity dates. The fair value of these loans approximates the carrying amounts.

The fair value of the liability component of convertible debentures, including accrued interest, was determined to be \$532,165, compared to the carrying amount of \$467,864.

The following table summarizes financial assets and liabilities fair value on a recurring basis:

	February 28, 2010	Quoted prices in active markets for identical assets (level 1)	Fair value measurements at reporting date using: Significant other observable inputs (level 2)	Significant unobservable inputs (level 3)
Cash and cash equivalents	\$ 1,093,194	\$ 1,093,194	\$	\$
Short-term investments	1,001,011		1,001,011	
Foreign currency forwards	5,528		5,528	

5. Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage, as outlined in note 21 to our audited consolidated financial statements. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Audit Committee and the Board of Directors review and approve the Company's operating budgets, and review the most important material transactions outside the normal course of business.

The following are the contractual maturities of financial liabilities, as well as the payments required under the terms of the operating lease as at February 28, 2010:

Required payments per year (in thousands of dollars)	Total	Less than one year	2 to 3 years	4 to 5 years	More than 5 years
Accounts payable and accrued liabilities	\$2,241	\$2,241	\$	\$	\$
Contractual obligations:					
Long-term debt	5,780	967	1,920	1,868	1,025
Loans guaranteed by investments in lease contracts ⁽ⁱ⁾	74	47	27		
Research and development contract	1,062	1,062			
Other lease contracts	727	245	345	137	
	\$9,884	\$4,562	\$2,292	\$2,005	\$1,025

⁽ⁱ⁾ Including interest costs

In addition, approximately \$593,051 of advance payments at February 28, 2010 may be refundable in the next year if the Company fails to meet certain development milestones.

An option totaling \$275,000 for the acquisition of an intellectual property represents an additional contractual obligation. See note 23 to the 2010 audited consolidated financial statements.

6. Short-term investments:

As at February 28, 2010, short-term investments are with a Canadian financial institution having a high credit rating. Short-term investments have a weighted-average maturity date of November 30, 2010 and weighted-average interest rate of 0.41%, and are cashable at any time at the discretion of the Company.

ITEM 12: DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

Not applicable.

PART II

ITEM 13: DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

Not applicable.

ITEM 14: MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

Not applicable.

ITEM 15: CONTROLS AND PROCEDURES

Effectiveness of disclosure procedures and controls

In accordance with Multilateral Instrument 52-109 (MI 52-109), *Certification of Disclosure in Issuers Annual and Interim Filings*, the Company's CEO and CFO have designed, or have caused to be designed under their supervision, controls and procedures that provide reasonable assurance that information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under provincial or territorial securities legislation is recorded, processed, summarized and reported within the time periods specified in the provincial and territorial securities legislation. The Company's CEO and CFO are assisted in such functions by a Disclosure Policy Committee (the Committee) responsible for the Company's disclosure policy established by the Board to ensure that the communication of material information to the public is timely, factual and accurate and broadly disseminated in accordance with all applicable legal and regulatory requirements. The Committee is currently composed of the CEO, the CFO and the Controller. The CEO and the CFO, after evaluating the effectiveness of the Company's disclosure controls and procedures as at February 28, 2010, have concluded that the Company's disclosure controls and procedures are adequate and effective to ensure that material information relating to the Company would have been known to them, particularly during the period in which the annual filings are being prepared

Internal control over financial reporting

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of the Company's financial reporting and its compliance with GAAP in its consolidated financial statements.

An evaluation was carried out under the supervision and with the participation of the Company's Chief Executive Officer and the Chief Financial Officer to evaluate the design and operating effectiveness of the Company's internal controls over financial reporting as at February 28, 2010. Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the internal control over financial reporting, as defined by National Instrument 52-109, was appropriately designed and operating effectively. The evaluations were conducted in accordance with the framework criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), a recognized control model, and the requirements of National Instrument 52-109, *Certification of Disclosures in Issuers Annual and Interim Filings*.

Disclosure Controls and Procedures

In accordance with Multilateral Instrument 52-109 (MI 52-109), *Certification of Disclosure in Issuers Annual and Interim Filings*, the Company's CEO and CFO have designed, or have caused to be designed under their supervision, controls and procedures that provide reasonable assurance that information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under provincial or territorial securities legislation is recorded, processed, summarized and reported within the time periods specified in the provincial and territorial securities legislation. The Company's CEO and CFO are assisted in such functions by a Disclosure Policy Committee (the Committee) responsible for the Company's disclosure policy established by the Board to ensure that the communication of material information to the public is timely, factual and accurate and broadly disseminated in

accordance with all applicable legal and regulatory requirements. The Committee is currently composed of the CEO, the CFO and the Controller. The CEO and the CFO, after evaluating the effectiveness of the Company's disclosure controls and procedures as at February 28, 2010, have concluded that the Company's disclosure controls and procedures are adequate and effective to ensure that material information relating to the Company would have been known to them, particularly during the period in which the annual filings are being prepared

Internal Control Over Financial Reporting

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of the Company's financial reporting and its compliance with GAAP in its consolidated financial statements.

An evaluation was carried out under the supervision and with the participation of the Company's Chief Executive Officer and the Chief Financial Officer to evaluate the design and operating effectiveness of the Company's internal controls over financial reporting as at February 28, 2010. Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the internal control over financial reporting, as defined by National Instrument 52-109, was appropriately designed and operating effectively. The evaluations were conducted in accordance with the framework criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), a recognized control model, and the requirements of National Instrument 52-109, Certification of Disclosures in Issuers' Annual and Interim Filings.

Attestation Report

This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit the Company to provide only management's report in this annual report.

Changes in Internal Control Over Financial Reporting

During the period ended February 28, 2010, the CEO and the CFO evaluated whether there were any material changes in internal control over financial reporting pursuant to MI 52-109 and as required by paragraph (d) of Rules 13a-15 or 15d-15 under the Exchange Act of 1934, as amended. They individually concluded that there was no change during the year ended February 28, 2010 that affected materially the Company's internal controls over financial reporting and disclosure controls and procedures.

ITEM 16. AUDIT COMMITTEE FINANCIAL EXPERT

16A:

The Audit Committee is composed of four (4) members of the Board of Directors. Dr. Ronald Denis, Mr. Daniel Perry, Mr. Michel Chartrand and Mr. Jean-Claude Debard. From the experience set forth in Item 6A, the Company believes that these persons have sufficient knowledge and background to actively participate on the Audit Committee.

The Company's Board of Directors has determined that Michel Chartrand qualifies as an audit committee financial expert as such term is defined in the instructions to Item 16A of Form 20-F. Mr. Chartrand is independent based on the standard for independent audit committee members set forth in National Instrument N2-110.

ITEM 17. CODE OF ETHICS

17B:

1. Ethical Business Conduct

(a) Code of Business Conduct and Ethics

The Board of Directors adopted a Code of Business Conduct and Ethics for its directors, officers and employees on May 31, 2007 is included as Exhibit 11 to this annual report. Since its adoption by the Board of Directors, any breach of the Code of Ethics must be brought to the attention of the Board of Directors by the Chief Executive Officer or other senior executive of the Company. No material change

report has ever been filed which pertains to any conduct of a director or executive officer that constitutes a departure from the Code.

The Board of Directors also adopted an Insider Trading Program for its directors, officers and employees on August 21, 2008.

(b) *Steps the Board takes to ensure directors exercise independent judgment*

Since the adoption of the Code of Business Conduct and Ethics and the following policies, the Board of Directors actively monitors compliance with the Code of Ethics and Conduct and promotes a business environment where employees are encouraged to report malfeasance, irregularities and other concerns. The Code of Ethics and Conduct provides for specific procedures for reporting non-compliant practices in a manner which, in the opinion of the Board of Directors, encourages and promotes a culture of ethical business conduct.

In addition, under the *Civil Code of Quebec*, to which the Company is subject as a legal person incorporated under the *Companies Act (Quebec)*, a director of the Company must immediately disclose to the Board of Company any situation that may place him in a conflict of interest. Any such declaration of interest is recorded in the minutes of proceeding of the Board of Directors of the Company. The director abstains, except if required, from the discussion and voting on the question. In addition, it is the policy of the Company that an interested director recuse himself or herself from the decision-making process pertaining to a contract or transaction in which he or she has an interest.

ITEM PRINCIPAL ACCOUNTANT FEES AND SERVICES

16C:

We paid the following fees to KPMG LLP fees in each of the years ended February 28, 2009 and 2010 for professional services:

Fees ⁽⁴⁾	2010	2009
Audit Fees ¹	\$ 153,000	\$ 135,000
Audit-Related Fees ²	50,446	30,000
Tax Fees ³	18,800	14,200
All Other Fees	-	-
Total	222,246	179,200

¹ Audit fees comprise professional services for the audit of our annual financial statements and services normally provided in connection with our statutory and regulatory filings.

² Audit-Related fees comprise amounts paid for consultations on accounting developments and the accounting for potential corporate transactions.

³ Tax fees comprise amounts paid for tax compliance and advisory services.

⁴ Audit fees, Audit related fees and Tax fees are presented on a consolidated basis, therefore they include fees related to Neptune's subsidiary Acasti Pharma Inc.

From time to time, management of the Company recommends to and requests approval from the audit committee for non-audit services to be provided by the Company's auditors. The audit committee routinely considers such requests at committee meetings. During such deliberations, the audit committee assesses, among other factors, whether the services requested would be considered prohibited services as contemplated by the United States Securities and Exchange Commission and whether the services requested and the fees related to such services could impair the independence of the auditors. During the period ended February 28, 2010, all of the services described above under Principle Accountant Fees and Services under the captions Audit Related Fees, Tax Fees, and All Other Fees were approved by the Audit Committee.

ITEM EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

16D:

Not applicable.

ITEM PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

16E:

Not applicable.

ITEM CHANGE IN CERTIFYING ACCOUNTANT

16F:

Not applicable

ITEM CORPORATE GOVERNANCE

16G:

1. Board of Directors

(a) Independent directors.

The Board of Directors considers that Mr. Ronald Denis, Mr. Daniel Perry, Mr. Michel Chartrand and Jean-Claude Debard are independent within the meaning of Regulation 52-110, as it applies to the Board of Directors.

(b) Directors who are not independent.

The Board of Directors considers that Mr. Henri Harland is not independent within the meaning of Regulation 52-110, as it applies to the Board of Directors in that he is an executive officer and employee of the Company.

(c) Majority of directors are independent.

The Board of Directors considers that four of the five members of the Board of Directors are independent within the meaning of Regulation 52-110, as it applies to the Board of Directors. Accordingly, a majority of the directors on the Board are independent.

All directors of the Board are also on the Acasti and NeuroBioPharm Boards of Directors.

(d) Independent directors do not regularly scheduled closed meetings.

The independent directors do not hold regularly scheduled meetings at which non-independent directors and members of management are not in attendance. However, the Audit Committee, composed of all the independent directors, holds such meetings.

(e) Attendance record of directors for Board meetings.

Since the beginning of fiscal year ended February 28, 2010, the Board of Directors has held 8 meetings, of which 4 were by telephone. Attendance of directors at the meetings is indicated in the table below:

Board Members	Meeting Attendance	Telephone Meeting Attendance
Henri Harland	5/5	-
Ronald Denis	5/5	-
Michel Chartrand	5/5	-
Daniel Perry	-	5/5

Jean-Claude Debard

-

3/3

2. Board Mandate

How the Board delineates its role and responsibilities.

82

There is no specific mandate for the Board of Directors, since the Board has plenary power. Any responsibility that is not delegated to senior management or a committee of the Board remains with the full Board of Directors.

3. Position Descriptions

- (a) *How the Board delineates the role and responsibilities of the chair and the chair of each Board committee.*

No written position description has been developed for the chair of the Board of Directors and for the chairs of each committee. The primary role and responsibility of the chair of each committee of the Board of Directors is to: (i) in general, ensure that the committee fulfills its mandate, as determined by the Board of Directors; (ii) chair meetings of the committee; (iii) report thereon to the Board to the Board of Directors; and (iv) act as liaison between the committee and the Board of Directors and, if necessary, management of the Company. The primary role and responsibility of the chair of the Board of Directors is to: (i) in general, ensure that the committee fulfills its mandate, as determined by the Board of Directors; (ii) chair meetings of the board; and (iii) act as liaison between the Board of Directors and, if necessary, management of the Company.

- (b) *How the Board delineates the role and responsibilities of the CEO.*

The Board of Directors has not developed a written position description for the Chief Executive Officer. The Chief Executive Officer's objectives are discussed and decided during a Board of Directors meeting following the Chief Executive Officer's presentation of the Company's annual plan. These objectives include a general mandate to maximize shareholder value. The Board of Directors approves the Chief Executive Officer's objectives for the Company on an annual basis.

4. Orientation and Continuing Education

- (a) *Measures the Board takes to orient new directors*

The Company provides orientation for new appointees to the Board of Directors and committees in the form of informal meetings with members of the Board and senior management, complemented by presentations on the main areas of the Company's business.

- (b) *Measures the Board takes to ensure that its directors maintain the skill and knowledge necessary to meet their obligations as directors.*

The Board does not formally provide continuing education to its directors. The directors are experienced members. The Board of Directors relies on professional assistance when judged necessary in order to be educated/updated on a particular topic.

5. Ethical Business Conduct

See Item 16B: Code of Ethics .

6. Nomination of Directors

The selection of the nominees for the Board of Directors is made by the other members of the Board, based on the needs of the Company and the qualities required to sit on the Board of Directors, including ethical character, integrity and maturity of judgment of the candidates; the level of experience of the candidates, their ideas

regarding the material aspects of the business of the Company, the expertise of the candidates in fields relevant to the Company while complementing the training and experience of the other members of the Board; the will and ability of the candidates to devote the necessary time to their duties, the Board and its committees, the will of the candidates to serve the Board for numerous consecutive financial periods and finally, the will of the candidates to refrain from engaging in activities which conflict with the responsibilities and duties of a director of the Company and its shareholders. The Company researches the training and qualifications of potential new directors which seem to correspond to the selection criteria of the Board and, depending on the results of said research, organizes meetings with the potential candidates.

In the case of serving directors whose term is expiring, the Company will review the services of said director during the period for which he served on the Board, including the number of meetings to which he has assisted, his level of participation, the quality of his performance and all transactions which were entered into between said director and the Company during his term.

The Company may use various sources in order to identify the candidates for the Board, including its own contacts and the references of other directors, officers, advisors of the Company and executive placement agencies. The Company will consider candidates recommended by shareholders and will evaluate such candidates in the same manner as other candidates recommended by other sources. In making recommendations as to nominee directors at the annual shareholders meeting, the Company will consider all such written recommendation made by shareholders received by the Company secretary at the latest 120 days prior to the anniversary date of the preceding annual meeting of shareholders. The recommendations must be mailed to the Company and must include the name of the candidate, his coordinates as well as a statement of the training and the qualifications of the candidate.

Following the selection of the candidates by the Board of Directors, the Company will propose a list of candidates to the shareholders, for the annual meeting of the Company.

The Board of Directors does not have a nominating committee.

7. Compensation

The compensation committee has the responsibility of evaluating the compensation, performance incentives as well as the benefits granted to the Company's upper management in accordance with their responsibilities and performance as well as to recommend the necessary adjustments to the Board of Directors of the Company. This committee also reviews the amount and method of remuneration granted to the directors. The remuneration committee may mandate an external firm in order to assist it during the execution of its mandate. The Compensation Committee considers time commitment, comparative fees and responsibilities in determining remuneration. See Item 6: Compensation of Directors .

8. Other Board Committees

Other than the audit committee and the compensation committee, the Company also has a corporate governance committee, which is composed of five members. Of this number, two members are considered not at arm's length, namely the president and chief executive officer as well as the Chairman. The corporate governance committee is in charge of establishing the procedure which must be followed by the Company in order for it to comply with the guidelines of the TSX Venture Exchange regarding corporate governance set out in its Policy 3.1.

9. Assessments

No formal evaluation is in place. Assessments are not conducted on a regular basis. The Board of Directors from time-to-time examines and comments on its effectiveness and that of its committees and makes adjustments when warranted.

PART III**ITEM 17: FINANCIAL STATEMENTS**

The Auditor's Report and 2010 Audited Consolidated Financial Statements for the Company are attached hereto as Exhibit F-1 and are incorporated herein by reference. Such Financial Statements have been prepared on the basis of Canadian GAAP. A reconciliation to United States GAAP appears in note [26] thereto.

ITEM 18: FINANCIAL STATEMENTS

Not applicable.

ITEM 19: EXHIBITS

The following are filed as exhibits to this annual report.

(a) Exhibits

Exhibit Number	Description of Exhibit
F-1*	Consolidated Financial Statements for the year ended February 28, 2010, the nine-month period ended February 28, 2009 and the year ended May 31, 2008.
1.1	Articles of Incorporation and Bylaws (translation) (incorporated by reference to Exhibit 1.1 to the Company's amended annual transition report on Form 20-F, filed with the Commission on September 18, 2009 (File No. 001-33526)).
4.1	Technology License Agreement, dated August 7, 2008, between the Company and Acasti Pharma Inc. (confidential treatment requested) (incorporated by reference to Exhibit 4.1 to the Company's amended annual transition report on Form 20-F, filed with the Commission on November 23, 2009 (File No. 001-33526)).**
4.2	Technology License Agreement, dated October 15, 2008, between the Company and NeuroBioPharm Inc. (confidential treatment requested) (incorporated by reference to Exhibit 4.2 to the Company's amended annual transition report on Form 20-F, filed with the Commission on November 23, 2009 (File No. 001-33526)).**
<u>7.1*</u>	<u>Calculation of Financial Ratios.</u>
8.1	List of subsidiaries (incorporated by reference to Exhibit 8.1 to the Company's annual transition report on Form 20-F, filed with the Commission on August 31, 2009 (File No. 001-33526)).
10.1	Shareholder Rights Plan Agreement (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 6-K, furnished to the Commission on June 22, 2010 (File No. 001-33526)).
11.1	Code of Business Conduct and Ethics for Directors, Officers and Employees (incorporated by reference to Exhibit 11.1 to the Company's annual transition report on Form 20-F, filed with the Commission on August 31, 2009 (File No. 001-33526)).
<u>12.1*</u>	<u>Certification of the Chief Executive Officer required by 17 CFR 240.15d-14(a).</u>
<u>12.2*</u>	<u>Certification of the Chief Financial Officer required by 17 CFR 240.15d-14(a).</u>
<u>13.1*</u>	<u>Certification of the Chief Executive Officer required by 17 CFR 240.15d-14(b) and 18 U.S.C. Section 1350.</u>
<u>13.2*</u>	<u>Certification of the Chief Financial Officer required by 17 CFR 240.15d-14(b) and 18 U.S.C. Section 1350.</u>
15.1	Interim Consolidated Financial Statements (unaudited) for three month periods ended May 31, 2010 and 2009 (incorporated by reference to Exhibit 99.1 to the Company's current report on Form 6-K, furnished to the Commission on July 15, 2010 (File No. 001-33526)).
15.2	Management's Discussion and Analysis for three month period ended May 31, 2010 (incorporated by reference to Exhibit 99.2 to the Company's current report on Form 6-K, furnished to the Commission on July 15, 2010 (File No. 001-33526)).

* filed herewith

** Confidential material has been redacted and has been separately filed with the Securities and Exchange Commission.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

**NEPTUNE TECHNOLOGIES & BIORESSOURCES
INC.**

Dated August 31, 2010

/s/ Henri Harland
Name: Henri Harland
Title: President and Chief Executive Officer
86

Consolidated Financial Statements of

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Year ended February 28, 2010, nine-month period ended February 28, 2009
and year ended May 31, 2008

KPMG LLP
Chartered Accountants
600 de Maisonneuve Blvd. West
Suite 1500
Tour KPMG
Montréal (Québec) H3A 03A

Telephone (514) 840-2100
Fax (514) 840-2187
Internet www.kpmg.ca

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors:

We have audited the accompanying consolidated balance sheets of Neptune Technologies & Bioresources Inc. as at February 28, 2010 and 2009, and the related consolidated statements of earnings and comprehensive loss, shareholders' equity and cash flows for the year ended February 28, 2010, the nine-month period ended February 28, 2009 and the year ended May 31, 2008. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at February 28, 2010 and 2009, and the results of its operations and its cash flows for the year ended February 28, 2010, the nine-month period ended February 28, 2009 and the year ended May 31, 2008 in accordance with Canadian generally accepted accounting principles.

Canadian generally accepted accounting principles vary in certain significant respects from US generally accepted accounting principles. Information relating to the nature and effect of such differences is presented in note 27 to the consolidated financial statements.

/s/ KPMG LLP
Chartered Accountants

Montréal, Canada

August 30, 2010

*CA Auditor permit no 14114

KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (KPMG International), a Swiss entity. KPMG Canada provides services to KPMG LLP.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Financial Statements

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

Financial Statements

Consolidated Balance Sheets	1
Consolidated Statements of Earnings and Comprehensive Loss	2
Consolidated Statements of Shareholders' Equity	3
Consolidated Statements of Cash Flows	4
Notes to Consolidated Financial Statements	5

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Balance Sheets

February 28, 2010 and 2009

	2010	2009 (Recast - note 2 (a))
Assets		
Current assets:		
Cash	\$ 1,093,194	\$ 835,772
Short-term investments (note 22 (f))	1,001,011	3,318,254
Accounts receivable (note 10)	3,290,654	5,007,430
Tax credits receivable	664,131	726,510
Inventories (note 11)	2,645,752	1,773,563
Prepaid expenses	99,859	274,522
	8,794,601	11,936,051
Government grant receivable (note 12)	150,000	
Property, plant and equipment (note 13)	7,398,231	5,022,640
Intangible assets (note 14)	1,223,309	1,195,365
	\$ 17,566,141	\$ 18,154,056
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities:		
Company controlled by an officer and director (note 5)	\$ 175,177	\$ 221,629
Others	2,241,236	2,319,798
Advance payments (note 4)	878,814	879,469
Current portion of long-term debt (note 16)	1,002,337	578,989
	4,297,564	3,999,885
Convertible debentures (note 15)	467,864	2,166,383
Long-term debt (note 16)	4,805,024	2,985,525
	9,570,452	9,151,793
Shareholders' equity:		
Capital stock and warrants (note 17)	25,530,162	25,233,271
Contributed surplus and subsidiary call-options	9,278,767	9,047,034
Deficit	(26,813,240)	(25,278,042)
	7,995,689	9,002,263
Commitments and contingencies (note 23)		
Subsequent events (note 26)		
	\$ 17,566,141	\$ 18,154,056

See accompanying notes to consolidated financial statements.

On behalf of the Board:

/s/ Ronald Denis
Dr. Ronald Denis
Chairman of the Board

/s/ Michel Chartrand
Michel Chartrand
Director

F-1

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Earnings and Comprehensive Loss

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

	2010 (12 months)	2009 (9 months) (Recast - note 2 (a))	2008 (12 months) (Recast - note 2 (a))
Revenue from sales and research contracts	\$ 12,664,462	\$ 8,589,272	\$ 10,263,825
Cost of sales and operating expenses (excluding amortization and stock-based compensation)	11,156,493	6,908,496	8,858,429
Research and development expenses (note 6)	2,743,519	1,276,962	484,524
Financial expenses (note 7)	678,396	519,534	468,426
Amortization (note 8)	768,319	531,142	590,995
Stock-based compensation	484,606	2,171,668	4,491,371
	15,831,333	11,407,802	14,893,745
Loss before undernoted items	(3,166,871)	(2,818,530)	(4,629,920)
Interest income	45,478	61,337	99,124
Foreign exchange (loss) gain	(635,735)	1,000,347	(248,548)
Royalties paid in retractable shares (note 5)		(137,000)	
Gain on dilution (note 8 (b))	2,221,930	9,231	
Net loss and comprehensive loss	\$ (1,535,198)	\$ (1,884,615)	\$ (4,779,344)
Basic and diluted loss per share	\$ (0.04)	\$ (0.05)	\$ (0.13)
Weighted average number of shares outstanding	37,913,163	37,622,735	37,105,672

See accompanying notes to consolidated financial statements.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Shareholders' Equity

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

	Common shares		Warrants		Subsidiary options		Contributed surplus	Deficit
	Number	Dollars	Number	Dollars	Number	Dollars		
			(note 17 (b))		(note 17 (c))			
Balance, February 28, 2009, as previously reported	37,683,422	\$ 24,953,096	1,100,000	\$ 280,175	21,695,533	\$	\$ 9,047,034	\$ (25,130,000)
Adjustment to reflect change in accounting policy for intangible assets (note 2 (a))								(140,000)
Balance, February 28, 2009, as recast	37,683,422	24,953,096	1,100,000	280,175	21,695,533		9,047,034	(25,270,000)
Conversion of convertible debentures (note 15)	73,198	72,485	36,598	20,506	9,455,867	163,006	(365,510)	
Stock-based compensation					(1,040,000)		484,606	
Exercise of stock options								
Cash	448,125	116,031						
Ascribed value		50,369					(50,369)	
Exercise of warrants	30,000	45,141	(30,000)	(7,641)	(203,391)			
Net loss								(1,530,000)
Balance, February 28, 2010	38,234,745	\$ 25,237,122	1,106,598	\$ 293,040	29,908,009	\$ 163,006	\$ 9,115,761	\$ (26,810,000)
Balance, May 31, 2008, as previously reported	37,481,797	\$ 24,839,769	31,618	\$ 62,825		\$	\$ 6,425,114	\$ (23,230,000)
Adjustment to reflect change in accounting policy for intangible assets (note 2 (a))								(150,000)
Balance, May 31, 2008, as recast	37,481,797	24,839,769	31,618	62,825			6,425,114	(23,380,000)
Dividend and exchange of notes for subsidiary shares and warrants (note 18 (b))					9,230,533			(9,230,533)

Edgar Filing: Neptune Technologies & Bioresources Inc. - Form 20-F

Royalty (note 5)					190,000			
Expiry of warrants		(31,618)	(62,825)				62,825	
Issuance of convertible debentures, warrants and call-options		1,100,000	280,175	1,100,000			445,940	
Stock-based compensation				11,175,000			2,171,668	
Exercise of stock options:								
Cash	201,625	54,814						
Ascribed value		58,513					(58,513)	
Net loss								(1,888,000)
Balance, February 28, 2009	37,683,422	\$ 24,953,096	1,100,000	\$ 280,175	21,695,533	\$	\$ 9,047,034	\$ (25,278,000)
Balance, May 31, 2007, as previously reported	36,729,547	\$ 23,119,647	31,618	\$ 62,825		\$	\$ 2,974,533	\$ (18,448,000)
Adjustment to reflect change in accounting policy for intangible assets (note 2 (a))								(150,000)
Balance, May 31, 2007, as recast	36,729,547	23,119,647	31,618	62,825			2,974,533	(18,600,000)
Stock-based compensation							4,491,371	
Exercise of stock options:								
Cash	752,250	679,332						
Ascribed value		1,040,790					(1,040,790)	
Net loss								(4,779,000)
Balance, May 31, 2008	37,481,797	\$ 24,839,769	31,618	\$ 62,825		\$	\$ 6,425,114	\$ (23,388,000)

See accompanying notes to consolidated financial statements.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Consolidated Statements of Cash Flows

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

	2010	2009	2008
	(12 months)	(9 months) (Recast - note 2 (a))	(12 months) (Recast - note 2 (a))
Cash flows from operating activities:			
Net loss	\$ (1,535,198)	\$ (1,884,615)	\$ (4,779,344)
Non-cash items:			
Amortization of property, plant and equipment	719,666	400,273	581,394
Amortization of intangible assets	48,653	6,480	9,601
Amortization of other assets		124,389	
Stock-based compensation	484,606	2,171,668	4,491,371
Accretion of the liability component of the convertible debentures (note 15)	158,906	86,307	
Accrued interest on convertible debentures (note 15)	173,636	86,191	
Gain on dilution	(2,221,930)	(9,231)	
Unrealized foreign exchange (gain) loss on advance payments	(85,550)	31,000	55,050
Foreign exchange loss (gain) on cash and short-term investments	369,653	(192,509)	18,234
Net change in operating assets and liabilities (note 9)	1,380,927	(1,214,885)	(749,196)
	(506,631)	(394,932)	(372,890)
Cash flows from investing activities:			
Additions to property, plant and equipment	(3,580,536)	(904,375)	(188,647)
Additions to intangible assets	(76,597)	(254,197)	(553,099)
Maturity (purchases) of short-term investments	2,317,243	(1,104,689)	558,709
Increase in other assets		(28,412)	
	(1,339,890)	(2,291,673)	(183,037)
Cash flows from financing activities:			
Decrease in bank loan			(210,000)
Increase in long-term debt	2,999,999	3,453,296	77,609
Repayment of long-term debt	(761,290)	(3,396,823)	(929,663)
Convertible debenture issue (note 15)		2,750,000	
Financial expenses on the issuance of debenture (note 15)		(30,000)	
Exercise of subsidiary warrants	81,356		
Issue of share capital on exercise of warrants	37,500		
Issue of share capital on exercise of options	116,031	54,814	679,332
Settlement of notes payable (note 18)		(149)	
Advance payments			818,210
	2,473,596	2,831,138	435,488

Edgar Filing: Neptune Technologies & Bioresources Inc. - Form 20-F

Foreign exchange (loss) gain on cash held in foreign currencies	(369,653)	145,643	6,681
Net increase (decrease) in cash	257,422	290,176	(113,758)
Cash, beginning of period	835,772	545,596	659,354
Cash, end of period	\$ 1,093,194	\$ 835,772	\$ 545,596
Supplemental cash flow disclosures (note 9)			

See accompanying notes to consolidated financial statements.

F-4

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

1. Nature of operations:

Neptune Technologies & Bioresources Inc. (the "Company") was incorporated under Part 1A of the *Companies Act* (Québec) on October 9, 1998.

The Company focuses on the research, development and commercialization of products derived from marine biomasses for the nutraceutical, pharmaceutical and cosmetic industries. During the period ended February 28, 2009, the Company transferred certain rights to its subsidiaries, Acasti Pharma Inc. and NeuroBioPharm Inc., in order to develop pharmaceutical products in the fields of cardiovascular and neurological diseases, respectively.

The Company develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process Neptune OceanExtract . The Company develops and industrializes its extraction process and markets its marine oil Neptune Krill Oil - NKO® as well as its protein concentrated Neptune Krill Aquatein - NKA . Its products are aimed for the nutraceutical, biopharmaceutical, cosmetics and pet food markets. The Company's profitability in the future relies on various factors, such as: successful completion of its clinical studies, obtaining product regulatory approval from health authorities and the ability of the Company to commercialize and market its products with success.

2. Changes to accounting policies:

(a) New accounting policies adopted in 2010:

On March 1, 2009, the Company adopted the following accounting standards issued by the Canadian Institute of Chartered Accountants ("CICA").

Goodwill and Intangible Assets:

The CICA issued Handbook Section 3064, *Goodwill and Intangible Assets*, which replaced Section 3062, *Goodwill and Other Intangible Assets*, and Section 3450, *Research and Development Costs*. The new standard provides guidance on the recognition of intangible assets in accordance with the definition of an asset and the criteria for asset recognition as well as clarifying the application of the concept of matching revenues and expenses, whether these assets are separately acquired or internally developed.

As a result of this standard, direct costs incurred to secure patents related to internally- generated assets in the research phase will no longer be capitalized by the Company. The Company applied this standard on a retrospective basis. The impact of adopting this standard was to increase the opening deficit and reduce intangible assets, as at June 1, 2007, June 1, 2008 and March 1, 2009, by \$156,470, \$151,010 and \$146,915, respectively, for such assets capitalized prior to the date of commercialization, May 31, 2002. The impact of the adjustment on the net loss in 2009 and 2008 is not significant.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

2. Changes to accounting policies (continued):

- (a) New accounting policies adopted in 2010 (continued):

Financial Instruments:

Effective September 1, 2009, the Company has adopted an amendment to CICA Handbook Section 3862, *Financial Instruments - Disclosures*, which requires additional disclosures about fair value and liquidity risk. The amendments introduce a "fair value hierarchy" for disclosures which intends to provide information to financial statement users about the relative reliability of fair value measurements. The new standard relates to disclosure only and did not impact the financial results of the Company. See note 22 (d).

Presentation of unrealized gains and losses on foreign exchange:

The Company recast the consolidated statement of cash flows for the nine-month period ended February 28, 2009 and the year ended May 31, 2008 in order to present the effects of unrealized gains and losses on foreign exchange, as was required by CICA Handbook Section 1540, *Cash Flow Statements*. As a result of the correction, for the nine-month period ended February 28, 2009, cash flows from operating activities (foreign exchange gain (loss) on cash and short-term investments) decreased by \$192,509, cash flows from investing activities (maturity (purchases) of short-term investments) increased by \$46,866 and the foreign exchange gain (loss) on cash held in foreign currencies was added, in the amount of \$145,643. For the year ended May 31, 2008, cash flows from operating activities (foreign exchange gain (loss) on cash and short-term investments) increased by \$18,234, cash flows from investing activities (maturity (purchases) of short-term investments) decreased by \$24,915 and the foreign exchange gain (loss) on cash held in foreign currencies was added, in the amount of \$6,681.

- (b) New accounting policies adopted in 2009:

Effective June 1, 2008, the Company adopted the CICA Handbook Section 1535, *Capital Disclosures*, Section 3031, *Inventories*, Section 3862, *Financial Instruments - Disclosures*, and Section 3863, *Financial Instruments - Presentation*.

CICA Handbook Section 1535, *Capital Disclosures*, establishes guidelines for disclosure of both qualitative and quantitative information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital. See note 21.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

2. Changes to accounting policies (continued):

(b) New accounting policies adopted in 2009 (continued):

CICA Handbook Section 3862, *Financial Instruments - Disclosures*, describes the required disclosure for the assessment of the significance of financial instruments for an entity's financial position and performance and of the nature and extent of risks arising from financial instruments to which the entity is exposed and how the entity manages those risks. Section 3863, *Financial Instruments - Presentation*, establishes standards for the disclosure and presentation of the financial instruments and non-financial derivatives. See note 22.

These new standards relate to disclosure only and did not impact the financial results of the Company.

CICA Handbook Section 3031, *Inventories*, replaces Section 3030 on this same subject matter. The new section provides guidance on the determination of cost and its subsequent recognition as an expense, including any write-down to net realizable value. It also provides guidance on the cost formulas that are used to assign costs to inventories. The changes brought forth in this section affect the following in particular:

- (i) Certain costs, such as storage costs and general and administrative expenses that do not contribute to bringing the inventories to their present location and condition, are excluded from the cost of inventories and expensed during the year in which they are incurred.
- (ii) The reversal of the write-down to net realizable value amounts when there is a subsequent increase in the value of the inventories is now required.
- (iii) The valuation of inventory at the lower of cost and replacement cost is no longer allowed; all inventories are valued at the lower of cost and net realizable value.

Adoption of this new standard had no impact on the consolidated financial statements for the nine-month period ended February 28, 2009.

(c) Future accounting changes:

Business Combinations:

CICA Handbook Section 1582, *Business Combinations*, replaces Section 1581, *Business Combinations*. The Section establishes standards for the accounting for a business combination. It provides the Canadian equivalent to the IFRS standard, IFRS 3 (Revised), *Business Combinations*. The Section applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2011.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

2. Changes to accounting policies (continued):

- (c) Future accounting changes (continued):

Consolidated Financial Statements:

CICA Handbook Section 1601, *Consolidated Financial Statements*, and Section 1602, *Non-Controlling Interests*, together replace Section 1600, *Consolidated Financial Statements*. Section 1601 establishes standards for the preparation of consolidated financial statements. Section 1602 establishes standards for accounting for a non-controlling interest in a subsidiary in consolidated financial statements subsequent to a business combination. The sections are equivalent to the corresponding provisions of IFRS Standard, IAS 27 (Revised), *Consolidated and Separate Financial Statements*. The Sections apply to interim and annual consolidated financial statements relating to fiscal years beginning on or after January 1, 2011. Earlier adoption is permitted as of the beginning of a fiscal year. The Company does not anticipate that it will ever adopt these new Sections because they become effective only when the Company is expecting to adopt the International Financial Reporting Standards ("IFRS").

International Financial Reporting Standards:

In February 2008, Canadian Accounting Standards Board ("AcSB") confirmed that Canadian generally accepted accounting principles ("GAAP"), as used by publicly accountable enterprises, would be replaced by IFRS, as issued by the International Accounting Standards Board ("IASB"). The changeover date is for interim and annual financial statements relating to fiscal years beginning on or after January 1, 2011. Therefore, the Company will be required to report under IFRS for its 2012 interim and annual financial statements with comparative figures for the previous period. The Company will convert to these new standards according to the timetable set within these new rules. The Company has performed an initial high-level analysis of the key accounting areas that may be impacted by the transition to IFRS, but has not yet performed a detailed assessment of the impact these new standards will have on its financial statements.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies:

These consolidated financial statements have been prepared in accordance with Canadian GAAP. Significant accounting policies are described below:

(a) Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its subsidiaries, Acasti Pharma Inc., NeuroBioPharm Inc. and Neptune Technologies & Bioresources USA Inc. All significant intercompany balances and transactions have been eliminated on consolidation.

(b) Use of estimates:

The preparation of financial statements in accordance with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the recorded amount of assets and liabilities and the reported amount of contingent assets and liabilities at the date of the financial statements and the recorded amounts of income and expenses during the year. Actual results may differ from those estimates. Significant areas requiring the use of management estimates include estimating the useful life and recoverability of long-lived assets, including property, plant and equipment and intangible assets, determining the fair value of financial instruments and estimating the fair value of stock-option awards as well as assessing the recoverability of research tax credit receivable and future income tax assets. Consequently, actual results could differ from those estimates.

(c) Revenue recognition:

Revenues from sales are recognized when persuasive evidence of an arrangement exists, the product has been delivered and the significant risks and advantages related to ownership are transferred, the consideration is fixed or determinable and collection is reasonably assured.

Revenue from research contracts is recognized when services to be provided are rendered and all conditions under the terms of the underlying agreement are met.

Payments received under partnerships agreements may include upfront payments and milestone payments, which require the Company's ongoing involvement. Upfront payments are deferred and recognized as revenue on a systematic basis over the period during which the related products or services are delivered and all obligations are performed. Milestone payments based on product development, for which the Company has no future involvement or obligations to perform related to that specified element of the arrangement, are recognized into income upon the achievement of the specified milestones, and collectibility is reasonably assured. Contract payments received in advance that are potentially refundable are recorded as "advance payments" on the consolidated balance sheet.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(c) Revenue recognition (continued):

Interest income on investments is recognized using the effective interest method.

(d) Cash and cash equivalents:

Cash and cash equivalents consist of highly liquid investments purchased three months or less from maturity.

(e) Short-term investments:

Short-term investments consist of investments with maturities of less than one year.

(f) Inventories:

Raw materials are valued at the lower of cost and net realizable value, with cost being determined by the average cost method. Finished goods are valued at the lower of cost and net realizable value; cost is determined per project and includes direct and indirect costs related to production (monthly average cost). Each project corresponds to one month of production. Net realizable value is the estimated selling price in the ordinary course of business, less the selling costs.

The Company provides for obsolete products based on turnover. As at February 28, 2010 and 2009, turnover of the Company's principal product, Neptune Krill Oil - NKO[®] is such that no provision for obsolescence is required.

(g) Tax credits and government grants:

Tax credits and government grants are accounted for using the cost reduction method. Under this method, tax credits and government grants related to eligible expenses or property, plant and equipment are accounted for as a reduction of related costs in the year during which the expenses or costs are incurred as long as there is reasonable assurance of their realization.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(h) Property, plant and equipment:

Property, plant and equipment are recorded at cost less related tax credits and government assistance. Assets acquired under capital leases are carried at cost, being the present value of the minimum lease payments after deduction of executory costs.

Amortization of property, plant and equipment and assets acquired under capital leases are calculated over their estimated useful lives using the following methods, rates and periods:

Property, plant and equipment	Method	Rate/period
Plant	Straight-line	40 years
Processing equipment	Straight-line	10 years
Laboratory equipment	Straight-line	5 years
Furniture and fixtures	Diminishing balance	20%
Office equipment	Diminishing balance	30%
Computer equipment	Straight-line	3 to 4 years
Software	Straight-line	2 years

(i) Research and development expenses:

Research expenses are charged to income in the year of expenditure less related tax credits. Development costs net of related tax credits are charged to income as incurred unless a development project meets generally accepted accounting criteria for deferral and amortization. During 2010, expenses of \$11,324 (2009 - \$43,218, 2008 - \$296,527) have been deferred and presented as intangible assets. The costs are mainly related to the deodorisation of Neptune Krill Oil - NKO[®] as part of partnership and collaboration agreements. No amortization has been recorded as at February 28, 2010 for those costs since commercial production or use of the product or process has not begun.

F-11

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(j) Intangible assets:

Intangible assets consist of patents, trademarks and license rights. The patent costs include legal fees to obtain patents and patent application fees.

Patents are recorded at cost and amortized according to the straight-line method over their remaining expected life over a maximum period of 20 years.

Trademarks and licenses are recorded at cost and are not amortized since the Company considers they have an indefinite life given they can be renewed at a minimal cost.

Deferred development costs are amortized beginning in the year of commercial production or use of the product or process over a maximum period of 5 years.

(k) Impairment and disposal of long-lived assets:

Long-lived assets, including property, plant and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized for the difference between the carrying amount and the fair value. Quoted market values are used whenever available to estimate fair value. When quoted market values are unavailable, the fair value of the long-lived asset is generally based on estimates of discounted expected net cash flows. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or the fair value less selling costs, and would no longer be depreciated. The assets and liabilities of a disposed group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the balance sheet.

Intangible assets with indefinite useful lives are not amortized and are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset may be impaired. The impairment test compares the carrying amount of the intangible asset with its fair value, and an impairment loss is reorganized in income for the excess, if any.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(l) Foreign currency translation:

Monetary assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the year-end exchange rate, non-monetary assets and liabilities are translated at the historical exchange rate, and revenue and expense items are translated in Canadian dollars at rates of exchange in effect at the related transaction dates. Exchange gains and losses arising from these transactions are included in income during the period.

(m) Foreign currency forwards:

The Company enters into foreign currency forward contracts to protect itself against foreign exchange rate fluctuations. The Company does not hold or use derivative instruments for speculative purposes. In addition, the Company does not use hedge accounting; accordingly, the foreign currency forward contracts are recognized at fair value on the balance sheet and changes in fair value are recognized in earnings for the period.

(n) Loss per share:

Loss per common share is calculated on the weighted average number of common shares outstanding during the year. The Company uses the treasury stock method to determine the dilutive effect of options and warrants. Under this method, a number of additional shares, if they are dilutive, are calculated assuming that the outstanding stock options and warrants are exercised, and that the proceeds from the transactions are used to purchase common shares at the average market price during the period.

The dilutive effect of the convertible debentures is reflected in diluted earnings per share by application of the "if-converted" method, if dilutive. Under the if-converted method, convertible debentures are assumed to have been converted at the beginning of the period (or at the time of issuance, if later) and the resulting common shares are included in the denominator for purposes of calculating diluted earnings per share.

Warrants, stock options and convertible debentures described in notes 15, 17 and 19 were not included in the calculation of diluted earnings per share in 2010, 2009 and 2008 because the Company sustained losses and their inclusion would be anti-dilutive. All outstanding warrants, stock options and convertible debentures could have an effect on the calculation in the future.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(o) Financial instruments:

Financial instruments are initially recognized at fair value and classified into one of the following five categories: held-for-trading, held-to-maturity investments, loans and receivables, available-for-sale financial assets or other financial liabilities. Subsequently, financial instruments are measured in accordance with the measurement provision of the category to which they have been initially classified. Transaction costs are expensed as incurred for financial instrument classified as held-for-trading. For other financial instruments, transaction costs are presented as a reduction of the underlying financial instruments and expensed using the effective interest rate method. Financial assets and financial liabilities held for trading are measured at fair value with changes recognized in income. Available-for-sale financial assets are measured at fair value with changes recorded in comprehensive income. Financial assets held to maturity, loans and receivables, and other financial liabilities are measured at amortized cost.

The Company has designated its cash and cash equivalents and short-term investments as held-for-trading financial assets. The Company has also classified its receivables and other receivables as loans and receivables, and all other financial liabilities as other financial liabilities, and they are measured at amortized cost.

Financial instruments that comprise a liability component and equity components are classified separately on the balance sheet on initial recognition in accordance with the substance of the contractual agreement.

(p) Stock-based compensation:

The Company has stock-based compensation plans which are described in note 19. The Company accounts for stock options granted to employees and non-employees based on the fair value method using the Black-Scholes model. For stock options granted to non-employees, the Company measures the cost using either the fair value of the equity instruments granted or the fair value of the goods or services rendered, whichever is more reliably measured. Under the fair value method, compensation cost is measured at fair value at date of grant and is expensed over the award's vesting period, with a corresponding increase in contributed surplus. The Company does not estimate forfeitures as of the grant date and accounts for their impact on expense as they occur.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

3. Significant accounting policies (continued):

(q) Income taxes:

The Company follows the liability method of accounting for income taxes. Under this method, future income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using substantively enacted tax rates and laws that are expected to be in effect in the periods in which the future tax assets or liabilities are expected to be realized or settled. A valuation allowance is provided to the extent that it is more likely than not that future income tax assets will not be realized.

4. Partnership and collaborations agreements:

In 2008, the Company received a first payment of €500,000 out of several payments scheduled under the terms of a partnership agreement. The agreement foresees the Company's commitment of developing a clinical research program and the development of products incorporating Neptune Krill Oil - NKO® in a dietary matrix. 62.5% of the amount of the initial payment is refundable only if the parties fail to meet certain developmental milestones, prior to the release of the products on the market. In addition, as at February 28, 2010, the Company recorded a receivable for €100,000 which was conditional to the Company receiving the Novel Food status as well as meeting positive organoleptic results as defined in an amendment to the partnership agreement between the two parties. No revenues have been recognized by the Company under the agreement. The amount, \$862,620, is included in "advance payments" in the consolidated balance sheet.

The Company also entered into a collaboration agreement under which it can receive \$299,860. Under the terms of the agreement, the Company will conduct a clinical research project on the effects of Neptune Krill Oil - NKO® and its concentrates on certain human health conditions. The agreement includes a period of exclusivity on the rights by the partner to the use of the clinical study results. At February 28, 2010, the Company has received \$199,860 under the agreement with the final amount of \$100,000 to be received at the conclusion of the research project. For the year ended February 28, 2010, revenues of \$58,875 were recognized in consolidated earnings on the basis of percentage of completion of the clinical study. As of February 28, 2010, the difference between the payments received of \$199,860 and revenues recognized to that date amounts to \$16,194, and it is included in "advance payments" in the consolidated balance sheet.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

5. Related party transactions:

Under the terms of an agreement entered into with a company controlled by an officer and director (which is also a shareholder of the Company), the Company is committed to pay royalties of 1% of its revenues in semi-annual instalments, for an unlimited period. The annual amount disbursed cannot exceed net earnings before interest, taxes and amortization of the Company on a non-consolidated basis. For the year ended February 28, 2010, total royalties included in operating expenses amounted to \$120,328 (nine-month period ended February 28, 2009 - \$221,629, including royalties on the transfer of licenses to the subsidiaries of \$137,000 as described below; year ended May 31, 2008 - \$102,638). As at February 28, 2010, the balance due to this company under this agreement amounts to \$175,177 (2009 - \$221,629). This amount is presented in the balance sheet under accounts payable and accrued liabilities.

During the nine-month period ended February 28, 2009, the Company issued worldwide licenses to its subsidiaries, Acasti Pharma and NeuroBioPharm, in consideration of shares and warrants of these subsidiaries. The Company recorded the value of the following shares and warrants of its subsidiaries as payments of the royalties due to the company controlled by an officer and director on the transactions. These shares were valued at \$137,000 and no value was attributed to the warrants:

Acasti Pharma	NeuroBioPharm
50,000 Class B shares	50,000 Class B shares
260,000 Class C shares	350,000 Class C shares
60,000 Series 4 warrants	70,000 Series 4 warrants
30,000 Series 5 warrants	30,000 Series 5 warrants

Since the Class B and Class C shares of Acasti Pharma and NeuroBioPharm are redeemable at the option of the holder, the amount of \$137,000 was recorded in current liabilities.

These transactions are measured at the exchange amount, which is the amount of consideration determined and accepted by the parties involved.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

6. Research and development expenses:

The costs encountered for research and development projects in process are:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Salaries and employee benefits	\$ 1,725,876	\$ 558,372	\$ 732,323
Subcontracting	892,906	1,154,139	49,629
General and study expenses	380,049		5,538
Travel expenses	61,185	26,158	11,954
	3,060,016	1,738,669	799,444
Tax credits	(316,497)	(461,707)	(314,920)
	\$ 2,743,519	\$ 1,276,962	\$ 484,524

Research tax credits recorded by the Company are subject to audit by the tax authorities; accordingly, amounts granted may differ from those recorded.

7. Financial expenses:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Bank charges and changes in fair value of forward contracts	\$ 74,133	\$ 122,648	\$ 31,158
Interest - operating line of credit	11,856	12,314	3,113
Interest - long-term debt and convertible debentures	592,407	384,572	434,155
	\$ 678,396	\$ 519,534	\$ 468,426

F-17

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

8. Information included in the consolidated statement of earnings:

(a) Amortization:

	2010 (12 months)	2009 (9 months) (Recast - note 2 (a))	2008 (12 months) (Recast - note 2 (a))
Property, plant and equipment	\$ 719,666	\$ 400,273	\$ 581,394
Intangible assets	48,653	6,480	9,601
Other assets		124,389	
	\$ 768,319	\$ 531,142	\$ 590,995

Amortization of property, plant and equipment includes amortization of asset under capital lease of \$37,325 (nine-month period ended February 28, 2009 - \$34,925; 2008 - \$43,609).

(b) Gain on dilution:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Settlement of notes payable through issuance of Acasti shares and warrants (note 18 (b))	\$	\$ 9,231	\$
Conversion into Acasti units (note 15)	2,140,574		
Exercise of Acasti warrants (note 18 (e))	81,356		
	\$ 2,221,930	\$ 9,231	\$

F-18

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

9. Supplemental cash flow disclosures:

(a) Net changes in operating assets and liabilities are detailed as follows:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Accounts receivable	\$ 1,766,776	\$ (480,143)	\$ (1,459,906)
Tax credits receivable	62,379	(461,707)	(163,945)
Inventories	(872,189)	(390,387)	732,476
Prepaid expenses	174,663	(49,644)	(171,839)
Accounts payable and accrued liabilities	164,403	191,787	314,018
Advance payments	84,895	(24,791)	
	\$ 1,380,927	\$ (1,214,885)	\$ (749,196)

(b) Non-cash transactions:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Acquired property, plant and equipment included in accounts payable and accrued liabilities	\$ 208,286	\$ 497,703	\$ 29,260
Government grant affected to property, plant and equipment included in government grant receivable	200,000		
Property, plant and equipment acquired by way of capital leases	4,138		140,199
Dividend payable through issuance of notes payable		9,380	
Conversion of convertible debentures and accrued interest into shareholders' equity and non-controlling interest	2,031,062		
Increase of other assets in accounts payable and accrued liabilities			95,977

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

9. Supplemental cash flow disclosures (continued):

(c) Other:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Interest paid	\$ 260,539	\$ 399,559	\$ 420,644

10. Accounts receivable:

	2010	2009
Trade accounts	\$ 2,940,878	\$ 4,696,534
Sales taxes	230,740	218,919
Current portion of government grant receivable (note 12)	50,000	
Other	69,036	91,977
	\$ 3,290,654	\$ 5,007,430

11. Inventories:

	2010	2009
Raw materials	\$ 1,760,912	\$ 925,664
Work in process	735,357	186,535
Finished goods	149,483	661,364
	\$ 2,645,752	\$ 1,773,563

During the year ended February 28, 2010, \$6,276,403 (nine-month period ended February 28, 2009 - \$3,862,482) of inventories were recognized as cost of sales.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

12. Government grant receivable:

In 2010, the Company entered into an agreement to receive a financial contribution of \$200,000 under a government grant program for its investments in the plant expansion. The amount is to be received in annual equal installments of \$50,000. The Company will receive the first portion of \$50,000 in the year ended February 28, 2011.

	2010	2009
Government grant receivable	\$ 200,000	\$
Less current portion (note 10)	(50,000)	
	\$ 150,000	\$

13. Property, plant and equipment:

	2010		
	Cost	Accumulated amortization	Net book value
Land	\$ 40,540	\$	\$ 40,540
Plant	4,005,557	500,708	3,504,849
Processing equipment	5,947,906	2,622,560	3,325,346
Laboratory equipment	596,943	446,737	150,206
Furniture and fixtures	116,573	91,509	25,064
Office equipment	111,287	75,037	36,250
Computer equipment and software	106,976	45,006	61,970
Computer equipment - project in progress	179,750		179,750
	11,105,532	3,781,557	7,323,975
Assets under capital leases:			
Processing equipment	48,560	26,205	22,355
Office equipment	47,889	28,507	19,382
Computer equipment	90,069	57,550	32,519
	186,518	112,262	74,256
	\$ 11,292,050	\$ 3,893,819	\$ 7,398,231

During the year, fully amortized property, plant and equipment with a cost of \$39,367 have been written off.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

13. Property, plant and equipment (continued):

	2009		
	Cost	Accumulated amortization	Net book value
Land	\$ 40,540	\$	\$ 40,540
Plant	1,960,212	422,862	1,537,350
Processing equipment	3,781,175	2,106,872	1,674,303
Laboratory equipment	493,514	400,745	92,769
Furniture and fixtures	116,573	85,160	31,413
Office equipment	93,745	63,320	30,425
Computer equipment and software	42,593	20,257	22,336
Plant - project in progress	1,325,969		1,325,969
Computer equipment - project in progress	150,895		150,895
	8,005,216	3,099,216	4,906,000
Assets under capital leases:			
Processing equipment	48,560	21,349	27,211
Office equipment	47,890	23,662	24,228
Computer equipment	134,494	69,293	65,201
	230,944	114,304	116,640
	\$ 8,236,160	\$ 3,213,520	\$ 5,022,640

F-22

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

14. Intangible assets:

	2010		
	Cost	Accumulated amortization	Net book value
Amortized intangible assets:			
Patents	\$ 652,347	\$ 73,047	\$ 579,300
Development costs	351,068		351,068
	1,003,415	73,047	930,368
Unamortized intangible assets:			
Licenses	182,334		182,334
Trademarks	110,607		110,607
	292,941		292,941
	\$ 1,296,356	\$ 73,047	\$ 1,223,309

	2009 (Recast - note 2 (a))		
	Cost	Accumulated amortization	Net book value
Amortized intangible assets:			
Patents	\$ 611,803	\$ 24,394	\$ 587,409
Development costs	339,745		339,745
	951,548	24,394	927,154
Unamortized intangible assets:			
Licenses	159,970		159,970
Trademarks	108,241		108,241
	268,211		268,211
	\$ 1,219,759	\$ 24,394	\$ 1,195,365

F-23

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures:

	Debentures	Accrued interest	Total
Aggregate principal amount of convertible debentures at issuance	\$ 2,750,000	\$	\$ 2,750,000
Financial expenses on the issuance of debentures	(30,000)		(30,000)
Equity component of convertible debentures	(445,940)		(445,940)
Debenture Warrants	(280,175)		(280,175)
Accrued interest		86,191	86,191
Accretion of the liability component	86,307		86,307
Liability balance of convertible debentures as at February 28, 2009 (principal amount of \$2,750,000)	2,080,192	86,191	2,166,383
Accrued interest		173,636	173,636
Accretion of the liability component	158,906		158,906
Debentures converted into Neptune units	(69,168)	(9,552)	(78,720)
Debentures converted into Acasti units	(1,755,452)	(196,889)	(1,952,341)
Liability balance of convertible debentures as at February 28, 2010 (principal amount of \$496,000)	\$ 414,478	\$ 53,386	\$ 467,864

On October 9, 2008, the Company completed a financing transaction where an aggregate number of 2,750 units of convertible debenture with a nominal amount of \$1,000 per unit were issued. Concurrently with the issuance of the convertible debenture units the Company issued 1,100,000 options to acquire 1,100,000 Class A shares of Acasti Pharma held by the Company at a price per share equal to the lesser of \$0.25 and the price per share from a new financing (the "Debenture Call-Options"), until April 30, 2010 and 1,100,000 warrants to purchase 1,100,000 common shares of the Company for \$1.25 per share until April 30, 2010 (the "Debenture Warrants"). The Company can require the exercise of the Debenture Warrants if the market price of the shares reaches \$3.75 for three consecutive days. The consideration received by the Company for the convertible debenture, the Debenture Call-Options and the Debenture Warrants amounted to \$2,750,000.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures (continued):

The debentures bear interest at 8%, payable annually in cash or in kind at the Company's option and are further convertible at the holder's option into Neptune or Acasti units (as defined below). The debentures mature on October 9, 2011, at which time the Company may either reimburse the amount owed (principal and interest) in cash, or issue shares for the principal amount plus interest and a 15% premium. The shares will be issued at market price, subject to a minimum purchase price of \$1.25 per common share.

Conversion option in Neptune units:

Convertible at the option of the holder before November 30, 2010 at a price of \$1.25 per unit as to the principal and at market price of the shares of the Company at the date of conversion as to the unpaid interest. A unit is comprised of one common share and one-half warrant of the Company (the "Conversion Warrant"). Each Conversion Warrant entitles its holder to purchase one common share at the market price prevailing at the date of issuance until the earliest of (i) the debenture maturity date, (ii) two years after the issuance of the warrants or (iii) 30 days after the market price of the shares of the Company has reached a price equal to two times the market price prevailing at the date of issuance of the warrants for a period of three consecutive days. The Company can also require the conversion if the market price of the shares reaches \$3.75 for three consecutive days.

Conversion option in Acasti units:

Convertible at the option of the holder before November 30, 2010 in units, each unit being comprised of one Class A share of Acasti Pharma held by the Company and one option to acquire from the Company one Class A share of Acasti Pharma (the "Conversion Call-Options"). The base price (the "Base Price") for the conversion will be the lowest of \$0.25 per unit and the price per share from an Acasti new financing. The conversion price varies as follows:

Date of conversion	Conversion price	Exercise price of Conversion Call-Options
Before November 30, 2009	Base Price	Base Price plus \$0.25
December 1, 2009 to May 31, 2010	Base Price plus \$0.25	Base Price plus \$0.75
June 1 to November 30, 2010	Base Price plus \$0.75	Base Price plus \$1.25

The Conversion Call-Options expire after a period of twelve months from the date of issuance.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures (continued):

Under Canadian GAAP, convertible debentures composed of a debt instrument and various equity components are recorded as compound financial instruments and are presented as liability or equity components in accordance with the substance of the contractual agreement. At the date of their issuance, the Company allocated the consideration received of \$2,750,000 between the instruments issued; being the convertible debentures and their conversion options, the Debenture Warrants and the Debenture Call-Options, using the relative fair value method.

The fair value of each component along with their allocated value is as follows:

	Fair value	Relative fair value	Valuation
1,100,000 Debenture Warrants	\$ 340,485	\$ 280,175	Binomial
1,100,000 Debenture Call-Options			Black-Scholes
Equity component	541,933	445,940	Binomial and trinomial
Debentures	2,459,545	2,023,885	Discount rate
	\$ 3,341,963	\$ 2,750,000	

F-26

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures (continued):

The assumptions used to determine the fair value of each component are presented below:

(a) Debenture Warrants:	
Fair value of common shares	\$1.03
Risk-free interest rate	2.14%
Estimated life	1.5 year
Expected volatility	79%
Exercise price	\$1.25
(b) Debenture Call-Options:	
Fair value of Class A shares	\$0.02
Risk-free interest rate	1.93%
Estimated life	1.5 year
Expected volatility	75%
Exercise price	\$0.25
(c) Equity component:	
Fair value of common shares	1.03
Risk-free interest rate	2.16%
Estimated life	2.2 years
Expected volatility	83%
Exercise price	\$1.25 - \$3.75
(d) Debentures:	
Use of a discount rate of 12.43%	

The fair value of the equity component relates to the higher of the fair value of the Neptune units conversion option and the fair value of the Acasti units conversion option attached to the convertible debenture. The Company accretes the book value of the liability component of the convertible debentures to their par value through a charge to earnings in accordance with the effective interest rate method. The effective interest rate of the debenture is 20.7% .

(i) Conversions into Neptune units:

During the year ended February 28, 2010, convertible debentures of a nominal amount of \$88,000 plus \$6,126 of accrued interest were converted into Neptune units. Each unit comprises one common share and one-half Conversion Warrant.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures (continued):**(i) Conversions into Neptune units (continued):**

A total of 73,198 units have been issued corresponding to 73,198 common shares and 36,598 Conversion Warrants. Each Conversion Warrant allows its holder to buy one share of the Company until October 9, 2011 at various prices ranging from \$2.05 to \$2.25 depending on the market price of Neptune shares at their date of conversion.

These transactions decreased the balance of convertible debentures and contributed surplus by \$78,720 and by \$14,271, respectively, and increased the capital stock and warrants by a total of \$92,991. This value has been proportionately allocated to capital stock and Conversion Warrants based on their relative fair value at time of issuance.

The fair value of the Conversion Warrants issued of \$20,506 was determined by using a binomial method with the following assumptions:

Fair value of common shares	\$2.05 to \$2.25
Risk-free interest rate	1.03% to 1.40%
Estimated life	1.7 to 2 years
Expected volatility	84%
Exercise price	\$2.05 to \$2.25

(ii) Conversion into Acasti units:

On November 30, 2009, holders of debentures having a nominal value of \$2,166,000 exercised their right to convert into Acasti units. The Company also decided to settle the related accrued interest of \$196,889 by delivering Acasti units. As a result, 9,455,867 Acasti Class A shares held by the Company and as many Conversion Call-Options, were delivered to the debenture holders.

The Company valued the Conversion Call-Options by (i) estimating the fair value of Acasti subsidiary and (ii) using a binomial method with the following additional assumptions:

Fair value of Class A shares	\$0.47
Risk-free interest rate	1.41%
Estimated life	1 year
Expected volatility	25%
Exercise price	\$0.50

F-28

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

15. Convertible debentures (continued):

(ii) Conversion into Acasti units (continued):

As a result of the valuation, the fair value of the Conversion Call-Options was determined to be \$338,432 while the fair value of the Acasti Class A shares was determined to be \$4,444,257. The allocated carrying value of the Conversion Call-Options using the relative fair value method was determined to be \$163,006, and was recorded as a component of equity.

No amount was allocated to non-controlling interest for the Acasti Class A shares delivered because the carrying amount of Acasti net assets after accounting for the Company's own preference shares is negative. As a result, the full difference between the carrying amount of the components being extinguished of \$2,303,580 (comprised of the proportionate shares of the equity component of the debentures and of the carrying amount of convertible debentures), and the fair value of the Conversion Call-Options, in the amount of \$163,006, was recorded as a gain on dilution.

The model used to measure derivative components including the Conversion Call-Options as well as the estimated fair value of Acasti Class A shares comprise a number of subjective assumptions. Any changes to such assumptions would result in a significant variation of the estimated fair value of the components.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

16. Long-term debt:

	2010	2009
Mortgage loan, principal balance of \$3,500,000, bearing interest at the prime rate plus 2%, partly secured (38.46%) by Investissement Québec (for an annual premium of 2.5% on the secured amount), through a savings guarantee from Neptune of \$1,000,000, and through a first-ranking mortgage on the plant, a first-ranking hypothec on all movable assets (except for accounts receivable and merchandise) current and future, corporeal and incorporeal, and tangible and intangible except for intellectual property (which is subject to a negative pledge agreement) and a second-ranking hypothec on all accounts receivable and merchandise, reimbursable in monthly principal payments of \$41,667 until November 2015. The amount recorded is net of related financial expenses.	\$ 2,833,502	\$ 3,327,621
Mortgage loan, principal balance of \$3,000,000, bearing interest at the prime rate plus 2%, secured as indicated above, reimbursable in monthly principal payments of \$36,165 until August 2016	2,820,852	
Obligations under capital leases, interest rates varying from 6.17% to 15.46%, payable in average monthly instalments of \$4,123 (\$4,301 as at February 28, 2009), maturing at different dates until 2013	68,551	119,909
Refundable contribution obtained from a federal program available for small and medium-sized business, without collateral or interest, payable in semi-annual instalments of \$9,701 until October 2012	58,207	77,609
Refundable contribution obtained from a federal program available for small and medium-sized business, without collateral or interest, payable in semi-annual instalments of \$6,562 until December 2011	26,249	39,375
	5,807,361	3,564,514
Current portion of long-term debt	1,002,337	578,989
	\$ 4,805,024	\$ 2,985,525

F-30

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

16. Long-term debt (continued):

The instalments on long-term debt during the next five years without considering financing fees of \$41,498 are detailed as follows:

	Obligations under capital leases	Other loans
2011	\$ 46,951	\$ 966,503
2012	23,355	966,503
2013	3,676	953,379
2014		933,977
2015 and thereafter		1,959,944
Total minimum lease payments	73,982	
Interest expense included in minimum lease payments	5,431	
	\$ 68,551	

Included in financial expenses in the Consolidated Statement of Earnings and Comprehensive Loss is interest expense related to obligations under capital leases of \$7,487 (February 28, 2009 - \$3,436; 2008 - \$3,023).

During the nine-month period ended February 28, 2009, the Company refinanced its debt and entered into a debt agreement totaling \$6,500,000, of which \$3,500,000 has been disbursed by the lender up to February 28, 2009 in the form of a mortgage loan and \$3,000,000 has been disbursed by the lender up to February 28, 2010 in the form of a mortgage loan. Previous debts were paid back using the capital of the new debt. The Company is subject to certain covenants requiring the maintenance of ratios. As at February 28, 2010, the Company was in compliance with those ratios.

The Company renegotiated and now has an authorized operating line of credit of \$1,000,000 bearing interest at the prime rate plus 2.25% (February 28, 2009 - 1.75%). The line of credit is guaranteed by a first-ranking movable hypothec on all accounts receivable and merchandise, a second-ranking hypothec on the production plant and a third-ranking hypothec on all other movable assets, current and future, corporeal and incorporeal, and tangible and intangible except for intellectual property (which is subject to a negative pledge agreement). The Company has an authorized exchange line of credit of \$200,000 bearing interest at the prime rate plus 1.75%. The exchange line of credit is to support risk content of forward contracts. The exchange line of credit bears the same conditions as the operating line of credit. As at February 28, 2010, (nil as at February 28, 2009) no amounts were used under the operating and exchange line of credit.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

17. Capital stock and warrants:

(a) Authorized capital stock:

Unlimited number of shares without par value

- Common shares

Preferred shares, issuable in series, rights, privileges and restrictions determined at time of issuance:

- Series A preferred shares, non-voting, non-participating, fixed, preferential and non-cumulative dividend of 5% of paid-up capital, exchangeable at the holder's option under certain conditions into common shares (none issued and outstanding)

(b) Warrants:

Warrants of the Company are composed of the following as at February 28, 2010 and 2009:

	2010		2009	
	Number outstanding	Amount	Number outstanding	Amount
Debenture Warrants	1,070,000	\$ 272,534	1,100,000	\$ 280,175
Conversion Warrants	36,598	20,506		
	1,106,598	\$ 293,040	1,100,000	\$ 280,175

The characteristics of warrants are described in note 15.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

17. Capital stock and warrants (continued):

(c) Subsidiary options:

Subsidiary options held by the Company are eliminated upon consolidation. Subsidiary options not held by the Company and Call-Options on the Company's own subsidiary shares are detailed as follows as at February 28, 2010 and 2009:

	2010		2009	
	Number outstanding	Amount	Number outstanding	Amount
Acasti Pharma Inc.:				
Series 2 warrants	9,027,142	\$	9,230,533	\$
Series 4 warrants	4,755,000		5,385,000	
Series 5 warrants	30,000		30,000	
Options outstanding under stock-based compensation plan (note 19 (b))	850,000		850,000	
Debenture Call-Options (note 15)	1,100,000		1,100,000	
Conversion Call-Options (note 15)	9,455,867	163,006		
	25,218,009	163,006	16,595,533	
NeuroBioPharm Inc.:				
Series 4 warrants	4,660,000		5,070,000	
Series 5 warrants	30,000		30,000	
	4,690,000		5,100,000	
	29,908,009	\$ 163,006	21,695,533	\$

Additional options exist on subsidiary stock, in the form of a conversion option on convertible debentures (note 15).

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

17. Capital stock and warrants (continued):

(c) Subsidiary options (continued):

The characteristics of the Acasti subsidiary warrants are as follows:

- Series 2 allows the holder to purchase one Class A share for \$0.40 per share until November 17, 2010.
- Series 3 allows the holder to purchase one Class A share for \$0.40 per share until December 31, 2010.
- Series 4 allows the holder to purchase one Class A share for \$0.25 per share until October 8, 2013.
- Series 5 allows the holder to purchase one Class A share for \$0.30 per share until December 31, 2010.

18. Non-controlling interest:

Until August 7, 2008, all of the Company's subsidiaries were wholly-owned. During 2009 and 2010, the Company changed, through various transactions, its participation in Acasti Pharma and NeuroBioPharm, as follows:

- (a) As described in note 5, redeemable, non-participating shares in the Company's subsidiaries were granted as payment of royalties on the sale of licenses to the subsidiaries. The portion assigned to these shares is presented at their redemption price as current liabilities on the consolidated balance sheet.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

18. Non-controlling interest (continued):

- (b) In July 2008, the Company's Board of Directors declared a dividend of \$0.00025 per share amounting to \$9,380 to be settled by the issuance of non-convertible notes payable with a two-year maturity, bearing interest at a rate of 10%. In August 2008, the Board of Directors of both the Company and Acasti Pharma approved an exchange offer by Acasti Pharma to the holders of the notes. Under the exchange offer, Acasti Pharma offered to acquire up to 9,380,355 notes at a price equal to the notes value, payable by issuance of up to 9,380,355 units, each unit comprised of one Class A share of Acasti Pharma and one Series 2 warrant to purchase one Class A share of Acasti Pharma. On November 17 and 27, 2008, Acasti Pharma exchanged 9,230,533 notes for an equal number of units of Acasti Pharma, each consisting of one Class A share and one warrant. The balance of 149,822 notes held by persons in jurisdictions where the applicable legislation did not allow for the exchange was paid in cash (\$149) on November 27, 2008.

As the carrying amount of the Acasti net assets, after accounting for the Company's preference share, was negative at the time of the transaction, the value of the notes extinguished upon the exchange, in the amount of \$9,231, was recognized as a gain on dilution and no amount was allocated to non-controlling interest.

- (c) On November 2, 2009, the Company converted 38,240,000 Acasti Class C shares it owned into Class A shares.
- (d) As described in note 15, on November 30, 2009, the Company distributed 9,455,867 Acasti Class A shares upon conversion of debentures and recorded a gain on dilution of \$2,140,574 with no amount allocated to non-controlling interest.
- (e) Throughout the year ended February 28, 2010, holders of Acasti warrants have exercised their right to purchase Class A shares of Acasti, resulting in the issuance of 203,391 shares by Acasti. As the carrying amount of the Acasti net assets, after accounting for the Company's preference share, was negative at the time of the transaction, the cash collected on exercise of warrant and options in the amount of \$81,356, was recognized as a gain on dilution and no amount was allocated to non-controlling interest.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

18. Non-controlling interest (continued):

The distribution of the shareholdings of issued and outstanding Acasti Pharma's capital stock between the Company and other shareholders as at February 28, 2010 and 2009 is detailed as follows:

	2010			2009		
	Company	Other shareholders	Total	Company	Other shareholders	Total
Class A shares	28,784,133	18,889,791	47,673,924		9,230,533	9,230,533
Class B shares	4,950,000	50,000	5,000,000	4,950,000	50,000	5,000,000
Class C shares		260,000	260,000	38,240,000	260,000	38,500,000
	33,734,133	19,199,791	52,933,924	43,190,000	9,540,533	52,730,533
Votes	80%	20%	100%	84%	16%	100%
Participation	60%	40%	100%		100%	100%

The characteristics of Acasti Pharma's issued and outstanding classes of capital stock are detailed as follows:

- Class A shares, voting (one vote per share), participating and without par value.
- Class B shares, voting (ten votes per share), non-participating, without par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class B shares are exchangeable, at the holder's discretion, for Class A shares, on a one-for-one basis, as of January 1, 2009. Class B shares are redeemable at the holder's discretion for \$0.80 per share, subject to certain conditions.
- Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class C shares are exchangeable, at the holder's discretion, for Class A shares, on a one-for-one basis, as of January 1, 2009. Class C shares are redeemable at the holder's discretion for \$0.20 per share, subject to certain conditions.

Under Canadian GAAP, upon consolidation, losses of the subsidiaries cannot be allocated to non-controlling interests in excess of their carrying amount. Consequently, all of the subsidiaries' losses have been allocated to the Company during the year ended February 28, 2010 and the nine-month period ended February 28, 2009.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

19. Stock-based compensation plans:

(a) Company stock-based compensation plan:

The Company has established a stock-based compensation plan for administrators, officers, employees and consultants. The plan provides for the granting of common share options. The purchase price of the shares covered by the stock options granted under the plan is the closing price of the common shares listed on the TSX Venture Exchange on the eve of the grant. Under this plan 6,850,000 common shares have been reserved for issuance. The terms and conditions for acquiring and exercising options are set by the Board of Directors, as well as the term of the options which, however, cannot be more than five years or any other shorter period as specified by the Board of Directors, according to the regulations of the plan. The total number of shares issued to a single person cannot exceed 5% of the Company's total issued and outstanding common shares, with the maximum being 2% for any one consultant.

Every stock options issuance in the stock option plan will be subject to conditions no less restrictive than a minimal vesting period of 18 months, with the vesting rights acquisition gradual and equal, at least on a quarterly basis.

Activities within the plan are detailed as follows:

	2010 (12 months)		2009 (9 months)		2008 (12 months)	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Options outstanding, beginning of period	3,669,750	\$ 1.57	4,468,437	\$ 2.92	4,970,000	\$ 2.58
Granted	175,000	2.01	1,041,000	2.40	520,000	6.59
Exercised	(448,125)	0.26	(201,625)	0.27	(752,250)	0.90
Cancelled			(1,460,395)	5.93	(269,313)	5.99
Forfeited	(476,375)	2.61	(177,667)	5.81		
Options outstanding, end of period	2,920,250	1.63	3,669,750	1.57	4,468,437	2.92
Exercisable options, end of period	2,619,500	\$ 1.54	2,850,500	\$ 1.31	3,055,888	\$ 2.49

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

19. Stock-based compensation plans (continued):

(a) Company stock-based compensation plan (continued):

2010						
	Weighted		Options		Exercisable options	
	average	remaining	Number of	Number of	Weighted	
	exercise	contractual	options	options	average	
	price	life	outstanding	exercisable	exercise	
		outstanding			price	
\$0.25	\$ 0.25	0.29	870,000	870,000	\$	0.25
\$1.00	1.00	0.89	450,000	450,000		1.00
\$1.25	1.25	2.11	30,000	7,500		1.25
\$2.25	2.25	2.81	65,000			
\$2.50 to \$2.60	2.55	1.40	1,465,250	1,262,000		2.57
\$4.00	4.00	1.08	40,000	30,000		4.00
			2,920,250	2,619,500	\$	1.54

The fair value of the options granted has been estimated according to the Black-Scholes option pricing model and based on the weighted average of the following assumptions for options granted during the period:

	2010 (12 months)	2009 (9 months)	2008 (12 months)	2008 Non- employees
	Employees	Employees	Employees	
Dividend				
Risk-free interest rate	1.46%	2.84%	3.87%	4.88%
Estimated life	2.5 years	2.5 years	2.18 years	4 years
Expected volatility	92%	76%	84%	109%

The weighted average of the fair value of the options granted to employees during the period is \$0.87 (2009 - \$1.02; 2008 - \$2.06) and to non-employees is not applicable (2009 - not applicable; 2008 - \$3.88) .

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

19. Stock-based compensation plan (continued):

(b) Acasti Pharma stock-based compensation plan:

During the period ended February 28, 2009, the subsidiary Acasti Pharma initiated a stock-based compensation plan for administrators, officers, employees and consultants. The plan, which obtained all required approvals on June 9, 2009, provides for the granting of options to purchase Acasti Class A shares. Under this plan, the maximum number of options that can be issued equals the lower of 1,530,000 or 10% of Acasti Class A shares held by public shareholders, as approved annually by such shareholders. As at February 28, 2010, 923,053 Class A shares are reserved for issuance. The terms and conditions for acquiring and exercising options are set by the Company's Board of Directors, subject, amongst others, to the following limitations: the term of the options cannot exceed ten years and every stock option granted under the stock option plan will be subject to conditions no less restrictive than a minimal vesting period of 18 months, a gradual and equal acquisition of vesting rights, at least on a quarterly basis.

The following table presents information on outstanding stock options:

	2010		2009	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Options outstanding, beginning of period	850,000	\$ 0.25		\$
Granted	25,000	0.25	850,000	0.25
Forfeited	(25,000)	0.25		
Options outstanding, end of period	850,000	0.25	850,000	0.25
Options exercisable, end of period	382,500	\$ 0.25		\$

The purchase price of the shares covered by the stock options granted in 2010 under the plan is equal to \$0.25 (2009 - \$0.25). The exercise price was determined to be higher than the estimated fair value per share of Acasti Pharma at date of grant.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

19. Stock-based compensation plan (continued):

(b) Acasti Pharma stock-based compensation plan (continued):

The options outstanding under the plan have a weighted average remaining contractual life of 8.63 years.

The fair value of the options granted has been estimated according to the Black-Scholes option pricing model and based on the following assumptions:

	2010	2009
Fair value of Class A shares		
Dividend		
Risk-free rate	2.67%	3.58%
Estimated life	6 years	6 years
Expected volatility	75%	75%

At the time of grant, a value near nil was assigned to these stock options. Consequently, no charge was recognized for the year ended February 28, 2010 (nil as at February 28, 2009).

(c) Other stock-based compensations:

Following the declaration of a dividend and transactions associated with the transfer of licenses to the subsidiaries during the period ended February 28, 2009, Acasti Pharma and NeuroBioPharm, the Company awarded a bonus having a nominal value to dedicated insiders and employees of the Company's subsidiaries. The award to insiders and employees consisted of 4,045,000 and 1,280,000 Acasti Pharma Series 4 warrants, respectively, and 3,800,000 and 1,200,000 NeuroBioPharm Series 4 warrants, respectively. The value of Acasti Pharma Series 4 warrants was established using the Black-Scholes model, based on the following assumptions:

Fair value of the Class A shares	nil
Exercise price	\$0.25
Risk-free interest rate	2.78%
Estimated life	5 years
Expected volatility	75%

F-40

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

19. Stock-based compensation plan (continued):

(c) Other stock-based compensations (continued):

The value of the NeuroBioPharm Series 4 warrants was established using the Black-Scholes model, based on the following assumptions:

Fair value of the Class A shares	nil
Exercise price	\$0.25
Risk-free interest rate	1.84%
Estimated life	5 years
Expected volatility	75%

Following these evaluations, the awards were determined to have a nominal value. Consequently, no charge was recognized in the year ended February 28, 2010 (nil during the nine-month period ended February 28, 2009).

During the year ended February 28, 2010, 630,000 Acasti warrants and 410,000 NeuroBioPharm warrants were forfeited (nil during the nine-month period ended February 28, 2009).

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

20. Income taxes:

The income tax provision differs from the amount that would have been calculated by applying the combined Canadian statutory income tax rate (federal and provincial: 2010 - 30.73%, 2009 - 30.89% and 2008 - 31.56%) as follows:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Income tax at the combined Canadian statutory rate (federal and provincial)	\$ (471,766)	\$ (583,423)	\$ (1,510,084)
Increase (decrease) resulting from:			
Change in income tax rates:			
Reduction of future tax assets			304,819
Reduction of valuation allowance			(304,819)
Unrecognized deductible temporary differences for the period	543,889	(360,369)	(35,188)
Stock-based compensation	148,919	670,828	1,417,477
Non-deductible items and other	(221,042)	272,964	127,795
	\$	\$	\$

Net future income tax assets of approximately \$4,431,000 as at February 28, 2010 have not been reflected in these financial statements because the criteria for recognition of these assets was not met. These assets result primarily from unused non-capital losses and tax deductions resulting from expenses, which are recognized for accounting purposes but not deducted for tax purposes. These future income tax assets are available to reduce current income taxes in future years and are summarized as follows:

	2010	2009
Net future income tax assets resulting from the following:		
Tax losses	\$ 967,000	\$ 1,645,000
Research and development expenses	1,885,000	1,560,000
Excess of the tax basis of assets over their carrying amount	1,579,000	683,000
	4,431,000	3,888,000
Valuation allowance	(4,431,000)	(3,888,000)
Net future income tax assets recognized	\$	\$

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

20. Income taxes (continued):

As at February 28, 2010, the Company has losses for tax purposes, which are available to reduce future years' taxable income until the following expiry dates:

	Federal	Provincial
2014	\$ 1,093,000	\$ 987,000
2015	813,000	800,000
2029	675,000	675,000
2030	1,066,000	1,066,000
	\$ 3,647,000	\$ 3,528,000
Research and development expenses which can be carried forward indefinitely	\$ 5,922,000	\$ 9,165,000

As of February 28, 2010, the Company also has investment tax credits that have not been recognized in the financial statements. Investment tax credits are available to reduce future federal income taxes payable. The expiration dates are as follows:

	Federal
2022	\$ 156,000
2023	217,000
2024	74,000
2025	53,000
2026	91,000
2027	144,000
2028	228,000
2029	362,000
2030	409,000
	\$ 1,734,000

F-43

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

21. Capital disclosures:

The Company's objective in managing capital is to ensure sufficient liquidity to develop its technologies and commercialize its products, finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection, its overall capital expenditures and those related to its debt reimbursement. The Company is not exposed to external requirements by regulatory agencies regarding its capital. As explained in note 16, the Company is subject to certain financial covenants under its mortgage loan.

Since inception, the Company has financed its liquidity needs primarily through a public offering of common shares, private placements with or without warrants and issuance of long-term debt and convertible debentures. The Company optimizes its liquidity needs by non-dilutive sources whenever possible, including research tax credits, grants, interest income and revenues from strategic partnerships and collaboration agreements.

The Company defines capital to include total shareholders equity, long-term debt and convertible debentures.

The capital management objectives remain the same as for the previous fiscal period.

The Company's policy is to maintain a minimal level of debt. In 2009, the Company renegotiated the refinancing of its debt with an important financial institution, reduced its financial expenses and increased its production capacity to be able to face the increasing demand for its products (for more details see note 16). As at February 28, 2010, the Company had an authorized operating line of credit \$1,000,000, of which an amount of \$1,000,000 was available.

As at February 28, 2010, cash amounted to \$1,093,194, short-term investments amounted to \$1,001,011 and tax credit receivable amounted to \$664,131, for a total of \$2,758,336. During the nine-month period ended February 28, 2009, the Company raised an additional financing of \$2,720,000 after financing fees through the issue of convertible debentures. These additional funds were used for the acquisition of an additional participation in its subsidiary Acasti Pharma, which will use this financing to continue its clinical studies in progress.

F-44

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments:

(a) Credit risk:

Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations, and arises primarily from the Company's trade receivables. The Company may also have credit risk relating to cash, which it manages by dealing only with highly-rated Canadian institutions. The carrying amount of financial assets, as disclosed in the consolidated balance sheet, represents the Company's credit exposure at the reporting date, including trade receivables. The Company's trade receivables and credit exposure fluctuate throughout the year. The Company's average trade receivables and credit exposure during the year may be higher than the balance at the end of that reporting period.

The Company's credit risk for trade receivables is concentrated, as the majority of its sales are to a relatively small group of distributors. As at February 28, 2010, the Company had twenty trade debtors. Most sales' payment terms are set in accordance with industry practice. Three customers represent 56% (two customers represented 41% as at February 28, 2009) of total trade accounts included in accounts receivable.

Most of the Company's clients are distributors for a given territory and are privately-held enterprises. The profile and credit quality of the Company's retail customers vary significantly. Adverse changes in a customer's financial position could cause us to limit or discontinue conducting business with that customer, require us to assume more credit risk relating to that customer's future purchases or result in uncollectible accounts receivable from that customer. Such changes could have a material adverse effect on our business, consolidated results of operations, financial condition and cash flows.

The Company's extension of credit to customers involves considerable judgment and is based on an evaluation of each customer's financial condition and payment history. The Company has established various internal controls designed to mitigate credit risk, including a credit analysis by the insurer which recommends customers' credit limits and payment terms that are reviewed and approved by the Company. The Company reviews periodically the insurer's maximum credit quotation for each of its clients. New clients are subject to the same process as regular clients. The Company has also established procedures to obtain approval by senior management to release goods for shipment when customers have fully-utilized approved insurers credit limits. From time to time, the Company will temporarily transact with customers on a prepayment basis where circumstances warrant.

While the Company's credit controls and processes have been effective in mitigating credit risk, these controls cannot eliminate credit risk and there can be no assurance that these controls will continue to be effective, or that the Company's low credit loss experience will continue.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments (continued):

(a) Credit risk (continued):

Customers do not provide collateral in exchange for credit, except in unusual circumstances. Receivables from selected customers are covered by credit insurance, with amounts usually up to 100% of the invoicing, with the exception of some customers under specific terms. The information available through the insurers are the main element in the decision process to determine the credit limits assigned to customers.

The Company provides for trade receivable accounts to their expected realizable value as soon as the account is determined not to be fully collectable, with such write-offs charged to consolidated earnings unless the loss has been provided for in prior periods, in which case the write-off is applied to reduce the allowance for doubtful accounts. The Company updates its estimate of the allowance for doubtful accounts, based on evaluations of the collectibility of trade receivable balances at each balance sheet reporting date, taking into account amounts which are past due, and any available information indicating that a customer could be experiencing liquidity or going concern problems.

The aging of trade receivable balances as at February 28, 2010 was as follows:

Current	\$ 2,071,825
Past due 0-30 days	415,693
Past due 31-120 days	187,130
Past due 121-180 days	649,827
Trade receivables	3,324,475
Less allowance for doubtful accounts	(383,597)
	\$ 2,940,878

(b) Foreign exchange risk:

The Company is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Company's business transactions denominated in currencies other than the Canadian dollar. From time to time, the Company uses derivative financial instruments to reduce its foreign exchange exposure. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Company's operating results.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments (continued):

(b) Foreign exchange risk (continued):

Approximately 89% of the Company's revenues are in US dollars. A small portion of the purchases, except for the purchase of raw materials, are made in foreign currencies. There is a financial risk involved related to the fluctuation in the value of the US dollar in relation to the Canadian dollar.

The following table provides an indication of the Company's significant foreign exchange currency exposures as at February 28, 2010:

CAD	US\$	EURO
Cash	\$ 1,013,044	\$ 283,185
Accounts receivable	3,104,792	219,718
Accounts payable and accrued liabilities	(429,894)	(170,826)
Advance payments		(593,051)
	\$ 3,687,942	\$ (260,974)

The following exchange rates applied during the year ended February 28, 2010:

	Average rate	Reporting date rate
US\$ per CAD	1.1107	1.0525
EURO per CAD	1.5616	1.4377

Based on the Company's foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar and Euro would have respectively decreased (increased) the net loss as follows, assuming that all other variables remained constant:

	US\$	EURO
Decrease (increase) in net loss	\$ 184,397	\$ (13,049)

F-47

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments (continued):

(b) Foreign exchange risk (continued):

An assumed 5% weakening of the foreign currency during the year ended February 28, 2010 would have had an equal but opposite effect on the basis that all other variables remained constant.

The Company enters into currency forwards to purchase or sell amounts of foreign currency in the future at predetermined exchange rates. The purpose of these currency forwards is to fix the risk of fluctuations in future exchange rates.

(c) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.

The Company's exposure to interest rate risk is as follows:

Cash	Short-term fixed interest rate
Short-term investments	Short-term fixed interest rate
Bank loan - operating line of credit	Short-term variable interest rate
Long-term debt	Variable and fixed interest rate
Convertible debentures	Fixed interest rate

The risk that the Company will realize a loss as a result of the decline in the fair value of its short-term investments is limited because these short-term investments have short-term maturities and are generally held to maturity.

An assumed 0.5% interest rate increase during the year ended February 28, 2010 would have decreased net earnings by \$27,399, with an equal opposite effect for an assumed 0.5% decrease.

The capacity of the Company to reinvest the short-term amounts with equivalent returns will be impacted by variations in short-term fixed interest rates available in the market.

(d) Fair value of financial instruments:

The carrying amounts of the Company's short-term financial assets and liabilities approximate their fair value given that they will mature in the short-term.

The fair value of the variable interest rate mortgage loans is equivalent to the carrying amount as the loans bear interest at a rate which varies according to the market rate.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments (continued):

(d) Fair value of financial instruments (continued):

The fair value of obligations under capital leases, of the refundable contributions obtained under a federal grant program and of the government grant receivable, is determined by discounting future cash flows using rates that the Company can use for loans with similar terms, conditions and maturity dates. The fair value of these loans approximates the carrying amounts.

The fair value of the liability component of convertible debentures, including accrued interest, was determined to be \$532,165, compared to the carrying amount of \$467,864.

The following table summarizes financial assets and liabilities fair value on a recurring basis:

	February 28, 2010	Fair value measurements at reporting date using:		
		Quoted prices in active markets for identical assets (level 1)	Significant other observable inputs (level 2)	Significant unobservable inputs (level 3)
Cash and cash equivalents	\$ 1,093,194	\$ 1,093,194	\$	\$
Short-term investments	1,001,011		1,001,011	
Foreign currency forwards	5,528		5,528	

(e) Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure and financial leverage, as outlined in note 21. It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Audit Committee and the Board of Directors review and approve the Company's operating budgets, and review the most important material transactions outside the normal course of business.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

22. Financial instruments (continued):

(e) Liquidity risk (continued):

The following are the contractual maturities of financial liabilities, as well as the payments required under the terms of the operating lease as at February 28, 2010:

Required payments per year (in thousands of dollars)	Total	Less than one year	2 to 3 years	4 to 5 years	More than 5 years
Accounts payable and accrued liabilities	\$ 2,241	\$ 2,241	\$	\$	\$
Contractual obligations:					
Long-term debt	5,780	967	1,920	1,868	1,025
Loans guaranteed by investments in lease contracts ⁽ⁱ⁾	74	47	27		
Research and development contract	1,062	1,062			
Other lease contracts	727	245	345	137	
	\$ 9,884	\$ 4,562	\$ 2,292	\$ 2,005	\$ 1,025

⁽ⁱ⁾ Including interest costs

In addition, approximately \$593,051 of advance payments at February 28, 2010 may be refundable in the next year if the Company fails to meet certain development milestones.

An option totaling \$275,000 for the acquisition of an intellectual property represents an additional contractual obligation. See note 23.

(f) Short-term investments:

As at February 28, 2010, short-term investments are with a Canadian financial institution having a high credit rating. Short-term investments have a weighted-average maturity date of November 30, 2010 and weighted-average interest rate of 0.41%, and are cashable at any time at the discretion of the Company.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

23. Commitments and contingencies:

(a) License agreement:

The Company has entered into a licensing agreement, which calls for semi-annual payments of royalties based on the net realized sales of licensed products, according to the following conditions:

	Rate	Minimum royalty
To a Canadian university as of June 1, 2002 ⁽ⁱ⁾ (for the term of the patents or until the Company exercised its option)	4%	\$5,000
To a company controlled by an officer and director as of June 1, 2002 (for an unlimited period)	1%	

- (i) The Company has a \$275,000 purchase option relating to the intellectual property currently held by this Canadian university.

On August 18, 2004, the Company notified the Canadian university of its intention to exercise its \$275,000 purchase option relating to the intellectual property. As per the licensing agreement reached between the Canadian university and the Company, the terms of payment are as follows: \$100,000 on the transfer date of the intellectual property, \$50,000 on the first anniversary date of the transfer, \$50,000 on the second anniversary and \$75,000 on the third anniversary.

On August 23, 2004, university researchers filed an injunction against the Company and the Canadian university demanding cancellation of the purchase option of the intellectual property granted to the Company by the Canadian university.

In December 2008, a ruling was rendered against the Company. The judge determined that the Company had not exercised its option to purchase the intellectual property in August 2004, as claimed by the Company, and it had to pay additional royalties in the amount of \$1,031,134 in addition to \$145,000 in fees. The judge furthermore set at \$1,776,000 the purchase price for the intellectual property, although it had been previously established at \$275,000. Under the judgment, the Company had 45 days to exercise its option and it had to pay \$275,000 immediately.

Following the December 2008 ruling, the Company appealed the ruling and requested an immediate stay of its execution. The Company did not agree with the findings of the ruling and believed that its own arguments were well founded.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

23. Commitments and contingencies (continued):

(a) License agreement (continued):

In January 2010, the court of appeal ruled in favor of the Company confirming in its ruling the Company's rights to exercise its purchase option relating to the intellectual property at a purchase price of \$275,000 plus interests of \$36,000, for a total of \$311,000. The court also confirmed that the Company had exercised its option in August 18, 2004 and rejected all royalty claims to the exception of \$36,000 plus interests of \$11,000, for a total of \$47,000.

Following the January 2010 ruling, the Company has decided to present the \$311,000 as a commitment and the \$47,000 as an accrual.

(b) Litigation claim:

During the second quarter, the Company received a complaint filed by Schiff Nutrition Group Inc. ("Schiff"), a former distributor of Neptune's products, in the United States District Court for the District of Utah, Central division, alleging that Neptune failed to meet certain delivery thresholds. As a result, Schiff is seeking monetary damages in the minimum amount of US \$1 million from Neptune.

After careful review of this complaint and having sought legal advice, the Company filed, early in the third quarter, a response and counterclaims to the Schiff complaint in the federal district court in Utah. The Company denies all material allegations and the requested monetary compensation in the complaint and asserts federal and state law claims against Schiff, including that Schiff failed to pay the Company for shipments of NKO[®] accepted by Schiff, and that Schiff caused its contractor to encapsulate NKO[®] despite the Company's objections that the resulting product would not meet specifications after encapsulation by Schiff's contractor.

Despite the Company's warning to Schiff to cease directly and indirectly using the Company trademarks including NKO[®] and clinical support, Schiff continued to use the Company trademarks and claims, as it could be seen on websites of multiple Schiff's distributors.

No provision has been recorded by the Company as at February 28, 2010 for this matter because the outcome and the amount of loss, if any, is not determinable.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

23. Commitments and contingencies (continued):

(c) Research and development agreements:

In the normal course of business, the Company has signed agreements with various partners and suppliers for them to execute research projects to produce and market certain products. The Company has reserved certain rights relating to these projects. During the first quarter 2009, the Company initiated a clinical trial that is being conducted over a 30-month period for an amount of \$775,000. As at February 28, 2010, payments of \$459,208 have been made towards the total amount of the contract.

In addition, during the first quarter 2010, the Company initiated another clinical trial that is being conducted over a 20-month period for an amount of \$345,048 (240,000). As at February 28, 2010, payment of \$143,770 (100,000) has been made toward the total amount of the contract.

The Company initiated another research project during 2010 that will be conducted over a 12-month period for an amount of \$583,294. As at February 28, 2010, an accrual of \$37,899 is included in accrued liabilities.

(d) Rental agreements:

The Company has entered into long-term lease agreements, which call for payments of \$727,003 for the rental of premises. Minimum lease payments for the next years are \$245,311 in 2011, \$173,598 in 2012, \$171,342 in 2013 and \$136,752 in 2014.

F-53

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

24. Segment disclosures:

- (a) Descriptive information on the Company's reportable segments:

As a result of the reorganization of the Company's activities as described in note 5, the Company has three reportable operating segments structured in legal entities: the first is producing and commercializing nutraceutical products (Neptune), the second is the development and commercialization of pharmaceutical applications for cardiovascular diseases (Acasti Pharma), and the third is the development and commercialization of pharmaceutical neurological diseases (NeuroBioPharm).

The following tables show information by segment:

	2010 (12 months)			
	Nutraceutical	Cardiovascular	Neurological	Total
Sales and research contracts	\$ 12,605,587	\$	\$ 58,875	\$ 12,664,462
Cost of sales and operating expenses (excluding amortization and stock-based compensation)	(10,674,861)	(400,298)	(81,334)	(11,156,493)
Research and development expenses	(1,268,124)	(1,178,375)	(297,020)	(2,743,519)
Financial expenses	(677,942)	(454)		(678,396)
Amortization	(759,254)	(9,065)		(768,319)
Stock-based compensation	(484,606)			(484,606)
Interest income	25,474	20,004		45,478
Foreign exchange (loss) gain	(647,716)	11,981		(635,735)
Gain on dilution	2,221,930			2,221,930
Net income (loss) and comprehensive income (loss)	\$ 340,488	\$ (1,556,207)	\$ (319,479)	\$ (1,535,198)
Cash	\$ 680,372	\$ 412,822	\$	\$ 1,093,194
Short-term investments	1,001,011			1,001,011
Total assets	16,652,823	913,318		17,566,141
Expenditures for long-lived assets	\$ 3,640,992	\$ 16,141	\$	\$ 3,657,133

F-54

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

24. Segment disclosures (continued):

(a) Descriptive information on the Company's reportable segments (continued):

	2009			
	(9 months)			
	(Recast - note 2 (a))			
	Nutraceutical	Cardiovascular	Neurological	Total
Sales and research contracts	\$ 8,513,190	\$	\$ 76,082	\$ 8,589,272
Cost of sales and operating expenses (excluding amortization and stock-based compensation)	(6,539,922)	(368,574)		(6,908,496)
Research and development expenses	(650,382)	(429,944)	(196,636)	(1,276,962)
Financial expenses	(519,198)	(336)		(519,534)
Amortization	(528,762)	(2,380)		(531,142)
Stock-based compensation	(2,171,668)			(2,171,668)
Interest income	43,101	18,236		61,337
Foreign exchange gain	999,603	744		1,000,347
Royalties on transfer of license to subsidiaries	(137,000)			(137,000)
Gain on dilution	9,231			9,231
Net loss and comprehensive loss	\$ (981,807)	\$ (782,254)	\$ (120,554)	\$ (1,884,615)
Cash	\$ 507,223	\$ 328,549	\$	\$ 835,772
Short-term investments	1,300,018	2,018,236		3,318,254
Total assets	15,515,198	2,638,858		18,154,056
Expenditures for long-lived assets	\$ 1,601,860	\$ 25,155	\$	\$ 1,627,015

All of the Company's activities for the year ended May 31, 2008 relate to the nutraceutical segment.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

24. Segment disclosures (continued):

(b) Geographic information:

All of the Company's assets are located in Canada.

The Company's sales are attributed based on the customer's area of residence:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Canada	\$ 151,762	\$ 888,375	\$ 984,551
United States	7,877,542	6,280,838	5,764,579
Europe	2,790,004	1,200,107	1,727,013
Asia/Oceania	1,786,279	95,161	1,787,682
	\$ 12,605,587	\$ 8,464,481	\$ 10,263,825

Sales above exclude revenues from a partnership and collaboration agreement.

(c) Information about major customers:

During the year ended February 28, 2010, the Company realized sales amounting to \$4,708,867 from two customers (\$4,167,560 from three customers in the nine-month period ended February 28, 2009 and \$3,191,307 from two customers during the year ended May 31, 2008), individually accounting for more than 10% of sales:

	2010 (12 months)	2009 (9 months)	2008 (12 months)
Customer A	24.5%	14.6%	
Customer B	12.8%	13.0%	
Customer C		21.0%	14.5%
Customer D			16.9%

25. Comparative figures:

The comparative figures have been reclassified to conform with the financial statement presentation adopted for 2010.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

26. Subsequent events:

- (a) On April 30, 2010, 1,068,000 Debenture Warrants were exercised for total proceeds of \$1,335,000 and 1,086,400 Debenture Call-Options for total proceeds of \$271,600.
- (b) The Company held a special and annual shareholders' meeting on June 22, 2010 (the "Meeting"). At the Meeting a majority of shareholders approved, among other things, the amendment to the Company's stock option plan and adopted the Shareholder Rights Plan (the "SRP"), which had been previously approved by the Board of Directors of the Company.
 - (i) The Company's stock option plan now allows the Company to issue a number of incentive stock options not in excess of 15% of the number of shares issued and outstanding on the date of the Meeting. As at the date of the Meeting, the total number of common shares of the Company issued and outstanding was 40,172,744.
 - (ii) The Board determined that the establishment of a SRP was in the best interest of the Company's shareholders to have more time to consider any significant takeover bid for the Company without undue pressure, to allow the Board to propose, if appropriate, other alternatives to maximize shareholder value and to allow additional time for competing bids to emerge. The rights issue pursuant to the SRP required the approval by a majority of shareholders, which was obtained at the Meeting.

The SRP allow holders of common shares to purchase from the Company, for each common share held, an amount of common shares worth twice the market price on the date a triggering event occurs, at a price per common share equal to half the market price on the date of such triggering event. As defined in the SRP, a triggering event consists in a transaction that results in the acquisition by a person or group of persons (the "Acquirer") of 20% or more of the outstanding common shares of the Company through a transaction that is not considered a permitted bid. The Acquirer would not be entitled to exercise any right it may hold through such transaction.

The rights under the SRP are not triggered by the purchase of shares made pursuant to a permitted bid. A permitted bid is one that is open for not less than 60 days and that is made to all shareholders by way of a take-over circular prepared in compliance with applicable securities laws. It must also comply with certain other conditions set out in the agreement signed with Computershare Services Inc., acting as registrar and transfer agent for the Company, to implement the SRP.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

26. Subsequent events (continued):

(b) (continued):

(ii) (continued):

The Board retains discretion on the continuation of the SRP until its scheduled termination in three years, and on the waiving of dilutive effects of the provisions on triggering events for acquirers. A copy of the SRP is available on SEDAR and EDGAR under the Company's filings.

(c) On July 13, 2010, the Board of Directors of the Company has decided, after nearly 2 years without a general incentive option grant to employees and management, to grant a total of 790,000 incentive stock options of the Company, 695,000 rights on Acasti Series 4 warrants held by the Company and 760,000 rights on NeuroBioPharm Series 4 warrants held by the Company to insiders and employees. The Company's incentive stock options have an exercise price of \$1.50 and a 3-year maturity. Rights on Acasti Series 4 warrants and rights on NeuroBioPharm Series 4 warrants have an aggregate exercise price of \$0.50 and \$0.25 and maturities of October 9, 2013 and December 24, 2013, respectively, and are subject to shareholder approval.

F-58

F-NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles:

The consolidated financial statements of the Company are prepared in accordance with Canadian generally accepted accounting principles (Canadian GAAP), which differs in some respects from accounting principles generally accepted in the United States (US GAAP). The significant differences between Canadian and US GAAP are described below:

Consolidated statements of loss and comprehensive loss:

	Year ended February 28, 2010	Nine-month period ended February 28, 2009	Year ended May 31, 2008
Net loss and comprehensive loss - Canadian GAAP	\$ (1,535,198)	\$ (1,884,615)	\$ (4,779,344)
Other assets - start-up costs ⁽¹⁾		95,977	(95,977)
Development costs ⁽²⁾	(11,323)	(43,218)	(296,527)
Capitalized interest ⁽³⁾	41,551	36,000	
Convertible debentures ⁽⁴⁾	(119,527)	13,754	
Patents ⁽⁵⁾	(5,460)	(4,095)	(5,460)
Debenture Call-Options ⁽⁶⁾	(244,612)		
Transactions with non-controlling interest ⁽⁷⁾	(2,221,930)		
Net loss and comprehensive loss*			
- US GAAP	(4,096,499)	(1,786,197)	(5,177,308)
Less:			
Net loss and comprehensive loss attributable to the non-controlling interest - US GAAP	(1,156,297)		
Net loss and comprehensive loss attributable to Neptune Technologies & Bioresources Inc. - US GAAP	\$ (2,940,202)	\$ (1,786,197)	\$ (5,177,308)

* Since the Company is not recording income tax benefits due to its cumulative loss position, there is no tax effect reflected for any of the operating reconciling items.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles (continued):

Consolidated statements of loss and comprehensive loss (continued):

	2010	2009	2008
Weighted average number of common shares outstanding	37,913,163	37,622,735	37,105,672
Loss per common share attributable to Neptune Technologies & Bioresources Inc.'s shareholders - basic and diluted	\$ (0.08)	\$ (0.05)	\$ (0.14)

The cumulative effect of these adjustments on our equity is as follows:

	February 28, 2010	February 28, 2009	May 31, 2008
Shareholders' equity - Canadian GAAP	\$ 7,995,689	\$ 9,002,263	\$ 7,943,661
Other assets - start-up costs ⁽¹⁾			(95,977)
Deferred development costs ⁽²⁾	(351,068)	(339,745)	(296,527)
Capitalized interest ⁽³⁾	77,551	36,000	
Convertible debentures ⁽⁴⁾	(18,529)	(134,779)	
Patents ⁽⁵⁾	141,455	146,915	151,010
Equity - US GAAP	7,845,098	8,710,654	7,702,167
Non-controlling interest ⁽⁷⁾	(670,954)		
Neptune Technologies & Bioresources Inc.'s shareholders' equity - US GAAP	\$ 8,516,052	\$ 8,710,654	\$ 7,702,167

(1) Other assets - start-up costs:

In 2008, under Canadian GAAP, the Company deferred certain start-up costs totaling \$95,977 as a component of Other assets to be amortized on a straight-line basis during 2009. Under the US GAAP, such costs are to be expensed as incurred. In 2009, these costs were fully amortized for Canadian GAAP purposes.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles (continued):

(2) Development costs:

Under Canadian GAAP, the Company capitalizes certain development costs. Capitalized development costs of \$351,068 (2009 - \$339,745; 2008 - \$296,527) are to be amortized over a maximum period of five years, beginning at the time of the commercialization.

For US GAAP purposes, these costs are to be expensed as incurred. Accordingly, the Company decreased intangible assets and increased research and development expenses by \$11,323 (2009 - \$43,218; 2008 - \$296,527) and deficit in the amount of \$351,068 (2009 - \$339,745; 2008 - \$296,527) to reconcile the financial position and earnings to US GAAP.

(3) Capitalized interest:

Under Canadian GAAP, the Company expenses interest costs related to its plant expansion. For US GAAP, interest related to its plant expansion is capitalized as part of the historical cost of the plant expansion. Accordingly, interest expense of \$45,000 have been reversed for US GAAP purposes during the year ended February 28, 2010 (2009 - \$36,000), net of amortization of \$3,449 (2009 - nil).

(4) Convertible debentures:

In accordance with Canadian GAAP, the convertible debentures issued during the nine-month period ended February 28, 2009, are accounted for as a compound financial instrument and are presented in their component parts of debt and equity using the relative fair value method in accordance with the substance of the contractual arrangement. The debt component, net of debt issue costs, is accreted to its face value through a charge to earnings over its term using the effective interest method. The equity component comprises the value attributable to the detachable warrants and the holder conversion option.

Under US GAAP, the proceeds received from the convertible debentures were allocated to long-term debt and the detachable warrants and options using the relative fair value method. For US GAAP purposes, the holder's conversion option is not bifurcated and is included in the amount allocated to long-term debt. In addition, a beneficial conversion feature representing the intrinsic value attached to the conversion feature of the convertible debenture is recorded and accreted as financial expense from the date of issuance to the date on which the debentures are convertible. As well, the total issue costs relating to the convertible debentures are recorded in deferred financing fees under US GAAP.

NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles (continued):

(4) Convertible debentures (continued):

The total adjustments to US GAAP related to convertible debentures for the periods ended February 28, 2010 and 2009 are comprised as follows:

	2010		2009	
	Statement of loss	Equity	Statement of loss	Equity
Differences in accretion and other charges related to the convertible debentures, including amortization of beneficial conversion feature of \$191,678	\$ (119,527)	\$ (105,773)	\$ 13,754	\$ 13,754
Differences in the allocation of values between debt and equity		(391,714)		(391,714)
Beneficial conversion feature included in additional paid-in capital for US GAAP		243,181		243,181
Differences in the allocation of carrying amounts to equity upon conversion		235,777		
	\$ (119,527)	\$ (18,529)	\$ 13,754	\$ (134,779)

(5) Patents:

Under Canadian GAAP, direct costs incurred by the Company to secure patents related to internally-generated assets in the research phase are no longer capitalized, in accordance with CICA Handbook Section 3064, *Goodwill and Intangible Assets*. For US GAAP, these direct costs are capitalized as incurred. Therefore, the recast adjustments recorded for Canadian GAAP purposes, which are described in note 2 (a), have been reversed when reconciling to US GAAP.

F-62

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles (continued):

(6) Debenture Call-Options:

On March 1, 2009, the Company adopted new guidance contained in ASC 815 - *Derivatives and Hedging*, previously issued as EITF 07-5, *Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock*, and EITF 08-8, *Accounting for an Instrument (or an Embedded Feature) with a Settlement Amount That Is Based on the Stock of an Entity's Consolidated Subsidiary*. This new guidance has no equivalence in Canadian GAAP.

After the review of all its relevant financial instruments, the Company concluded that the Debenture Call-Options should be classified as liability until November 15, 2009 under US GAAP, as their conversion ratio remained subject to adjustment if a new financing had been concluded at a price per Class A share below \$0.25 until that date. After the expiry of this feature, the instrument was determined to meet the criteria for equity classification.

As derivative liabilities are to be recorded at their fair values through profit and loss, the Company determined that the instruments outstanding as at March 1, 2009 and November 15, 2009 had a fair value of nil and \$244,612, respectively. In reconciling to US GAAP, this increase in fair value was recognized as a loss, which became the carrying amount of the non-controlling interest equity instrument subsequent to November 15, 2009.

(7) Non-controlling interest:

On March 1, 2009, the Company adopted new guidance contained in ASC 810 - *Consolidation*, previously issued as FAS 160, *Non-controlling Interests in Consolidated Financial Statements an amendment of ARB No.51*, for which there currently is no equivalence in Canadian GAAP.

This new US GAAP standard impacted the Company's accounting for non-controlling interest in three different ways compared to past US GAAP policies and Canadian GAAP. First, in determining consolidated net loss and comprehensive loss, deduction is made for the portion attributable to the non-controlling interest, and the non-controlling interest is presented as a separate component of consolidated equity. Second, the non-controlling interest continues to be attributed its share of losses of a subsidiary even if that attribution results in a deficit non-controlling interest balance. Third, transactions with non-controlling interest that do not result in a change in control of the subsidiary are treated as equity transactions, with no gain or loss on dilution being recognized.

The Company adopted this new guidance prospectively as of March 1, 2009, except as it concerns the presentation requirements, for which retrospective application was applied.

NEPTUNE TECHNOLOGIES & BIORESOURCES INC.

Notes to Consolidated Financial Statements, Continued

Year ended February 28, 2010, nine-month period ended February 28, 2009 and year ended May 31, 2008

27. Reconciliation to United States generally accepted accounting principles (continued):

(7) Non-controlling interest (continued):

Previous US GAAP guidance and current GAAP guidance had resulted in non-controlling interest being continuously carried at nil. The recognition of the gain on dilution under Canadian GAAP, in the amount of \$2,221,930 for the year ended February 28, 2010 was reversed for US GAAP purposes, as it is now accounted for as an equity transaction. This entry has no impact on the shareholders' equity reconciliation as it is already included therein (Canadian GAAP retained earnings).

In accordance with new guidance, the Company allocated losses of its majority-owned subsidiary Acasti to controlling and non-controlling interests based on their proportionate shareholdings in Acasti's Class A shares throughout the year. Also, it calculated the changes in carrying amounts of non-controlling interest for each transaction that occurred during the year.

The following details the changes in non-controlling interest in accordance with US GAAP for the year ended February 28, 2010:

	2010
Non-controlling interest, beginning of period - US GAAP	\$
Conversion of Class C shares to Class A shares (note 18 (c))	744,476
Reclassification of Debenture Call-Options ⁽⁶⁾	244,612
Conversion of convertible debentures (note 18 (d))	(520,085)
Exercise of subsidiary warrants (note 18 (e))	16,340
Net loss and comprehensive loss attributable to the non-controlling interest	(1,156,297)
Non-controlling interest, end of period - US GAAP	\$ (670,954)

F-64